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Hepatocellular carcinoma (HCC) is a frequent neoplasm worldwide and constitutes the 
fourth highest incidence of cancer among males in Singapore. Our objective is to look for 
novel HCC-related genes which might serve as potential candidates for developing 
comprehensive molecular diagnostic assays or effective treatment for HCC. Two reciprocal 
HCC-related subtracted cDNA libraries were generated and screened by 18 pairs of HCC 
samples using microarrays. Twenty-five genes were found to be differentially expressed in 
HCC and the results were confirmed by 27 independent pairs of HCC samples using 
Affymetrix GeneChip analysis. Among the differentially expressed genes, we focused 
particularly on the study of hepcidin and C78, a novel cDNA fragment, because both genes 
gave the most dramatic reduction in detectable mRNA levels in cancerous compared to non-
cancerous liver tissues in HCC patients. 
 To date, the pathophysiological relationship between iron overload and HCC remains 
elusive. Recent studies reveal that hepcidin is a key regulator of iron absorption in mammals. 
The question arises whether reduction of hepcidin expression is associated with hepatic iron 
overload in HCC. We thus explored the expression of hepcidin in the context of the complex 
gene regulatory network governing iron homoeostasis in HCC. In this study, expression 
profiling of genes involved in iron homeostasis in conjunction with the pathological 
assessment of hepatic iron content in cancerous and non-cancerous tissues of HCC patients 
enabled us to unravel the underlying molecular mechanisms of iron overload in HCC. 
Although iron is a known potential carcinogen that plays a role in the development of HCC, 
our study suggests that the hepatic iron overload frequently found in HCC patients could be a 
physiological consequence of HCC development rather than its cause. This is supported by 
the impaired expression of many key regulators of iron homeostasis detected within the 
cancerous tissues of HCC patients that could perturb the homeostatic balance of iron 
metabolism, resulting in excessive absorption of dietary iron. Furthermore, it is also noted 
 viii
that the non-cirrhotic, non-cancerous liver tissues of HCC patients could still respond to iron 
loading.  
On the other hand, the cloning and characterization of C78 revealed that it has all the 
hallmark features of a mitochondrial carrier protein. We thus designated the novel protein as 
HDMCP (HCC-down-regulated mitochondrial carrier protein). The liver is a major 
contributor to energy expenditure. It is known that up to 25% of oxygen consumption in the 
liver is used to facilitate the so-called ‘proton leak’ process, that is, to drive the protons 
moving back into the mitochondrial matrix through endogenous proton conductance pathways 
in the inner mitochondrial membrane that circumvent the ATP synthase. However, no 
putative molecules have been suggested to be responsible for this uncoupling of oxidative 
phosphorylation in hepatocytes. The observations that HDMCP has the ability to induce 
potent dissipation of mitochondrial membrane potential and its exclusive expression in the 
liver have prompted us to suggest that HDMCP might be one of the long postulated 
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1.1. Liver 
1.1.1. Biological function and hepatic gene expression  
The liver is a vital organ that is able to remove poisonous ammonia, detoxify alcohol and 
drugs, control sugar levels, maintain cholesterol balance, produce bile for fat digestion and 
synthesize coagulation factors and plasma proteins. This is concordant with the identification 
of various hepatically expressed genes encoding plasma proteins and enzymes involved in a 
vast number of metabolic functions.  
It has been shown that among the 50 most abundant mRNAs found in liver, 29 encode 
secreted proteins (1). Another independent study using serial analysis of gene expression 
(SAGE) approach has also found that more than one fifth of the total transcripts in normal 
liver encodes plasma proteins (2). Transcripts encoding plasma proteins including albumin, 
apolipoproteins, alpha-1-antitrypsin, anti-thrombin III, complement component 3, and 
fibrinogen are abundantly expressed in the normal liver (2). On the other hand, the enzymes 
that are highly expressed in the normal liver include those associated with hexose and lipid 
metabolism, those catalyzing drugs and xenobiotics, and those involved in the biosynthesis of 
urea (2).  
1.1.2. Gene regulation by liver-enriched transcription factors 
Liver-specific gene expression in adult hepatocytes relies on four families of transcription 
factors which function in unique combinations, often synergistically, to stimulate liver-
specific transcription (3). The four families of liver-enriched transcription factors include the 
variant homeodomain containing family of hepatocyte nuclear factor 1 (HNF1), the leucine 
zipper CCAAT/enhancer binding protein family (C/EBP), the HNF3 winged helix family and 
members of the nuclear receptor superfamily, which includes the orphan receptor HNF4 (3). 
These transcription factors have been shown to be important components of the differentiation 
process that culminates in a fully functional liver (4). However, none of the defined liver-
enriched transcription factors are exclusively expressed in hepatocytes, indicating that some 
unknown mechanisms might be involved in regulating hepatic gene expression (3). When 
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genes encoding the transcription factors have been mutated in mice, the effect on hepatocyte 
differentiation and hepatic gene expression has been relatively benign indicating that there is 
a degree of functional redundancy among these transcription factors (5-7). 
1.1.3. Liver regeneration 
Hepatocytes are highly differentiated cells that rarely divide. However, in response to a 
reduction in liver mass caused by physical, infectious or toxic injury, quiescent hepatocytes 
will rapidly proliferate to restore the functional capacity of liver, as well as its mass. This 
restoration of liver mass by the compensatory hyperplasia of the cells in the remaining lobes 
is termed liver regeneration (8).  
In animal models with genetic inactivation of interleukin 6 (IL-6), tumor necrosis factor-
α, cytokine-inducible nitric oxide synthase or C/EBP-β, no obvious effect on hepatic 
organogenesis was observed. However, these animals have impaired liver regeneration 
leading to decreased survival after partial hepatectomy (9-12). These studies suggest that a 
portion of the genetic machinery regulating cell proliferation and metabolism during liver 
regeneration is not required for the liver to achieve all the hallmarks of development. 
Furthermore, the observation of impaired liver regeneration occurring in patients with liver 
cirrhosis suggests that some of the genes regulating proliferation, such as hepatocyte growth 
factor (HGF) might be dysregulated in cirrhotic liver (13, 14). 
1.1.4. Liver disease 
1.1.4.1.  Hepatitis 
Hepatitis is characterized by the destruction of a number of parenchymal cells and the 
presence of inflammatory cells in the liver tissue. Hepatitis can be caused by hepatitis viral 
infection and chemical injury. In general, there are acute and chronic forms of hepatitis. Drug-
induced hepatitis tends to be acute, whereas chronic hepatitis B and C are long-term 
infections of the liver that develop after a bout of acute hepatitis. Acute hepatitis occurs in the 
short-term and may heal in less than 6 months, although a minority may develop into a 
severe, life-threatening form of acute hepatitis called fulminant hepatitis.  Chronic hepatitis is 
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an on-going and long-term disease that may lead to liver fibrosis, regenerative nodules, and, 
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Figure 1-1. An overview of the pathogenesis of fibrosis and cirrhosis. (Diagram adapted 
from Ref.16.) 
 
1.1.4.2. Fibrosis and cirrhosis  
An overview of the pathogenesis of fibrosis and cirrhosis is shown in Figure 1-1. The 
development of fibrosis or cirrhosis is a byproduct of the regeneration process after 
progressive liver damage induced by chronic hepatitis virus infection, alcoholism, toxin 
exposure, or hepatic iron overload (15). Liver fibrosis is an accumulation of excess 
extracellular matrix (ECM), with or without accompanying inflammation. In moderately 
advanced disease, the excess ECM may take the form of connective tissue bridges linking 
portal and central areas. The transition to cirrhosis represents an extension of this process, 
with the formation of dense bands enclosing nodules of hepatocytes (16). Liver cirrhosis is 
the irreversible end result of chronic liver disease. It is believed to cause distortion of lobular 
blood flow, with portal hypertension as the principal outcome.  
1.1.4.3. Liver cancer  
Tumors of the liver are either primary or metastatic. Primary tumors of the liver, whether 
benign or malignant, may arise from hepatocytes, bile duct epithelium, the supporting 
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mesenchymal tissue, or a combination of these. The most common primary malignant liver 
cancer (80%) is hepatocellular carcinoma (HCC) which arises from the hepatocytes. 
On the other hand, the liver is a very common target of metastatic cancers of other 
origins; since it offers a soft, spongy blood-rich surface for metastatic cells to grow. Bowel, 
lung, breast, bladder, prostate and esophagus cancers have particular propensities for hepatic 
metastasis. However, several groups have reported that colorectal cancers seldom metastasize 
to the injured liver including fatty liver, cirrhotic liver and liver with chronic hepatitis B virus 
(HBV) and hepatitis C virus (HCV) infection (17-19). It seems plausible that the rare 
occurrence of hepatic metastasis in cirrhotic liver might be due to a decrease in blood flow to 
the liver, and changes in the architecture of hepatic tissue. 
 
1.2. Hepatocellular carcinoma (HCC) 
1.2.1. Epidemiology  
The epidemiology of HCC is widely variable in various parts of the world. The incidence 
of HCC is particularly high in Southeast Asia and Sub-Saharan Africa, but it is relatively 
uncommon in developed Western countries such as the United States and those of northern 
Europe. Parts of southern Europe, including Italy, Spain and Greece, have intermediate 
incidence. In Singapore, HCC ranked fourth in frequency among all malignancies of the male 
population from 1993-1997 (20). 
1.2.2. Etiology  
1.2.2.1. HBV infection  
Clinical, epidemiological, experimental and molecular studies have provided 
overwhelming evidence for a close association between HBV infection and HCC 
development (21). The woodchuck animal model in which woodchucks are infected with an 
agent very similar to HBV frequently develop HCC, further supporting the link of HBV 
infection with HCC (22). The notion that HBV infection is a risk factor for HCC has also 
been confirmed by an observation 10 years after implementation of a universal HBV 
vaccination program in Taiwan, showing significantly decreased incidence of HCC in parallel 
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with a striking decline of HBV carrier rate (23). In the high incidence regions of HBV 
infection including parts of China, Taiwan, Korea and Singapore, 80% of patients with HCC 
have serologic markers of HBV infection. Prospective studies demonstrate a 100-fold 
increased risk of HCC in HBV carriers (24). Although HBV infection is the main cause of 
HCC, only a minority of chronic HBV carriers develop HCC in their lifetime, suggesting that 
variations of the host immune system and some environmental cofactors are involved in 
hepatocarcinogenesis (24). It has been shown that the age of acquisition of HBV plays an 
important part in the eventual development of HCC. Perinatal (vertical transmission from 
mother to infants) or childhood HBV infection is usually asymptomatic but carries a high risk 
of becoming chronic carriers. Conversely, adult acquired infection is usually associated with 
symptomatic hepatitis, but confers a low risk of chronicity (25).  
The integration of the HBV genome into the host genome probably plays a crucial role in 
initiating malignant transformation during hepatocarcinogenesis. It might be through the 
disruption of the regulatory elements of cell cycling or via transactivation of host oncogenes 
by two transactivating proteins, either HBx protein or a truncated protein derived from the 
pre-S2/S region of the HBV genome (26). HBx protein has been shown to complex with p53 
and interfere with its functions, which might contribute to the molecular pathogenesis of HCC 
(27, 28). Transgenic mice harboring the HBx gene have been reported to develop HCCs, 
again showing the oncogenic activity of this viral protein (29).  
1.2.2.2. HCV infection 
The link between chronic HCV infection and HCC has been proposed by clinical, sero-
epidemiological studies and longitudinal follow-up studies (30). About 80% of HCC cases in 
Japan are associated with chronic HCV infection (21). It seems that HCV infection has a 
higher predisposition to HCC than HBV, judging from the frequency of HCC development 
among subjects afflicted with HBV- and HCV-induced cirrhosis (31, 32). Unlike HBV, HCV 
is a positive-stranded RNA virus that does not integrate into the host genome (33). However, 
there are preliminary observations on the molecular mechanism of HCV-associated HCC. The 
HCV core protein, a likely oncogenic candidate, induces the development of HCC in 
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transgenic mice (34). Furthermore, the non-structural protein 3 (NS3) and protein 5A (NS5A) 
have been shown to transform NIH3T3 cells (35, 36). In addition, the role of HCV in 
hepatocarcinogenesis may be indirectly achieved through continuous HCV-induced cycles of 
necroinflammatory liver injury and regeneration which may render the host DNA more 
susceptible to mutagens (37).  
Cohort studies have shown a greater incidence of HCC development in patients with dual 
HBV/HCV infection than in those with a single infection of either, suggesting that HBV and 
HCV have a synergistic effect in hepatocarcinogenesis (37, 38). HBV seems to be the initiator 
as a result of its capacity to insert into the genome and disarrange cellular genes (38). HCV 
may act as a promoter by causing persistent liver necroinflammation and regeneration (38). 
However, the respective roles of HBV and HCV during HCC development in patients with 
dual infection remain speculative. 
1.2.2.3. Cirrhosis 
It has been shown that irrespective of the etiology, cirrhosis is a predisposing risk factor 
for the development of HCC. Even though it has not been an absolute pre-requisite for the 
development of HCC, it might play an important role in hepatocarcinogenesis. This is 
supported by the detection of precancerous lesions, known as hyperplastic nodular lesions, in 
the vicinity of small HCC (less than 2cm) with liver cirrhosis but not HCC cases without liver 
cirrhosis (39, 40). 
1.2.2.4. Other risk factors 
In addition to chronic HBV and HCV infection, other risk factors for the development of 
HCC include dietary carcinogenic aflatoxins, alcohol consumption and hemochromatosis. It is 
proposed that viral, chemical and ethanol damage, as well as iron overload in the liver, may 
result in oxidative damage, producing oxygen free radicals that might act as tumor promoters, 
thus leading to HCC (41). Untreated hereditary hemochromatosis (HH) is an especially severe 
premalignant state. The risk of death from HCC in patients with hemochromatosis has been as 
high as 45% in some cases (42). Iron depletion, if done before the onset of cirrhosis, reduces 
the incidence of HCC (43).  
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1.2.3. Sequential morphological changes in the liver developing HCC  
The development and progression of HCC is a multi-step process as suggested by 
histological findings. Hepatocarcinogenesis in humans may take more than 30 years to 
develop after chronic infection with HBV or HCV is first diagnosed (Figure 1-2.) (44). Long 
lasting viral multiplication and HBV protein expression are known to stimulate the host 
immune response and thus liver inflammation and fibrosis (45). The tissue lesions that 
precede the appearance of HCC normally show sequential hepatocellular alteration including 
chronic hepatitis and cirrhosis containing foci of phenotypically altered and dysplastic 












Figure 1-2. Chronologic sequence of cellular lesions culminating in the development of 
HCC in human subjects. (Diagram adapted from Ref.44.) 
 
Adenomatous hyperplasia (AH), a hyperplastic parenchymal nodule frequently occurring 
in cirrhotic liver, is strongly associated with the development of HCC (40, 46, 48-50). AH can 
be further classified into ordinary and atypical forms (Figure 1-2.). Ordinary AH (OAH) (also 
known as macroregenerative nodule or large regenerative nodule) consists of hepatocytes 
similar to those of the surrounding liver and showing regularly distributed portal tracts (51). 
On the other hand, atypical AH (AAH) (also known as dysplastic nodule) is composed of 
hepatocytes with nuclear atypia and increased proliferative activity compared to the 
surrounding liver with irregular or sparse portal tracts (51). Furthermore, AAH occasionally 
contains overt malignant foci. These results indicate that OAH may be a large-sized 
regenerative nodule, whereas AAH may be a true precursor of HCC, a peculiar form of low-
 8
grade HCC or borderline lesion, in which overt HCC is likely to evolve through multiple 
steps (47;51-53). 
 1.2.4. Tumor marker 
Serum alpha-fetoprotein (AFP) is the most commonly used marker for diagnosis and 
prognosis of HCC. However, the use of AFP as a serum tumor marker for HCC is 
controversial, because it is only elevated (above 10 ng/mL) in about two thirds of HCC 
patients, and a significantly high level of serum AFP is found only in large tumors (54). 
Furthermore, the specificity of AFP is relatively low because moderately raised levels are also 
associated with some patients with hepatitis and toxic liver injury (54). An elevated level of 
AFP can also be detected in germ cell cancer of the ovary or testicle (55). Recently, mono-
sialylated AFP isoform has been proposed as a tumor marker for HCC; however, it has not 
shown satisfactory sensitivity and specificity (56, 57). In addition to AFP, des-gamma-
carboxy-prothrombin (DCP) has been proposed as a promising diagnostic and prognostic 
marker for HCC (58-61). Further studies have showed that the combined assay of AFP and 
DCP levels is useful for the diagnosis, prognosis and postoperative monitoring for recurrence 
of HCC (62, 63). 
1.2.5. Clinical outcome 
HCC can be considered as two diseases in one, a virulent malignancy that develops in the 
setting of chronic liver disease or cirrhosis. This dual problem severely compromises 
treatment options and clinical outcomes for HCC patients (24). Thus, the prognosis of patients 
with HCC should take into consideration four closely related factors: tumor stage, degree of 
liver function impairment, patients’ general condition and treatment efficacy (64). In addition, 
many pathologic features, such as tumor size, number, capsule state, cell differentiation, 
venous invasion, intrahepatic spreading, and advanced pTNM stage, may also affect the 
prognosis of patients with HCC. 
Surgical resection is not feasible in patients with large or multiple HCC nodules. Even 
after successful removal of the tumor mass, patients with cirrhosis in the remnant liver are 
also at extremely high risk for recurrent cancer or new primary cancer.  The cumulative 5-
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year tumor recurrence rates ranges from 40 to 70 % (65). Taken together, the prognosis for 
the majority of HCC patients is very poor. Death is often due to liver failure associated with 
cirrhosis and/or rapid outgrowth of multilobular HCC (66). 
1.2.6. Treatment 
Treatment for HCC is largely palliative and long-term survival is rare. Surgical treatments 
such as curative resection or liver transplantation are potentially curative. Unfortunately, the 
vast majority of patients diagnosed with HCC do not qualify for hepatic resection because of 
tumor spread or poor liver function. Similarly, the number that can be treated by liver 
transplantation is also limited, in large measure because of a lack of donor organs. In addition, 
the use of percutaneous ethanol injection therapy (PEIT), transcatheter arterial 
chemoembolization are mainly performed with palliative intention (67, 68). 
1.2.7. Prevention 
The major causes of HCC worldwide are known and preventable. Prevention is thus the 
only realistic approach for reducing mortality from HCC. Theoretically, prevention of HBV 
and/or HCV infection and termination of viral replication and associated hepatitis activity in 
infected patients would be the most efficient approach for preventing the development of 
cirrhosis and thereby HCC. 
1.2.7.1. Hepatitis viral vaccination 
The availability of an effective vaccine against HBV has made it possible to reduce the 
incidence of HCC in endemic areas by preventing chronic HBV infection. In Taiwanese 
children, primary prevention of HBV by vaccination reduced the rate of chronic infection 
from 10% to less than 1% and was associated with a concomitant decrease in HCC (23, 69). 
In Singapore, all infants have been vaccinated since 1987, and mother-to-infant transmission 
has been reduced by 80%. At the same time, the age-standardized incidence of HCC in 
Singapore men decreased from 27.8 to 19 per 100,000 (70).  
On the other hand, no effective vaccine is available to prevent HCV infection. Knowing 
that HCV is transmitted primarily through repeated direct percutaneous exposures to blood 
such as blood transfusion and the use of shared, unsterilized, or poorly sterilized needles and 
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syringes, the primary prevention strategies are proper medical practices and screening of 
blood donors. It has been shown that the risk of HCV transmission through blood transfusion 
has been greatly reduced since the implementation of routine blood screening for anti-HCV 
antibody (71).  
1.2.7.2. Interferon-α (IFN-α) treatment 
IFN-α treatment improves liver function of patients with HCV infection. HCV carriers 
who respond to IFN-α therapy are less prone to developing HCC than non-responders, 
probably because treatment decreases the risk of HCC development by suppressing the virus, 
as well as the proliferating liver cells (72-75). 
1.2.7.3. Screening for HCC in high risk populations 
The association between chronic HBV and/or HCV infection, cirrhosis and HCC provides 
a definable population who are at risk for developing HCC, which makes screening cost-
effective. Patients with chronic liver disease are suggested to have regular liver function tests 
in order to estimate the severity of liver disease, assess the prognosis, and monitor the 
efficacy of therapy. The most commonly elevated blood tests with liver damage are aspartate 
aminotransferase (AST) and alanine aminotransferase (ALT), gamma-glutamyl transpeptidase 
(GGT) and alkaline phosphatase. The combination of serum marker screening and ultrasound 
monitoring might be advisable for individuals who are at high risk for HCC development, in 
order to detect the early appearance of HCC. 
 
1.3. Molecular pathogenesis of HCC 
1.3.1. Genetic alterations in HCC 
Hepatocarcinogenesis is a multifactorial and multistep process involving initiator-induced 
genetic alterations and promoter-induced proliferation and progression. Over the past few 
years, systematic efforts have been made to approach the genetic abnormalities of human 
cancer by screening for chromosomal regions with frequent allelic imbalance using 
microsatellite analysis (MSA), genotyping, microarray-based comparative genomic 
hybridization (CGH) and commercial single nucleotide polymorphism (SNP) arrays. Using 
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these technologies, HCC has been shown to exhibit a high degree of genetic heterogeneity, 
suggesting that multiple molecular pathways may be involved in the genesis of subsets of 
hepatocellular neoplasms. The heterogeneity of genomic aberrations may also reflect the 
actions of different causative agents (44). The identification of preneoplastic lesions in HCC 
provides a framework for identifying the temporal order with which genomic alterations 
develop during hepatocarcinogenesis. The incidence of genomic aberrations is low in chronic 
hepatitis and cirrhosis state, but increase markedly in dysplastic lesions and HCC (Figure 1-3) 
(44). The reported genetic abnormalities include loss of heterozygosity (LOH), microsatellite 









Figure 1-3.  Sequential development    
of genomic aberrations in 
hepatocarcinogenesis. Allelic deletion 
(red) and chromosome regional losses 
and gains (blue) were demonstrated in 
chronic hepatitis, cirrhosis, dysplastic 




Some genetic alterations involving the p53 family, Rb family and Wnt pathways are 
particularly important in the development of HCCs; however, the molecular pathogenesis of 
HCC differs with etiology to some extent. For instance, in geographic locations where 
aflatoxin contamination in the diet is prevalent, p53 mutations are found in 50% of patients 
with HCC, with G to T transversion at codon 249 which results in Arg to Ser substitution. 
However, this particular point mutation is seldom found in HCC with other etiologies (76-78). 
Furthermore, in patients with multifocal HCC, some of the internodule p53 mutation patterns 
are heterogeneous, or only one of the nodules is found to have p53 mutations, indicating that 
p53 mutations may be a late occurrence in hepatocarcinogenesis and not a prerequisite for 
malignant transformation (79). 
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1.3.2. Epigenetic alterations in HCC 
HCC always develops in the setting of chronic hepatitis and/or cirrhosis, and displays 
extensive heterogeneity of genomic lesions. However, despite the fact that virtually all HCCs 
contain multiple gene alterations, gain and loss of specific chromosomal loci rarely affect 
more than half of all HCCs analyzed. Thus, it is proposed that in addition to genetic 
alterations, HCC may also be generated by a selection of epigenetic alterations that comprise 
several regulatory pathways (80).   
The term 'epigenetics' defines heritable changes in gene expression that are not coded in 
the DNA sequence itself. DNA methylation is one of the best-understood epigenetic 
mechanisms. It has been firmly established that aberrant hypermethylation of CpG islands in 
gene promoter regions correlate with the lack of gene transcription (81). Aberrant de novo 
methylation of CpG islands is a hallmark of human cancers and is found in virtually every 
step in tumor progression (82, 83). 
In HCCs, a growing number of genes has been recognized as undergoing aberrant CpG 
island hypermethylation, which is associated with transcriptional inactivation and loss of gene 
function. In addition, the significant difference in methylated genes between chronic liver 
diseases with and without associated HCC suggests that HCC may arise in the liver with a 
methylation field defect (84). Concurrently, the expression of DNA methyltransferases 
(DNMTs) which catalyze the methylation of CpG groups, including DNMT1 and DNMT3a, 
is increased in a fraction of livers with chronic hepatitis and cirrhosis and strongly 
upregulated in HCCs (85). Taken together, CpG island hypermethylation is an early and 
frequent event and accumulates step-by-step during hepatocarcinogenesis (86-89).  
1.3.3. Differential gene expression in HCC 
Most of the genetic alteration studies in HCC have relied largely on precedent knowledge 
based on oncogene analysis in other types of cancer. For decades, methods have been used to 
identify differentially expressed genes including expressed sequence tag (EST) sequencing, 
subtractive hybridization, representative difference analysis (RDA) and differential display 
polymerase chain reaction (PCR). Until recently, advances in high throughput screening 
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technology including functional genomics databases, SAGE, microarrray techniques and 
proteome analysis have been shown to contribute greatly in identifying novel genes present in 
tumor cells, and the categorizing of tumors by expression profiling. These high throughput 
technologies have facilitated the study of global changes in gene expression in cancerous 
tissues compared to paired non-cancerous tissues from patients with HCC (90-92).  
Several of these studies identified ‘signature’ gene sets that may be useful as potential 
microarray-based diagnostic tools for HCC. Furthermore, genes related to HBV (+) and HCV 
(+) status, the degree of differentiation of HCC, as well as metastatic or recurrent potentials of 
HCC have also been identified (93-97). These unique genes or gene products associated with 
malignant transformation and recurrent or metastatic potentials may serve as molecular 
markers for early diagnosis, prediction of prognosis, and responsiveness to therapy. 
 
1.4. Objective and approaches for identifying differentially expressed 
genes in HCC 
The advances in understanding the molecular mechanisms underlying 
hepatocarcinogenesis may translate into new therapeutic options directed at HCC-specific 
targets. Our objective is to look for novel HCC-related genes which might be potential 
candidates for developing comprehensive molecular diagnostic assays or effective treatment 
for HCC.  
Two reciprocal subtracted cDNA libraries were generated using cancerous tissues and 
corresponding non-cancerous tissues from patients with HCC to identify HCC-up-regulated 
genes (cancerous tissue as a tester) and down-regulated genes (non-cancerous tissue as a 
tester). Using microarray analysis, we were able to screen the cDNA clones derived from both 
libraries. 18 pairs of cancerous and non-cancerous tissues from HCC patients and 10 normal 
liver controls were employed in these analyses. One way analysis of variance (ANOVA) F 
test with a significance level of 0.05 was applied to the microarray results in order to assess 
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2.1. Iron 
2.1.1. Biological importance of iron 
Iron is involved in numerous metabolic pathways in all cells and organisms. It is an 
essential element for many iron-containing proteins that catalyze key reactions involved in 
energy metabolism (cytochromes, mitochondrial aconitase, iron-sulfur proteins of the electron 
transport chain), respiration (hemoglobin, myoglobin), and DNA synthesis (ribonucleotide 
reductase). The biological importance of iron is largely attributable to its chemical properties 
as a transition metal. It readily engages in one-electron oxidation-reduction reactions between 
its ferric (Fe(III)) and ferrous (Fe(II)) form. This property has enabled it to be used in many 
oxidation-reduction (redox) reactions in the body. Fe(II) appears to be reasonably soluble at 
physiologic pH, while Fe(III) is almost completely insoluble. Due to the low solubility of 
ionic iron in aqueous solutions at physiologic pH levels, special molecules are required to 
maintain iron in a soluble and metabolically active form. As examples, transferrin allows the 
iron to be transported within the extracellular fluid, and ferritin allows iron to be stored 
intracellularly in a non-toxic form (1).  
2.1.2. Iron and free radical production 
Although iron is essential for life, it also has the potential to cause deleterious effects, 
such as suppressing the activity of host defense cells and acting as a mutagen or carcinogen. 
The same chemical properties described above explain why an excess of ‘free’ reactive iron is 
a serious hazard. Fe(II) reacts with hydrogen peroxide (H2O2) or lipid peroxides to generate 
Fe(III), OH−, and the highly reactive hydroxyl radical (OH•) or lipid radicals such as LO• and 
LOO• (2).  These Fe(II)-generated free radicals can cause lipid peroxidation and damage to 
cellular membranes, enzymes, structural proteins and nucleic acids. In the presence of iron 
overload and in some inflammatory conditions, these iron-catalyzed free radicals can 
contribute to pathological changes (1).   
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2.2. Iron homeostasis 
2.2.1. Systemic iron homeostasis 
The normal distribution of iron within the body is shown in Figure 2-1. In general, there 
are three iron pools in the body, a large metabolic pool in circulating hemoglobin and 
myoglobin, a variable storage pool in the liver and reticuloendothelial (RE) system, and a 
very small transit pool in the serum (2, 3). An organism must sense its internal iron load and 
respond appropriately by altering iron uptake and storage processes to meet the need of 

























Figure 2-1. Systemic iron 
homeostasis. The distribution of iron 
within the body is shown. In general, 
there are three iron pools: a large 
metabolic pool, a variable storage pool 
and a very small transit pool. About 1-
2 mg of dietary iron is absorbed each 
day by duodenal enterocytes. This 
intake is balanced by loss of a similar 
amount of iron through blood loss and 
the sloughing of skin and mucosal 
cells. Iron circulates in plasma bound 
to transferrin and delivered to 
developing erythroid bone marrow, 
mature erythrocytes, as well as to 
other tissues of the body. Iron is stored 
in parenchymal cells of the liver and 
reticuloendothelial macrophages. 
These macrophages provide most of 
the usable iron by degrading 
hemoglobin in senescent erythrocytes 
and reloading ferric iron onto 
transferrin for delivery to cells. 
(Diagram adapted from Ref.6.) 
 
 
2.2.1.1. Iron absorption 
Iron homeostasis is maintained by the strict regulation of iron absorption from the 
proximal small intestine (duodenum), rather than iron excretion. The process of iron 
absorption by the enterocytes can be divided into two main phases: iron uptake from the gut 








amount of iron transferred depends on two main factors, the ‘stores regulator’ which responds 
to the body’s iron store, and the ‘erythropoietic regulator’ which responds to the body’s 
requirement for erythropoiesis (4). An inverse relationship exists between the body’s iron 
stores and iron absorption, whereas increased erythropoietic activity is linked to enhanced 
iron absorption (5). 
Iron found in foods is sometimes referred to as ‘heme’ (from meat) or ‘non-heme’ (from 
plants, eggs and others). Heme iron is absorbed more efficiently than non-heme iron which 
exists primarily in the insoluble Fe(III) form. The schematic representation of intestinal iron 















Figure 2-2. Intestinal iron absorption. 
Fe(III) is reduced to Fe(II) in the lumen of 
the intestine by the membrane ferrireductase 
Dcytb and  transported across the apical 
membrane by DMT1. Iron can be stored as 
ferritin or exported across the basolateral 
membrane by IREG1. Exported Fe(II) is 
converted to Fe(III) by either membrane 
bound hephaestin or soluble ceruloplasmin, 
which is then bound to transferrin for 









In the intestinal lumen, Fe(III) is reduced to the more soluble Fe(II) by duodenal 
cytochrome b ferrireductase (Dcytb), a hemeprotein on the apical enterocyte membrane (7). 
Fe(II) then enters the cell through an apical H+/divalent cation symporter, divalent metal 
transporter 1 (DMT1) (also known as natural-resistance-associated macrophage protein 
(Nramp2) or divalent cation transporter 1 (DCT1)) (8, 9). Iron entering the absorptive 
enterocyte is either stored as ferritin or transferred across the basolateral membrane through 
an iron-regulatory transporter (IREG1) (also known as ferroportin 1, metal transport protein 
(MTP1) ) (10-12). For effective utilization of iron, Fe(II) exported from the intestine must be 
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converted to Fe(III) catalyzed by a ferroxidase, either membrane bound hephaestin (13, 14) or 
plasma protein ceruloplasmin (15). Fe(III) that enters the circulation is then loaded onto 
plasma transferrin (Tf) for transportation to the body tissues (16).  
2.2.1.2. Iron excretion 
Iron sequestered as ferritin that is not exported into the plasma is lost with exfoliation of 
the intestinal epithelium (5, 16). In addition, iron loss that results from the sloughing of 
epithelial cells from the skin or mucosa is a basal contribution to the overall iron balance (3). 
Hemorrhage is one way to get rid of excess iron. Women with heavy menstruation commonly 
lose significant quantities of iron. The treatment for patients with iron overload is to remove 
the excess iron by a process called phlebotomy (removing blood via blood vessel). 
2.2.2. Extracellular iron transport and utilization 
As a large, charged ion, iron cannot cross lipid bilayers directly and so requires cellular 
machinery to facilitate its transport (3). 
2.2.2.1. Transferrin-iron transport and uptake 
Transferrin (Tf) is a major plasma protein secreted by the liver that contains two iron-
binding sites. Tf can reversibly bind to Fe(III) with high affinity and solubilize it. Its main 
role is in inter-organ iron transportation (1). As shown in Figure 2-1, the major pathway of 
internal iron exchange is a unidirectional flow from plasma Tf to the erythron (erythroid 
elements at all stages of development) to the macrophage and back to plasma Tf (17). Only a 
small part of plasma Tf-iron is derived from intestinal iron absorption and/or storage pool 
(Figure 2-1). As the major circulating serum iron-binding protein, the extent of Tf saturation 
directly reflects the body’s iron status and thus represents a key physiological parameter of 
iron homeostasis.  
In most cells, especially in developing erythroid precursors, Tf-mediated iron uptake 
occurs mainly through binding of transferrin receptor 1 (TfR1). TfR1 is a homodimeric type 
II membrane glycoprotein that can bind two molecules of Tf. At physiologic extracellular pH, 
the receptor has a higher affinity for Tf-Fe(III) than for Apo-Tf (1). As shown in Figure 2-3, 
after Tf-Fe(III) binding to TfR1 at the cell surface, the Tf-Fe(III)-TfR1 complex is 
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endocytosed via clathrin-coated pits. This is followed by uncoating of the pits with the 
formation of endosomes, and acidification to a pH of 5.5 to 6.5 (1). The iron is then released 
from Tf and transferred into the cytoplasm through the action of DMT1 (18). The Tf-TfR1 
complexes will be subsequently cycled back to the cell surface by exocytosis, where, Tf 
dissociates from TfR1 at the extracellular pH to the plasma as an Apo-Tf (1, 2). In erythroid 
cells, most iron moves into mitochondria, where it is incorporated into protoporphyrin to 










Figure 2-3. A schematic diagram of the uptake of iron into cells via the TfR1. (Diagram 
taken from Ref.6.) 
 
Transferrin receptor 2 (TfR2), the second receptor for Tf has recently been identified (19-
21). The function of TfR2 does not seem to be redundant of TfR1 function because TfR1 
knockout mice is lethal to embryos (22). The high level of TfR2 expression in the liver (20) 
suggests a tissue-specific function of TfR2 that may be distinct from TfR1. In contrast to 
TfR1, expression of TfR2 is not regulated by intracellular iron status (19). Most importantly, 
the affinity of TfR2 for Tf is 25-30 times lower than TfR1 for Tf (23, 24). Under normal 
physiological conditions, plasma diferric Tf levels (micromolar range) are above that required 
to saturate the binding to TfR1 on hepatocytes (nanomolar range) (25). Hence, the uptake of 
diferric Tf by the liver is likely to occur primarily by the non-TfR1 dependent (NTfR1) 
pathway and TfR2 is proposed to be the putative molecule that involved in the pathway (26).  
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2.2.2.2. Non-transferin-iron transport and uptake 
Besides plasma Tf, several plasma proteins including ferritin, hemopexin, haptoglobin 
and albumin bind iron or iron-containing compounds. These may play subsidiary roles in the 
extracellular transport of iron, especially in abnormal conditions such as iron overload, 
hemolytic states, and inflammatory conditions. These proteins transport iron to the liver for 


















Figure 2-4. Summary of the major 
pathways for uptake and intracellular 
metabolism of iron in the hepatocytes. 
Various iron-containing complexes bind to 
receptors or binding sites on the cell 
membrane and endocytosis by the cell, 
occasionally the uptake can be through 
fluid phase endocytosis. Iron exchange can 
occur between the labile iron pool and 
intracellular iron enzymes or the 
extracellular environment (not shown in 
the figure). ER= endoplasmic reticulum; 
E= endosome; NTB Fe= NTBI (Diagram 




In normal individuals, plasma ferritin is at a very low level that is unlikely to provide a 
significant route for iron transport. However, elevated plasma ferritin is detected in patients 
with iron overload or liver cell damage (27). Plasma ferritin is selectively taken up by 
hepatocytes, probably through specific ferritin receptors (28, 29). 
Several pathologic conditions including hemoglobinopathies, trauma, malaria, and 
bacterial infections with complication of intravascular hemolysis might result in heme-
catalyzed free radical production. Haptoglobin and hemopexin, by binding with high-affinity 
hemoglobin and heme, respectively, exert an antioxidant effect by preventing heme-catalyzed 
free radical production. Furthermore, double knockout mice of haptoglobin and hemopexin 
revealed that both molecules are essential for protection from splenomegaly and liver fibrosis 
resulting from intravascular hemolysis (30).  
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In patients with thalassemia and hemochromatosis, a form of “free” iron, non-transferrin 
bound iron (NTBI) will appear in the serum during iron overload, when the binding sites of 
plasma Tf are saturated with iron (31-33). NTBI is thought to form complexes with low 
molecular weight molecules, such as citrate, ascorbate, and amino acids. NTBI is able to 
generate oxidant stress, being capable of freely entering the cell membrane and by-passing the 
normal regulatory mechanism of receptor-mediated iron uptake. Uptake of NTBI, probably 
driven by the negative electrical potential difference across the cell membrane, has been 
shown to occur primarily in the liver (34-36).  
2.2.3. Intracellular iron metabolism 
There is tight control of iron uptake, storage and exports in the liver and the 
reticuloendothelial (RE) system, two major sites of iron stores that mobilize iron in response 
to acute need.  
2.2.3.1. Hepatocyte iron metabolism 
The liver is intimately involved in many aspects of iron metabolism. First, it has a 
strategic position as being the first organ that receives intestinal absorbed iron from the portal 
circulation. Second, it is an iron storage organ and last, it has numerous iron-dependent 
metabolic functions (1). Iron can be distributed in three main pools in hepatocytes, namely the 
‘transit pool’,  ‘functional pool’ and ‘storage pool’ (37). The ‘transit pool’ (also known as 
labile iron pool) is transitory and serves as a crossroad of cellular iron homeostasis (38). The 
‘functional pool’ comprises iron-containing enzymes which catalyze redox reactions in 
numerous important metabolic pathways. The ‘storage pool’ includes ferritin-iron and 
hemosiderin.  
Normally, 95% of the stored iron in the liver is ferritin. The main functions of ferritin are 
to sequester potentially toxic iron inside the protein shell and to provide a readily accessible 
store of iron. The ferritin consists of an outer protein coat (apoferritin) and an inner core that 
can store up to 4,500 atoms of Fe(III). Apoferritin consists of 24 subunits of 2 species, the 
heavy (H) subunit for Fe(II) oxidation and the light (L) subunit which assists in core 
formation. The H-to-L ratio within ferritin varies in a tissue-specific manner and is also 
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influenced by pathophysiological conditions, including inflammation and malignancy. The L 
subunit-rich ferritins are named “basic” ferritin due to their higher pI, and are more abundant 
in iron-loaded tissues such as liver and spleen, while the H-subunit-rich ferritins, named 
“acidic” for their lower pI, are found in heart, kidney, hematopoietic and malignant cells (39, 
40). When the capacity for ferritin storage is exceeded, a complex of iron with phosphate and 
hydroxide, known as hemosiderin is formed.  Hemosiderin is an amorphous, insoluble, and 
biochemically ill-defined storage compound which is less chemically active and may be less 
available for mobilization. 
2.2.3.2. Reticuloendothelial cell iron metabolism 
RE macrophages play a major role in the recycling of heme iron from the degradation of 
hemoglobin of senescent erythrocytes. This is quantitatively important because only 1-2 mg 
of iron enters the body through the intestine each day, yet 25 mg are needed for erythropoiesis 
and other uses. Up to 80% of the available iron pool is derived from macrophage recycling 
(2). Following phagocytosis, senescent erythrocytes are degraded within secondary lysosomes 
and their iron is released from heme/hemoglobin by the action of microsomal heme 
oxygenase. Part of the recovered iron is held in storage (as ferritin), and the remainder is 
released into the plasma where it is oxidized by ceruloplasmin and transported via transferrin 
for reutilization. 
 
2.3. Molecular control of iron homeostasis 
2.3.1. Regulation of cellular iron homeostasis 
The expression of some iron homeostasis-related genes has been shown to be involved in 
the modulation of transcription, mRNA stability, translation, and post-translational 
modifications.  
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2.3.1.1. Post-transcriptional regulation by IRE/IRP complexes 
The post-transcriptional regulation of iron homeostasis-related genes is best characterized 
by the IRE/IRP system. Two cytosolic proteins, iron-regulatory protein 1 (IRP1) and IRP2 
can post-transcriptionally regulate several iron homeostasis-related gene transcripts through 
binding to the specific targets, iron-responsive element (IRE) stem-loop structures at the 5’ or 
3’ untranslated region (UTR) (41). IREs are located in the 5’ UTR of mRNAs encoding 
ferritin H and L chains (42-45), delta 5-aminolevulinic acid synthase (ALAS2) (46, 47), 










Figure 2-5. A representative of a [4Fe-4S] iron-sulfur cluster containing IRP1. IRP1 is a 
bifunctional protein. It contains a [4Fe-4S] iron–sulfur cluster which sits in a cleft between 
two domains of the protein. When the [4Fe-4S] cluster is intact, IRP1 exhibits aconitase 
activity in the cytosol. When the iron atom 4 of the [4Fe-4S] cluster is not coordinated to a 
cysteine residue of the protein, it may lead to cluster disassembly. The absence of the cluster 
results in the conformational change of IRP1, which allows it to act as a post-transcriptional 
regulatory factor because the cleft is open and accessible for interaction with IRE. (Diagram 
taken from Ref.1.) 
 
 
The RNA-binding activity of IRP1 is regulated by the insertion or extrusion of a [4Fe-4S] 
cluster (Figure 2-5). When the [4Fe-4S] is intact, IRP1 loses its IRE-binding ability and 
exhibits cytoplasmic aconitase activity by catalyzes the conversion of citrate to isocitrate. 
Conversely, when the [4Fe-4S] cluster disassembly, the protein will ‘open up’ and bind to 
IRE as a regulatory factor and loss its aconitase activity (49-51) (Figure 2-6). On the other 
hand, IRP2 is a homologous of IRP1 that lacks an iron-sulfur cluster but contains an 
additional 73 aa motif that has been implicated in iron-sensing and iron-mediated degradation 
by the proteasome. It has been shown that when iron levels are high, IRP2 is targeted for 
degradation. Conversely, when iron levels are low, IRP2 accumulates and binds to IRE 
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(Figure 2-6) (52). In addition to iron, IRPs are also controlled by other effectors including 
reactive oxygen species, nitric oxide and hypoxia (2).  
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Figure 2-6. The IRE/IRP regulatory system. At low intracellular levels, binding of IRPs to 
single 5’-IRE of L-ferritin mRNA will block their translation, whereas binding to multiple 3’-
IREs of TfR1 mRNA will protect them from degradation. At high intracellular iron levels, 
IRP1 binds iron and converted to cytoplasmic aconitase which is inactive to IRE binding. On 
the other hand, IRP2 is oxidized, ubiquitinated and degraded via proteasomes. Thus, without 
binding of IRPs to IREs, L-ferritin can be translated, whereas TfR1 mRNA will be rapidly 
degraded. (Diagram adapted from Ref.2.) 
 
It has been shown that by constantly responding to changes in the cellular-free iron pool, 
IRPs can maintain the iron homeostasis by regulating the expression of TfR1 for iron uptake 
and ferritin for iron sequestration (53). As shown in Figure 2-6, when cellular iron levels are 
low, activated IRPs bind to 5’IRE of L-ferritin mRNA which is in proximity to the 
transcription start site, and inhibit early translational processes by blocking the interaction of 
mRNA with polyribosomes (45, 54). At the same time, activated IRPs bind to the multiple 
IREs within the 3’-UTR of TfR1 mRNA (41) and inhibit the access of ribonuclease to the 
mRNA, hence reducing the extent of  mRNA degradation, and increasing translation and 
protein synthesis of TfR1 (Figure 2-6) (52, 55). Conversely, when cellular iron level is high, 
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IRP2 is degraded by the proteosome in an iron-dependent manner, and IRP1 is converted 
from an RNA-binding protein to a [4Fe-4S] cluster-containing protein that displays cytosolic 
aconitase activity. Hence, IRPs are inactivated and do not bind to IRE. These changes result 
in a rapidly degradation of TfR1 mRNA with a corresponding increase in L-ferritin 
translation.  
2.3.1.2. Transcriptional regulation 
For most non-erythroid cells, TfR1 expression is regulated by the IRE/IRP system, 
whereas in erythroid cells, transcriptional control appears to be more important and 
expression is independent of cellular iron content (56). On the other hand, cytokine responses 
have been reported to regulate the transcription of several iron-related genes which contribute 
to macrophage iron retention observed in inflammatory states, augmenting the host defence 
against microorganisms. For example, tumor necrosis factor–α, IL-1, IL-6 and IFN-γ all 
stimulate H-ferritin expression but reduce TfR1 expression (57). IFN-γ and 
lipopolysaccharide have been reported to induce DMT-1 and inhibit IREG1 expression in 
activated monocytes (58, 59).  
2.3.2. Regulation of systemic iron homeostasis 
The levels of iron must be carefully controlled to avoid iron deficiency or iron overload 
that may cause pathological changes. Transfer of iron must be orchestrated to maintain 
homeostasis, particularly in cells that consume iron (primarily erythroid precursors) and cells 
that acquire and store iron (duodenal enterocytes, hepatocytes, tissue macrophages).  
2.3.2.1. Systemic iron regulators 
Intestinal iron absorption is known to be regulated in response to the ‘stores regulator’ 
and ‘erythroid regulator’ (see 2.2.1.1.). The stores regulator acts on a pathway that facilitates 
a slow accumulation of dietary iron. For the erythroid regulator, an increase in erythropoiesis 
alone is not enough to increase iron absorption. Rather, the imbalance between the rate of 
erythropoiesis of the marrow and its iron supply is thought to induce iron absorption.  
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Iron homeostasis is also altered in response to hypoxia, through a humoral ‘hypoxia 
regulator’. In addition, cellular iron retention occurs rapidly in the setting of infection and 
inflammation, presumably to withhold nutrients from invading pathogens. This can be 
considered an ‘inflammatory regulator’. These different regulators (erythroid, stores, hypoxia 
and inflammatory) need not be completely independent. Rather, they might represent 
quantitative differences in responses mediated by the same molecules. These regulatory 
effectors that modulate iron absorption or release of iron from tissue macrophages and 
hepatocytes are thought to be plasma proteins that might act at multiple sites (2).  
2.3.2.2. Hepcidin is an iron regulatory effector 
Hepcidin, an important regulatory gene in iron homeostasis, was first identified as a 
cysteine-rich antimicrobial peptide predominantly expressed in the liver (60, 61). The 
demonstration of the essential role of hepcidin in iron homeostasis and acute phase response 
has been elucidated through mouse and human genetics, biochemistry, and cell biology. 
Based on the studies of hepcidin-deficient mice which develop severe tissue iron overload, 
hepcidin has been proposed to inhibit intestinal iron absorption and to enhance iron retention 
in RE cells (Figure 2-7) (62). Conversely, in support of this proposed function of hepcidin, 
transgenic mice overexpressing hepcidin have been found to exhibit severe iron deficiency 
(63). Hepcidin expression increases when excess iron is administered (64), suggesting a 
compensatory response to limit intestinal absorption. The key role of hepcidin was later 
confirmed by the presence of homozygous nonsense mutations in patients with severe 
juvenile hemochromatosis (65). Together, these findings support hepcidin as a candidate for a 
soluble regulator that is able to communicate body iron status, coordinate different organs and 
tissues, such as liver, intestine, bone marrow and spleen macrophages, and modulate intestinal 
iron absorption.  
A schematic representation of hepcidin as an iron regulator in systemic iron homeostasis 
is shown in Figure 2-7. Increased hepcidin expression observed in iron-loaded animals (64), 
as well as in mice and human patients with inflammation (66-68), suggests that hepcidin 
contributes to the role of ‘stores regulator’ and ‘inflammatory regulator’, respectively. Down-
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regulated hepcidin expression observed in mice treated with erythropoietin, or under hypoxic 




















Figure 2-7. The role of hepcidin in the regulation of systemic iron homeostasis. Hepcidin 
is secreted by the liver. It diminishes iron release from reticuloendothelial macrophages and 
inhibits intestinal iron absorption. As a consequence, serum iron levels decrease. Hepcidin 
expression is regulated by iron levels, inflammatory stimuli, the erythroid iron demand and 
hypoxia. Recent data indicate that the former two responses require HFE function. (Diagram 
adapted from Ref.2.) 
 
It has been shown that the regulation of hepcidin transcription by the iron pathway 
requires HFE, hemojuvelin and probably TfR2 (70). The inflammatory pathway requires IL-6 
as an effective mediator of the response to lipopolysaccharide (LPS) and to induce hepcidin 
mRNA expression (66, 70, 71) (Figure 2-7). However, no molecular link has yet been found 
between the regulation of transcription of hepcidin by the erythroid and hypoxia pathways.  
 
2.4. Diseases related to impairment of iron homeostasis 
Dysfunction of several key molecules involved in iron homeostasis have been shown to 
result in either iron overload and iron deficiency in animal models, as well as in human iron 
disorders.  
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2.4.1. Iron disorder in animal models  
Historically, animal models have taken advantage of strong parallels between human and 
rodent iron metabolism. Over the past few years, genetic studies of patients with inherited 
iron homeostasis disorders and the characterization of genetically modified animal models 
have revealed numerous components of previously unknown transport and metabolic 
pathways (3). Table 2-1 summarizes the dysfunction of iron homeostasis-related genes in 
relation to iron disorder in animal models and human. 
 
Table 2-1. Informative mutations in important iron-homeostasis related genes in animal 
models for understanding iron biology and related iron disorders. 
Gene 
(mutation) 
Animal model Loss-of-function phenotype Analogous Human 
disease 
ALAS2 zebrafish: missense 
mutation 
Sideroblastic anemia with progressive iron 
overload in human disease 
X-linked sideroblastic 
anemia 
B2m B2m-/- Parenchymal iron deposition ND 




DMT1 mk (mice) and b (rat): 
missense mutation 
Severe iron deficiency anemia, impaired iron 
uptake in the duodenum and in erythroid 
precursors 
ND 
Frataxin Frda-/-; Frda-tissue 
specific k.o. 
Embryonic death in homozygotes,mitochondrial 
iron overload in tissue specific k.o. 
Friedreich's ataxia 
(FRDA) 
Haptoglobin Hp-/- Sensitive to acute hemolysis ND 
Heme 
oxygenase I  
Hmox1-/- Hemolytic anemia, low serum iron levels, tissue 
iron deposition 
Hmox1 deficiency 
Hemopexin Hx-/- Sensitive to acute hemolysis ND 
Hepcidin Usf2-/-: complete 
defect in hepcidin 
gene expression 
Hepatocellular iron deposition, decrease 
macrophage iron, elevated transferrin saturation 
HH Type IIB  
(OMIM 606464) 
Hephaestin sla (mice): deletion Sex-linked microcytic hypochromic anemia, 
impaired intestinal iron transfer 
ND 
HFE HFE-/- ; HFE (C282Y) Hepatocellular iron deposition, decrease 
macrophage iron, elevated transferrin saturation 
HH Type I  
(OMIM 235200)  
H-ferritin Fth-/-; Fth+/- Embryonic death in homozygotes, 
hyperferritinemia in heterozygotes 
ND 
IREG1 weh  (zebrafish): 
truncation 
Severe hypochromic anemia, poor viability HH Type IV 
(OMIM 604250) 
IRP2 IRP2-/- Iron deposition in enterocytes, neurons and 
oligodendrocytes 
ND 
TfR1 TfR1-/-; TfR1+/- Embryonic death with severe anemia in 
homozygotes, microcytic hypochromic 
erythrocytes, decreased iron stores in 
heterozygotes 
ND 
TfR2 TfR2 (Y245X): 
premature stop codon
Hepatocellular iron deposition, decrease 
macrophage iron, elevated transferrin saturation 
HH Type III  
(OMIM 604250)  
Transferrin hpx (mice): aberrant 
splicing 








2.4.2. Iron overload  
2.4.2.1. Hereditary hemochromatosis  (HH) 
Hereditary Hemochromatosis (HH) is an inherited disorder of iron metabolism in which 
there is excessive intestinal iron absorption relative to body iron stores. Over time the excess 
absorbed iron results in Tf saturation and iron deposition in parenchymal cells of several 
tissues, leading to tissue damage and organ failure (72).  
Type 1 HH is associated with the gene defects of HFE (Table 2-1) (73). The interaction of 
HFE with TfR1 requires beta-2-microglobulin (B2m) (74). This complex can competitively 
inhibit the binding of iron-loaded Tf to TfR1, suggesting that HFE is a negative regulator of 
TfR1 activity (75). Both HFE-/- and B2m-/- mice show similar HH-like phenotypes (76-78). 
Furthermore, the C282Y mutant found in HH patients affects the normal function of HFE by 
disrupting the interaction of HFE and B2m. These findings suggest the importance of the 
HFE-B2m association in the regulation of iron homeostasis (75, 79, 80). On the other hand, 
not all C282Y homozygote mutants show clinical evidence of iron overload suggesting that 
other genetic or environmental factors might affect the phenotypic expression of the mutation 
(81). 
Type 2 or juvenile hemochromatosis (JH) is a rare autosomal recessive disorder 
characterized by early onset, before the age of 30 years. JH is a heterogeneous genetic 
disorder related to at least 2 distinct loci. Type 2A, also known as 1q-linked juvenile 
hemochromatosis, is associated with gene mutation of HFE2 (or hemojuvelin) (Table 2-1) 
(82), whereas Type 2B is associated with hepcidin gene mutation (Table 2-1) (65).  
Several different mutations of TfR2 have been found in patients with Type 3 HH (Table 
2-1) (83-87). Recent studies strongly suggest that TfR2 might act as a sensor of iron status 
such that receptor levels reflect Tf saturation (88). Type 4 HH showing selective iron 
overload of Kupffer cells coupled with normal Tf saturation is due to the mutation of an iron 




2.4.2.2. Mitochondrial iron disorders 
Friedreich’s ataxia (FRDA) and sideroblastic anemia represent two diseases that highlight 
the importance of mitochondrial iron transport and homeostasis.  
FRDA gene encodes frataxin protein, which is localized in the mitochondria. Down-
regulation of frataxin results in iron accumulated being within mitochondria, leading to 
increased oxidative stress and decreased activity of iron-sulfur cluster-containing proteins (92, 
93). Recently, frataxin was found to have a similar structure to ferritin (94), suggesting that 
frataxin might mediate mitochondrial iron homeostasis by maintaining iron stores or 
facilitating their efficient turnover. 
Sideroblastic anemia is a disease that affects the efficiency of heme production within 
erythroblast mitochondria, leading to iron-overloaded mitochondria that form a characteristic 
ring around the cell nucleus. A reduction in the efficiency of ALAS2, a critical enzyme in the 
heme biosynthetic pathway, is associated with sideroblastic anemia.  
2.4.2.3. Aceruloplasminemia 
Aceruloplasminemia is an iron-overload disorder caused by gene mutations in the 
ceruloplasmin (Table 2-1) (95, 96). Ceruloplasmin is a serum ferroxidase that contains 95% 
of the copper found in the plasma. It is involved in catalyzing the oxidation of Fe(II) to 
Fe(III), and the peroxidation of Fe(II)-Tf to form Fe(III)-Tf. It has been shown that 
ceruloplasmin plays an essential physiological role in determining the rate of iron efflux from 
cells with mobilizable iron stores (97, 98). Without oxidase activity of ceruloplasmin, iron 
cannot be efficiently recycled from storage sites in the liver. Instead, iron accumulates in the 
parenchymal and RE cells of the liver and pancreas, hence leading to anemia because iron is 
not efficiently delivered to RBC precursors (97).  
2.4.2.4. Atransferrinemia 
Patients or animals suffering from atransferrinemia have iron overload and anemia (Table 
2-1) (99). Without Tf as an iron transporter, iron cannot be delivered to erythroid precursors, 
hence resulting in anemia (100). On the other hand, all non-hematopoietic tissues develop 
iron overload because of the combination of increased intestinal iron absorption and rapid 
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internalization of NTBI from the circulation. Iron accumulation in the absence of Tf indicates 
that dietary iron absorption is independent of the Tf cycle (101). 
2.4.2.5. Secondary hemochromatosis 
Patients develop iron overload due to prolonged excessive oral ingestion of iron or the 
repeated administration of blood transfusions as in the treatment of chronic, refractory 
anemia, occasionally termed secondary hemochromatosis. Iron from transfused erythrocytes 
that is deposit in the RE system in the liver, spleen, and bone marrow normally has little 
clinical significance. However, in patients who have received more than 40 units of blood, the 
RE system is typically saturated with iron, and additional iron deposits are seen in the 
parenchymal cells of the liver, pancreas, and heart. The abnormal parenchymal iron 
deposition can cause organ dysfunction, similar to that seen in primary hemochromatosis. 
Iron chelation therapy is used in patients who receive large numbers of transfusions to remove 
excess iron and prevent organ damage. 
2.4.3. Iron deficiency 
Iron deficiency anemia arising from inadequate dietary iron intake or excessive blood 
loss, is the most common nutritional anemia. Iron deficiency can also be caused by a rare 
inherited defect in iron absorption. The mutated genes that underlie this condition include 
DMT1, TfR1 and hephaestin are directly involved in the pathway of iron absorption. In the 
case of iron deficiency, the priority of erythroid precursors is to take up iron and produce 
RBCs. When the iron stores are depleted, erythropoiesis becomes iron-limited. 
2.4.4. Anemia of chronic disease 
Anemia of chronic disease (ACD; also called anemia of inflammation) is a common 
clinical manifestation that afflicts patients with a wide variety of inflammatory conditions 
including arthritis, malignancies, infections, and inflammatory bowel disease (102). 
Inflammation reduces duodenal iron absorption and increases macrophage iron retention, 
resulting in low serum iron concentrations (hyposideremia) to protect against proliferating 
microorganisms. At the same time this 'iron withholding' also reduces the iron available to 
maturing red blood cells and eventually contributes to the development of anemia.  
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 2.4.5. Iron and cancer 
Iron overload is suggested as a risk factor for cancer (103, 104). In general, it is believed 
that free cellular iron may play a role in cancer initiation through activation of reactive 
oxygen species (ROS) that can cause DNA mutations (105, 106). On the other hand, iron may 
be involved in cancer promotion because iron is a mandatory co-factor of ribonucleotide 
reductase, an enzyme which is essential for DNA synthesis during cell proliferation  (104).  
 
2.5. Iron and HCC  
2.5.1. Iron overload and HCC 
Iron overload is associated with the development of HCC (107). This notion comes from 
several observations. It is well documented that patients with HH are predisposed to HCC 
(108). There have also been reports of HCC arising from patients with secondary 
hemochromatosis in a non-cirrhotic liver (109, 110). Increased serum ferritin levels have been 
shown to elevate the risk of the HCC development in patients with chronic HBV infection 
(111). An increased risk of developing liver cancer has been reported in black Africans with 
iron overload in comparison to matched patients without iron overload, after correction for 
confounding risk factors (112). Furthermore, an increase in liver iron stores were found in the 
non-cirrhotic, non-cancerous liver tissues of HCC patients (113-115). It has been suggested 
that excess hepatic iron may facilitate the persistence of chronic hepatitis B and C viral 
infection which indirectly promote the development of HCC (112). However, the 
pathophysiological relationship between hepatic iron-overload and HCC remains unclear. 
2.5.2. Iron free foci and HCC 
It is suggested that tumor cells require a larger iron supply than normal cells due to a 
higher rate of proliferation. Paradoxically, one of the hallmarks of HCC is the relative paucity 
of iron accumulation in cancerous tissue compared with surrounding non-cancerous tissue. 
The depletion of iron is also found in pre-neoplastic lesions of HCC that are defined as iron-
free foci (116). They are frequently found in the liver of HH patients with HCC (117, 118) 
and chemically induced HCC in rats overloaded with iron (119). A ‘nodule-within-nodule’ 
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appearance on MR images in HCC patients reflects this unique histopathology of iron-free 
malignant foci within the iron-accumulative regenerative nodules (120). The iron-free foci are 
undoubtedly proliferative lesions regardless of iron depletion (117). However, to date, the 
underlying mechanism of this well-recognized histological anomaly of HCC is unresolved.  
 
2.6. Objective and approaches for studying iron homeostasis in HCC 
The pathophysiological relationship between iron overload and hepatocellular carcinoma 
(HCC) remains elusive. While screening and identifying differentially expressed genes 
specific for HCC, hepcidin was found to be the most significantly and consistently down-
regulated gene in cancerous tissues in comparison to paired non-cancerous liver tissues. Since 
hepcidin is a pivotal regulator of iron absorption in mammals, the question arises whether 
reduction of hepcidin expression is associated with hepatic iron overload in HCC. Using 
Affymetrix GeneChip analysis, we explored the expression of hepcidin in the context of the 
complex gene regulatory network of iron homoeostasis in HCC. We focused specifically on 
the genes that are directly involved in iron metabolism or have iron as an essential constituent. 
The expression profiling of genes involved in iron homoeostasis in conjunction with the 
pathological assessment of hepatic iron content in cancerous and non-cancerous tissues of 
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3.1. Mitochondria  
3.1.1 Mitochondrial function 
Mitochondria perform multiple cellular functions including heme synthesis, respiration, 
and the metabolism of carbohydrates, amino acids, fatty acids and nucleotides. Most 
importantly, mitochondria are considered the powerhouse of a cell because mitochondrial 
energy metabolism can produce up to 80% of the energy needs of a cell to grow, reproduce 
and survive (1). In addition to the main function of ATP synthesis through oxidative 
phosphorylation, recent studies also suggest that mitochondria play critical roles in generation 
of free radicals, and in regulation of apoptosis (2, 3). 
3.1.2. Mitochondrial structure 
The diagram of a mitochondrion is shown in Figure 3-1. Briefly, mitochondria contain an 
outer mitochondrial membrane (OMM) and an inner mitochondrial membrane (IMM) which 
are separated by intermembrane space. Within the space enclosed by IMM is the matrix. In 
order to increase the total surface area, IMM is highly convoluted to form a series of 
infoldings which is known as cristae (4).  
The OMM contains numerous channel-forming proteins called ‘porins’ which allow 
molecules smaller than 5,000 daltons to pass through and enter the intermembrane space. 
However, most proteins cannot get into the matrix unless they pass through the IMM. IMM is 
highly impermeable to small ions to ensure the maintenance of an electrochemical proton 
gradient generated by oxidative phosphorylation. In order to fuel the several important 
metabolic pathways in mitochondria, metabolites, nucleotides and cofactors have to be 
continuously transported between the cytoplasm and the matrix. Most of these transport steps 
are being handled by the mitochondrial carrier proteins (MCP) which are embedded in the 



































Figure 3-1. A schematic representation of a mitochondrion and important molecules 
localized at the OMM and IMM. The permeable OMM is regulated by porin. IMM contains 
ATP synthase, the complexes of the respiratory chain and mitochondrial carriers (transporters, 
translocase) which are responsible for transport of various metabolites, cofactors, nucleotides 
and protons into the matrix for several important metabolism including energy metabolism. 
Permeability transition pore (PTP) across the IMM and OMM has been shown to be a critical 
molecule in relation to mitochondria-dependent apoptosis. (Diagram adapted from Ref.6.) 
 
3.1.3. Mitochondrial genome 
A mammalian cell typically contains 103-104 copies of mitochondrial DNA (mtDNA). 
Although mtDNA represents less than 1% of total cellular DNA, its gene products are 
essential for normal cell function. The genome located in the matrix is a 16.5 kb closed-
circular, double-stranded DNA carrying 37 genes that encode two ribosomal RNAs (rRNAs) 
and 22 transfer RNAs (tRNAs) which are required for protein synthesis, as well as 13 
polypeptides that form the seven subunits of respiratory enzyme complex I, one subunit of 
complex III, three subunits of complex IV, and two subunits of complex V (1). 
 
3.2. Mitochondrial energy metabolism 
It has been known that after food consumption, the generated energy is stored in the high 
energy phosphate bonds of ATP. In general, there are two main pathways of ATP generation 
in the cell. The first pathway occurring in the cytoplasm is called glycolysis. Glycolysis 
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extracts energy only from glucose. The conversion of one molecule of glucose into two 
molecules of pyruvate requires no oxygen and only produces two molecules of ATP. In the 
presence of oxygen, a second pathway occurs within the matrix of the mitochondria known as 
the Krebs cycle or the tricarboxylic acid cycle (TCA cycle). The Krebs cycle is coupled to 
oxidative phosphorylation and produces the main source of ATP in aerobic organisms. A 


























Figure 3-2. Mitochondrial energy metabolism. During glycolysis, glucose converts to 
pyruvate, ATP and NADH in the cytoplasm. Pyruvate is then transported into the 
mitochondria and loses CO2 to form acetyl-CoA and NADH. When acetyl-CoA is oxidized to 
CO2 in the Krebs cycle, energy is released and captured in the form of NADH, FADH2, and 
ATP. The respiratory chain consists of complex I, II, III and IV. Ubiquinone (Q) shuttles 
electrons from complex I and II to complex III while cytochrome c (C) shuttles electrons from 
complex III to IV. NADH derived from glycolysis, the Krebs cycle and fatty acid oxidation 
are oxidized by complex I. FADH2 derived from the Krebs cycle (succinate) and fatty acid 
oxidation are oxidized by complex II. Electrons are transferred through the electron transport 
chain to the final acceptor, O2. Free energy released by the electron transfer is used for 
complexes I, III and IV to pump out H+ and generate an electrochemical gradient (ΔμH+) 
across the IMM. This gradient is the driving force for ATP synthesis by the FoF1-ATPase 
(ATP synthase). Alternatively, H+ can enter the mitochondria matrix by mechanism that are 
not coupled to ATP synthesis, i.e. leak across the lipid bilayer or UCP-mediated H+ transport, 





3.2.1. The role of Krebs cycle in energy production 
Pyruvate and fatty acids are selectively transported into the mitochondrial matrix, where 
they are broken down into acetyl-CoA and enters the Krebs cycle (Figure 3-2).  The Krebs 
cycle involves 8 distinct steps, each catalyzed by a unique enzyme. Each round of the Krebs 
cycle can generate two molecules of CO2, three molecules of reduced nicotinamide adenine 
dinucleotide (NADH), one molecule of reduced flavin adenine nucleotide (FADH2), and one 
molecule of GTP. The most important contribution of the Krebs cycle to energy metabolism 
is the extraction of high-energy electrons (hydrogen atom) that are transiently held by NADH 
and FADH2. When these electrons are used to reduce molecular oxygen to water, a large 
amount of free energy is liberated, which can be used to generate ATP (Figure 3-2).  
3.2.2. Oxidative phosphorylation 
Oxidative phosphorylation is the process in which ATP is formed as a result of the 
transfer of electrons from NADH or FADH2 to O2 by a series of electron carriers embedded in 
the IMM, as shown in Figure 3-2.  NADH forms a soluble pool of reducing equivalents in the 
mitochondrial matrix and passes on its electrons after a random collision with an electron-
transport chain (also known as respiratory chain) with three proton pumps including complex 
I, III and IV. Briefly, complex I (NADH dehydrogenase or NADH-ubiquinone reductase) 
transfers electrons from NADH to the mobile electron carrier ubiquinone (also known as 
coenzyme Q). Complex III (cytochrome bc1 complex or ubiquinone-cytochrome c reductase) 
is involved in the transfer of electrons from ubiquinone to oxidized cytochrome c, another 
mobile electron carrier located on the outer surface of the IMM. Complex IV (cytochrome c 
oxidase) is the terminal electron acceptor that functions in the transfer of electrons from 
reduced cytochrome c to molecular oxygen, to form H2O. On the other hand, FADH2 being 
part of the respiratory chain complex II (succinate-ubiquinone reductase or succinate 
dehydrogenase complex), an enzyme complex not pumping protons in the IMM, passes its 
electrons directly to the electron-transport chain. 
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These electron transfers release energy that is used to pump protons (the hydrogen 
nucleus, H+) from the mitochondrial matrix into the intermembrane space and thus generate 
an electrochemical proton gradient (ΔμH+, also known as proton-motive force) across the 
IMM (Figure 3-2). According to the chemiosmotic hypothesis, which was first proposed by 
Peter Mitchell in 1961 (for which he received the Nobel Prize in Chemistry in 1978), the 
proton-motive force is used to drive the protons back into the matrix through FoF1-ATP 
synthase (Complex V), a reversible proton pump to phosphorylate ADP to ATP (4, 8, 9). 
3.2.3. Proton leak 
It has been shown that mitochondria still consume oxygen when ADP phosphorylation is 
inhibited suggesting that the coupling of respiration to ATP synthesis is imperfect. Oxidative 
phosphorylation is never fully coupled either in isolated mitochondria or in mitochondria in 
their natural intracellular environment (10). The electrochemical proton gradient can be 
dissipated by ‘proton leak’, whereby protons are able to move back into the matrix through 
endogenous proton conductance pathways in the IMM that circumvent the ATP synthase 
(Figure 3-2) (10-12). Proton leak can be catalyzed by multiple factors, such as 
carbonylcyanide-m-chlorophenylhydrazone (CCCP), a classical uncoupler of oxidative 
phosphorylation (13, 14), fatty acids (15) and the uncoupling protein 1 (UCP1) of brown 
adipose tissue (12, 16).  
The proton leak has functional roles beneficial to organisms. It is suggested to account for 
a significant part of an animal’s basal metabolic rate, or known as standard metabolic rate 
(SMR). In terms of physiology, uncoupling of respiration and dissipation of energy as heat 
are obviously important for energy balance and body weight control. Moreover, it was 
proposed that mild uncoupling of respiration could prevent the accumulation of oxygen 
radicals generated by mitochondria and increase the sensitivity and rate of response of 
oxidative phosphorylation to effectors (17). Another role for uncoupling of respiration is to 
control the NAD+/NADH ratio and regulate metabolic pathways such as ketogenesis, 
lipogenesis and amino acid synthesis, which are dependent on the levels of these coenzymes.  
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 3.2.4. Mitochondrial membrane potential  
The mitochondrial membrane potential (ΔΨm) arises from the net movement of positive 
charge across the IMM, reflecting the balance between processes that contribute to the 
generation of the proton gradient and those that consume it (4). It has been suggested that the 
optimal ΔΨm value for the synthesis of ATP by ATP synthase in vivo is at 100-140mV (18). 
Low ATP/ADP ratio decrease the ΔΨm, conversely, high ATP/ADP ratio increase it (18).  
Furthermore, it has been observed that mitochondria with a high ΔΨm value above 140mV 
would result in an exponential increase of ROS production and membrane proton 
permeability (18). 
3.3. Mitochondrial carrier proteins 
3.3.1. Biological functions and conserved structure 
Mitochondrial carrier proteins (MCP) located in the IMM are responsible for the transport 
of various metabolites, nucleotides and cofactors into and out of the matrix (Figure 3-2). The 
main carriers for import of reducing equivalents or substrates for oxidative phosphorylation in 
the matrix comprise of pyruvate carrier, carnitine carrier, oxoglutarate carrier, and 
aspartate/glutamate carrier (19). Most importantly, the ADP/ATP carrier and phosphate 
carrier are involved in oxidative phosphorylation. Other carriers are tissue specific and have 
special functions, e.g. dicarboxylate carrier involved in gluconeogenesis and citrate carrier 
involved in fatty acid and lipid synthesis (19).  Furthermore, UCP1, the molecule involved in 
proton leak is a H+ carrier. 
The MCP family members have similar molecular mass of ~30 kDa and related primary 
structures. Structurally, they consist of three highly conserved homologous tandem repeats of 
a domain of ~100 aa. Each of these domains contains two anti-parallel transmembrane 
hydrophobic α-helices joined by an extensive hydrophilic extra-membrane loop (Figure 3-3) 
(19). The conserved sequence of mitochondria carrier motif is: 
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GX3GX8PX(D/E)X(I/L/V)(K/R)X(R/K)XQX20-30GX4(Y/W)(R/K)GX9P (20). It is generally 
accepted that the MCP family are evolved from a common ancestor of ~100aa because the 
conserved three tandemly related sequences of ~100aa were found in Drosophila, C.elegans, 












Figure 3-3. Predicted topological 
model of mitochondrial carrier 
protein. The model is based on the 
hydrophobic profile of the carrier 
protein. The protein contains three 
highly conserved homologous tandem 
repeats of ~100 aa domain (denoted as 
A, B and C). The six transmembrane 
α-helices (I-VI) are hydrophobic 
segments that are connected by 






3.3.2. Uncoupling protein 
Uncoupling proteins (UCPs) are proteins that can lower the proton gradient and ATP 
production of the mitochondria (21). To date, five different uncoupling proteins have been 
identified in human, namely UCP1, UCP2, UCP3, UCP4 and UCP5/BMCP1, with different 
tissue distribution (22, 23). The functions of uncoupling proteins have been proposed as ROS-
activated mild uncouplers to protect cells from oxidative stress. The function of UCP1 in 
energy metabolism was originally described to be mediation of non-shivering thermogenesis 
in brown adipose through short-circuit of H+ generated by the respiratory chain, thus 
converting most of the oxidative energy into heat instead of ATP (24). Mice lacking UCP2 or 
UCP3 show signs of oxidative stress, suggesting a role for these proteins in decreasing the 
production of ROS (25, 26). 
Although hepatocyte mitochondria show a typical uncoupling of oxidative 
phosphorylation, yet there has been no report on the identification of a putative UCP in 
mammalian hepatocytes.  Several observations suggest that UCPs are either not present or 
present at very low levels in normal mammalian hepatocytes (27). 
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3.4. Mitochondria and cell damage 
3.4.1. Generation of ROS in mitochondria 
Mitochondrial electron transport is the major endogenous source of ROS in the cell (28). 
Respiratory chain complex I and III are shown to be responsible for much of the superoxide 
anion radicals generated by mitochondria (Figure 3-4). The yield of superoxide generation 
and subsequently ROS production depend mostly on oxygen concentration but can be 
efficiently modulated by UCPs through mitochondrial uncoupling. It has been estimated that 
more than 1% of the oxygen consumed by cells is converted to ROS under physiological 
conditions. However, a cascade of enzymes, including superoxide dismutase (SOD) and 
glutathione peroxidase (GPX-1), can scavenge superoxide anions and hydrogen peroxide, 

























Figure 3-4. The generation of ROS by mitochondria. Superoxide (O2-) produced at either 
complex I or complex III of the respiratory chain appears at both faces of the IMM. If 
produced in the intermembrane space, it is processed to hydrogen peroxide (H2O2) by 
CuZnSOD, if in the matrix, by MnSOD. Removal of the H2O2 in both compartments is 
achieved by glutathione peroxidase (GPX-1). The formation of hydroxyl radicals (OH-) from 
H2O2 can proceed by the Fenton reaction in the presence of free iron or copper ions that act as 
catalysts. The OH- then can damage lipids, proteins or DNA, particularly mtDNA. 
Alternatively, damage to telomeres in the nucleus can have an accelerating effect on ageing 
by increasing the shortening of telomeric DNA that occurs per unit of cell division. (Diagram 
taken from Ref.28.) 
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The accumulation of mutations in mtDNA is approximately 10 fold greater than that in 
nuclear DNA because mtDNA is exposed to high levels of ROS generated by oxidative 
phosphorylation (29, 30, 31). When mitochondria become dysfunctional due to mutation in 
the mtDNA, it may promote leakage of electrons from the mitochondrial electron transport 
chain, resulting in increased production of ROS and increased oxidative stress (32). These 
ROS can influence the ageing process through mechanisms involving mutagenesis of mtDNA 
or increase rates of shortening of telomeric DNA (Figure 3-4) (28). 
 
3.4.2. Mitochondria and cell death 
Cell death can proceed through at least two distinct pathways. Apoptosis is an energy-
dependent process characterized morphologically by cell shrinkage, whereas oncosis is a form 
of cell death induced by energy depletion and initially characterized by cell swelling. Oncosis 
and apoptosis refer to processes leading to cell death, whereas necrosis refers to those 
processes of cellular degradation that follow cell death. Because the mitochondrial generation 
of ATP requires the presence of an electrochemical gradient, a reduction in mitochondrial 
membrane potential may precede the morphologic changes seen in apoptotic and oncotic cell 
death (33). 
3.4.2.1. Mitochondrial permeability transition pore (PTP) and apoptosis 
Recently, many reports have focused on mitochondria as an important player in apoptosis 
(34-36). In general, mitochondrial membrane permeabilization is a near-universal hallmark 
and a critical step of several apoptotic pathways (37). The ΔΨm collapses in many apoptosis 
scenarios indicating the opening of mitochondrial permeability transition pore (PTP). PTP is a 
large conductance channel that is composed of multiple proteins including hexokinase, 
creatine kinase, voltage-dependant anion channel (VDAC), adenine nucleotide translocator 
(ANT) and the peripheral benzodiazepine receptor in the OMM and IMM, as well as 
cyclophilin D in the mitochondrial matrix (3). The PTP is permeable to solutes with a 
molecular mass of ~1,500 daltons and functions as a Ca++-, voltage-, pH- and redox-gated 











Figure 3-5. PTP opening mediates the release of cytochrome c from mitochondria 
during apoptosis. The OMM ruptures as a result of swelling of the mitochondrial matrix, 
allowing cytochrome c and other proteins to escape from the intermembrane space. The PTP 
opens and then the IMM permeability increases, causing mitochondrial-matrix swelling. Bax 
might induce this PTP to open by binding to the ANT at the contact sites between the IMM 
and OMM after translocation to the IMM. (Picture adapted from Ref.38.) 
 
 
It has been shown that the opening of PTP will result in a volume dysregulation of 
mitochondria due to the hyperosmolarity of the matrix, which causes the matrix space to 
expand. Because the IMM with its folded cristae possesses a larger surface area than the outer 
membrane, this matrix volume expansion can eventually cause OMM rupture, releasing 
caspase-activating proteins located within the intermembrane space into the cytosol, such as 
cytochrome c and apoptosis inducing factor (AIF) (Figure 3-5) (38). The redistribution of 
cytochrome c is an important step in initiating the effector caspase activation. Inhibitors of 
PTP opening, including cyclosporin A (which bind cyclophilin D, associated with the ANT) 
and bongkrekic acid (which also inhibits the ANT), appear to block apoptosis in some 
systems, thus providing support for the idea that the PTP is central to apoptotic processes (3). 
 
3.4.2.2. Loss of mitochondrial membrane potential and oncosis
In oncosis, cellular energy depletion following metabolic insults such as severe ischemia 
produces dramatic reductions in mitochondrial respiration and ATP synthesis, resulting in a 
loss of ionic homeostasis and cellular swelling (39). It has been demonstrated that cells 
subjected to ATP reduction between approximately 25 and 70% of control cells all died by 
apoptosis (40, 41). In contrast, cells subjected to ATP depletion below approximately 15% of 




3.5. Liver energy metabolism 
3.5.1. Energy metabolism in the normal liver 
The liver is a major contributor to whole animal energy expenditure and rapidly changes 
weight in response to energy restriction (42). It has been shown that the mitochondrial 
biogenesis and function of the liver change abruptly at birth, resulting in a switch from fetal 
glycolysis to postnatal oxidative phosphorylation (43, 44). These alterations in mitochondrial 
function could result from changes in proton conductivity of the IMM. On the other hand, 
proton leak is shown to responsible for ~25% of oxygen consumption of resting isolated liver 
cells (10). However, the underlying mechanism is still unresolved. 
3.5.2. Energy metabolism in the regeneration liver  
It is speculated that ATP is consumed for active biosynthesis of components such as DNA 
and protein during liver regeneration. As a result, an increased demand for energy was 
observed after major hepatectomy in rabbit liver through an increase in the rate of 
mitochondrial respiration (45-47). The ability to maintain an increased rate of mitochondrial 
oxidative phosphorylation and glycolysis under aerobic conditions is thought to be important 
for rapidly growing regenerating liver, as well as in liver cancer. 
 
3.6. Dysfunction of mitochondria and cancer development  
3.6.1. Mitochondrial abnormality in cancer cells 
Most remarkably, the glycolytic phenotype has been demonstrated in many cancer cells 
(48). Otto Warburg (the winner of the Nobel Prize for medicine in 1931 for elucidating the 
chemistry of cell respiration) observed that cancer cells have lower respiration rates and 
produce excess lactic acid compared with normal cells. He hypothesized that the glycolytic 
phenotype of cancer was caused by an insufficient supply of oxygen (49). Consistent with the 
observation, hexokinase, an enzyme catalyzing the first step in the anaerobic glycolytic 
pathway, was overexpressed significantly in malignant cancer cells compared with normal 
cells (50). In addition, the impairment of mitochondrial function within the cancer cells could 
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also be a cause of compensatory increases in glycolytic ATP production. A number of 
mitochondrial defects have been proposed to contribute to the development and progression 
of various cancer types (51-53). These defects comprise altered gene expression and activity 
of respiratory chain subunits and glycolytic enzymes, as well as the decreased oxidation of 
NADH-linked substrates (1, 51-54). The mitochondrial dysfunction appears to be associated 
with the mtDNA mutation (55). The types of mutations observed in mtDNA range from point 
mutations, to deletions and duplications. Indeed, mutated mtDNA in tumor cells is reported to 
be 220 times as abundant as a mutated nuclear marker (56). 
3.6.2. Mitochondrial abnormality in  HCC
Similar to other cancer cell types, the activity of type II hexokinase in the glycolytic 
pathway was elevated in hepatoma cells when compared with normal cells (57). Furthermore, 
mitochondria isolated from cancerous tissue of HCC patients have decreased rates of 
respiration-linked ATP synthesis and a reduction of phosphorylative capacity compared to 
that found in normal liver (54, 58, 59). Furthermore, the impairment of mitochondrial 
biogenesis is accompanied by the reduced amount of the organelles themselves in malignant 
human hepatocytes (44). 
3.6.3. Elevated mitochondrial membrane potential in cancer cells 
In the early 1980s, Chen and co-workers (60-64) discovered that relative to the 
mitochondria in normal cells, those in cancer cells displayed a greater uptake and retention of 
Rhodamine 123, a ΔΨm-dependent staining dye, suggesting that cancer cells generate higher 
ΔΨm compared with normal cells (60-63). This is in agreement with a later report showing 
that ΔΨm of carcinoma cells is ~60mV higher than that of control epithelial cells (65). It has 
been shown that the differences in mitochondrial respiratory enzyme complexes, electron 
carriers, ATP synthase, and membrane lipid structure that affect electron transfer activity, are 
candidates for the molecular basis for increased ΔΨm in carcinoma cells (1). However, to 
date, the underlying mechanism is unresolved.   
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It is noteworthy that the inherent differences in the ΔΨm between malignant epithelial 
cells and normal cells result in the selective accumulation of rhodacyanine dyes and 
delocalized lipophilic cations (DLC) in the mitochondria of malignant cells (63-66). Certain 
DLCs used in photodynamic therapy (PDT) respond to localized photoirradiation and convert 
to a more reactive and highly toxic species, hence enhancing the selective toxicity to 
carcinoma cells and providing a means of highly specific tumor cell killing without injury to 
surrounding healthy tissues.  
 
3.7. Objective and approaches for identifying a novel liver-specific 
uncoupling protein 
The liver is a major contributor to energy expenditure. It is known that up to 25% of 
oxygen consumption is used to drive the proton leak in resting hepatocytes (10). Yet there has 
been no report on the identification of a putative molecule that mediates the uncoupling of 
oxidative phosphorylation in normal mammalian hepatocytes. While screening for 
differentially expressed genes in HCC, C78 was found to be the most significantly and 
consistently down-regulated novel cDNA fragment in the cancerous tissue compared with 
paired non-cancerous liver tissue. The cloning and characterization of this novel gene 
revealed that it bears all the hallmark features of the mitochondrial carrier proteins. 
Furthermore, the specific expression in the liver tissue and its ability to induce the potent 
dissipation of ΔΨm have prompted us to suggest that it might be one of the long-postulated 
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4.1. Tissue specimens  
Paired samples of cancerous and non-cancerous liver tissues of a total of 52 patients 
undergoing partial hepatectomy as treatment for HCC, as well as 20 non-cancerous liver 
tissues resected from the tumor mass of metastatic colorectal adenocarcinoma (referred as 
normal liver control) were retrieved from the National Cancer Centre Tissue Repository. 
Resected tissue was immediately snap-frozen in liquid nitrogen. All samples were collected 
with written informed consent from the patients. Among the 52 pairs of HCC samples, 18 
were randomly selected for spotted array analysis, 7 for real time RT-PCR analysis and 27 for 
Affymetrix analysis and iron staining. 
 
4.2. Cell lines 
HepG2, Hep3B, WRL68, SNU-182, SNU-398, SNU-449 and SKHep1 were obtained 
from the American Type Culture Collections. HuH7, HLE, PCL/PRL/5 and HuH6, clone 5 
(HuH6-C5) were obtained from the Japanese Cancer Research Resources Bank. CNE-2 (a 
nasopharyngeal carcinoma cell line) was obtained from Prof. H.M.Wang (Cancer Institute, 
Sun Yat-Sen University of Medical Sciences, Guangzhou, People’s Republic of China). 
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Human embryonic kidney (HEK) 293T cell line was obtained from Dr. Paula Lam (National 
Cancer Centre, Singapore). 
 
4.3. Primers 
4.3.1. RT primers for cDNA synthesis in library construction  
NotI primer-adapter: 5’-GACTAGTTCTAGATCGCGAGCGGCCGCCC(dT)15-3’ 
(Underlined sequence is NotI site) 
 
4.3.2. Primers for amplifying or sequencing the cDNA inserts in pSPORT vector  
SP6: 5’-ATTTAGGTGACACTATAG-3’  
T7: 5’-TAATACGACTCACTATAGGG-5’  
(PCR annealing tempt: 48 oC) 
        
4.3.3. Primers for amplifying or sequencing the cDNA inserts in pCR2.1TOPO  
M13F: 5’-GTAAAACGACGGCCAG-3’ 
M13R: 5’-CAGGAAACAGCTATGAC-3’ 
(PCR annealing tempt: 48 oC) 
 
4.3.4. DNA capture sequence (two-step 3DNATM expression array detection kit) 
Cy3TMRT primer capture:5’-GGCCGACTCACTGCGCGTCTTCTGTCCCGCC-3’             
Cy5TMRT primer capture: 5’-CCTGTTGCTCTATTTCCCGTGCCGCTCCGGT-3’  
 
4.3.5. RT primers for cDNA synthesis in Affymetrix system, HPLC purified 
T7-oligo(dT): 5’-GGCCAGTGAATTGTAATACGACTCACTATAGGGAGGCGG(dT)24-3’ 
 
4.3.6. Primers specific for 18S rRNA (real-time PCR)  
18sRNA-F: 5’-CCTGCGGCTTAATTTGACTC-3’ 
18sRNA-R: 5’-CGCTGAGCCAGTCAGTGTAG-3’ 
(PCR annealing tempt: 55 oC; product size: 318 bp) 
 
4.3.7. Primers specific for hepcidin (real-time RT-PCR) 
Prohep-F: 5’-CCTGACCAGTGGCTCTGTTT-3’ 
Prohep-R: 5’-TGGGGCAGCAGGAATAAATA-3’ 
(PCR annealing tempt: 55 oC; product size: 251 bp) 
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4.3.8. Primers specific for C78 (real-time RT-PCR) 
C78RT-F: 5’-TTCACGAGCTGTCCCTTACAGGCA-3’ 
C78-R: 5’-GGGTCTTTAAGTGGCAGGTG-3’ 
(PCR annealing tempt: 55 oC; product size: 268 bp) 
 
4.3.9. Primers specific for beta-actin (probe generated for northern blot analysis) 
B-actin-F: 5’-GTGATGGTGGGCATGGGTCA-3’ 
B-actin-R: 5’-TTAATGTCACGCACGATTTCCC-3’ 
(PCR annealing tempt: 55 oC; product size: 510 bp) 
 
4.3.10. Primers designed for GeneScan predicted C78 
C78-F: 5’-GTGTCCGTGGTATCTTCCGTGTCT-3’ 
C78-R: 5’-GGGTCTTTAAGTGGCAGGTG-3’ 
(PCR annealing tempt: 55 oC; product size: 1477 bp) 
 
4.3.11. Primer for sequencing predicted C78 
C78-MR: 5’-ACACACCTGACTCCCTGGAG-3’ 
 
4.3.12. 5’RACE Adapter  (FirstChoice TM RLM-RACE kit) 
5’RACE Adapter: 5’-GCUGAUGGCGAUGAAUGAACACUGCGUUUGCUGGCUUU  
                                     GAUGAAA-3’ 
 
4.3.13. Primers for 5’RACE of C78 
5’RACE outer primer: 5’-GCTGATGGCGATGAATGAACACTG-3’ 
C78RC-OR: 5’-TCAGTGGGCGACGTCAGGAACAC-3’ 
(1st PCR: PCR annealing tempt: 55 oC) 
 
5’RACE inner primer: 5’-CGCGGATCCGAACACTGCGTTTGCTGGCTTTGATG-3’ 
C78RC-IR: 5’-AAGACACGGAAGATACCAGGGACAC-3’ 
(2nd PCR: PCR annealing tempt: 55 oC) 
 
4.3.14. Primers for generating HDMCP-FLAG fusion protein 
HDMCP-F: 5’-TTCATGGATTTTGTCGCTGGAGC-3’ 
HDMCP-R: 5’-ACCTCAACGCTCTCATCAA-3’ 






(FLAG sequence is underlined.) 




(FLAG sequence is underlined, stop codon is bold.) 
(3rd PCR: PCR annealing tempt: 42 oC for 5 cycles and 56 oC for 25 cycles) 
 
4.3.15. Primers for generating UCP2-FLAG fusion protein 
UCP2-F: 5’-ATCATGGTTGGGTTCAAGGCCACAGAT-3’ 
UCP2-FLGR: 5’-GTCGTCATCCTTGTAATCGAAGGGAGCCTCTCGGGA-3’ 
(FLAG sequence is underlined.) 




(FLAG sequence is underlined, stop codon is bold.) 
 (2nd PCR: PCR annealing tempt: 42 oC for 5 cycles and 62 oC for 25 cycles) 
 
4.3.16. Primer for synthesizing full-length of rat HDMCP 
RatMCP-F: 5’- CAGCAAGACCAGAGCCCTTC-3’ 
RatMCP-R: 5’- AGCAAGCACAGAAACATTTATTAACAG-3’ 
(PCR annealing tempt: 55 oC; product size: 1550 bp) 
 
4.3.17. Primer for sequencing of rat HDMCP 
RatMCP-IF: 5’- GCCAGATGTCCTAGGTGTGC -3’ 
RatMCP-IR: 5’- AGTTGAGTGCCAGTCCCTTG-3’ 
 
 
4.4. Plasmid vectors 
4.4.1 pSPORT1: for subtractive libraries construction (see Chapter 5.2.1). 
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4.4.2 pCR2.1-TOPO: TA cloning vector system (see Chapter 5.1.8). 
 




4.5.1. anti-FLAG M2 mAb, mouse IgG1, 2 mg/ml (Strategene, P/N 200472) 
 
4.5.2. anti-FLAG pAb, rabbit IgG, 0.8 mg/ml (Sigma, P/N F7425) 
 
4.5.3. mitochondria Ab-2, Clone MTC02, 200 μg/ml (NeoMarkers, P/N MS-1372-P0) 
 
4.5.4. anti-cytochrome c mAb, Clone6H2.B4, 1 mg/ml (Promega, P/N G7421) 
 
4.5.5.  Alexa Fluor 488 goat anti-mouse IgG, 2 mg/ml (Molecular Probes, P/N A-11001) 
 
4.5.6.  Alexa Fluor 546 goat anti-mouse IgG, highly cross-adsorbed, 2 mg/ml (Molecular 
Probes, P/N A-11030) 
 
4.5.7.  Alexa Fluor 633 goat anti-mouse IgG, 2 mg/ml (Molecular Probes, P/N A-21050) 
 
4.5.8.  Alexa Fluor 488 goat anti-rabbit IgG, 2 mg/ml (Molecular Probes, P/N A-11008) 
 
 
4.6. General buffer Preparation 
4.6.1. phosphate buffered saline (PBS)  (137 mM NaCl, 2.7 mM KCl, 4.3 mM Na2HPO4, 
1.4 mM KH2PO4, pH 7.4) 
 
4.6.2. DEPC treated water (0.1% DEPC (Sigma, P/N D5758) in dH2O, still overnight and 
autoclave) 
 
4.6.3. TE buffer (10 mM Tris-HCl, pH 8.0, 1 mM EDTA, pH 8.0) 
 
4.6.4. 20x SSPE (3 M NaCl, 0.2 M NaH2PO4, 0.02 M EDTA, adjust pH to 7.4) 
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4.6.5. 20x SSC (3 M NaCl, 0.3 M trisodium citrate, adjust pH to 7.0) 
 




4.6.7. SOC media (2% bactotryptone, 0.5% yeast extract, 10 mM NaCl, 2.5 mM KCl, 10 
mM MgCl2, 10 mM MgSO4, 20 mM glucose) 
 
4.6.8. TfbI buffer (for competent cells preparation) (30 mM KOAc, 100mM Rubidium 
Chloride (RuCl), 10 mM CaCl2⋅2H2O, 50 mM MnCl2⋅4H2O, 15% (v/v) glycerol, 
adjust pH to 5.8 with diluted acetic acid.) 
 
4.6.9. TfbII buffer (for competent cells preparation) (10 mM MOPS, 75 mM 
CaCl2⋅2H2O, 10 mM RuCl, 15% (v/v) glycerol, adjust pH to 6.5 with diluted NaOH) 
 
 
4.7. Buffers used in Affymetrix system 
4.7.1. 5x fragmentation buffer (200 mM Tris-acetate, pH 8.1, 500 mM KOAc, 150 mM 
MgOAc) 
 
4.7.2. 12x MES Stock buffer (1.22 M MES, 0.89 M [Na+]) 
70.4 g  MES free acid monohydrate (Sigma, P/N M5287) 
193.3 g  MES sodium salt (Sigma, P/N M5057) 
800 ml  dH2O 
Mix and adjust volume to 1000 ml. The pH should be adjusted between 6.5 and 6.7. Filter 
through 0.2 μm filter. Stored at 4 oC, and shield from light. 
 
4.7.3. 2x Hybridization buffer (200 mM MES, 2M [Na+], 40 mM EDTA, 0.02% Tween 
20) 
8.3 ml 12x MES stock buffer 
17.7 ml  5 M NaCl 
4 ml  0.5 M EDTA 
0.1 ml 10% Tween 20 (Pierce Chemical, P/N 28320) 
19.9 ml dH2O 
Filter through 0.2 μm filter. Stored at 4 oC, and shield from light.  
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4.7.4. 2x Stain buffer (200 mM MES, 2 M [Na+], 0.1% Tween 20) 
41.7 ml 12x MES stock buffer 
92.5 ml  5 M NaCl 
2.5 ml 10% Tween 20 
113.3 ml dH2O 
Filter through 0.2 μm filter. Stored at 4 oC, shield from light.  
 
4.7.5. Streptavidin phycoerythrin (SAPE) solution (1x MES, 2 mg/ml acetylated BSA, 
10 μg/ml SAPE) 
600 μl 2x Stain buffer 
48 μl  50 mg/ml acetylated BSA 
12 μl  1 mg/ml R-Phycoerythrin streptavidin (Molecular Probes, P/N S-866) 
540 μl dH2O 
 
4.7.6. Biotinylatd anti-streptavidin IgG solution (1x MES, 2 mg/ml acetylated BSA, 100 
μg/ml normal goat IgG, 3 μg/ml biotinylated anti-streptavidin IgG) 
300 μl 2x Stain buffer 
24 μl  50 mg/ml acetylated BSA 
6 μl  10 mg/ml normal goat IgG (Sigma, P/N I5256) 
3.6 μl  0.5 mg/ml biotinylated anti-streptavidin IgG (Vector Laboratories, P/N BA-
0500) 
266.4 μl dH2O 
 
4.7.8. Wash A (Non-stringent wash buffer) (6x SSPE, 0.01% Tween 20) 
 
4.7.9. Wash B (Stringent wash buffer) (100 mM MES, 0.1 M [Na+], 0.01% Tween 20) 
83.3 ml 12x MES stock buffer 
5.2 ml 5 M NaCl 
1 ml  10% Tween 20 
910.5 ml dH2O 
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5.1. General protocols 
5.1.1. Cell culture
All cell lines were maintained in Dulbecco’s modified Eagle’s medium (DMEM) 
(GIBCO) supplemented with 10% heat-inactivated fetal bovine serum (Hyclone, P/N 
SH30088.03), 100 U/ml penicillin, 100 μg/ml streptomycin, 2 mM L-glutamine, 0.1 mM non-
essential amino acid (GIBCO) and 1 mM sodium pyruvate (GIBCO) in a 37 oC humidified 
incubator with 5% CO2. For long term storage of cell stock, ~106 cells were resuspended in 
cryovials in 0.5 ml culture media containing 10% DMSO (Sigma, P/N D2650), kept overnight 
at –80 oC and then transferred to liquid nitrogen. 
5.1.2. RNA isolation  
Frozen tissue samples or cell pellets were homogenized in 1 ml TRIzol reagent 
(Invitrogen, P/N 15596-018). After homogenization, another 0.5 ml of TRIzol reagent and 0.3 
ml of chloroform: isoamyl alcohol (24: 1) were added and vortexed vigorously for 1 min. The 
mixture was incubated at room temperature (RT) for 10 min and then centrifuged at 13,000 
rpm for 10 min at 4 oC. The aqueous phase was extracted twice with an equal volume of acid 
phenol: chloroform: isoamyl alcohol (50: 24: 1) and once with chloroform: isoamyl alcohol 
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(24: 1). RNA was precipitated by mixing the aqueous phase with an equal volume of 
isopropanol, incubation at RT for 10 min and centrifugation at 13,000 rpm for 10 min at 4 oC. 
The RNA pellet was then rinsed with 75% ethanol, air dried and resuspended in DEPC dH2O.  
5.1.3. mRNA isolation  
mRNA isolation was performed using Poly(A) PureTM RNA isolation kits (Ambion, P/N 
1915) according to the manufacturer’s instructions. 2 mg of total RNA was mixed with 1/10 
volume of 5 M NaCl and then further diluted in binding buffer (high salt) to a final volume of 
4 ml in a 15 ml conical tube. The mixture was denatured at 65 oC for 5 min, chilled on ice for 
1 min and then mixed with one pre-packaged vial of 100 mg oligo-dT cellulose with 
continuous rocking for 60 min at RT. After this, the cellulose was washed three times with 10 
ml of binding buffer and twice with 10 ml of wash buffer (low salt) at RT. The cellulose was 
then resuspended in 0.6 ml of wash buffer before it was transferred to a spin column and 
washed three times with wash buffer. mRNA was eluted with 65 oC pre-warmed elution 
buffer (10 mM Tris, pH 7.5, 1 mM EDTA) and precipitated with 2.5 volumes of absolute 
ethanol, 1/10 volume of 5 M ammonium acetate and 2 μl of glycogen (Ambion, P/N 9510) 
overnight at –20 oC.  
5.1.4. Quantitation of isolated RNA and mRNA  
Total RNA concentration was determined using spectrophotometric measurement (one 
absorbance unit at 260 nm is equivalent to 40 μg/ml RNA). mRNA quantitation was 
determined by Ethidium Bromide (EtBr) Spot Assay. A standard curve was generated by 
serial dilution of total RNA to concentrations of 80, 40, 20, 10, 5, 2.5 and 1.25 ng/μl. For 
isolated mRNA, a 2x serial dilution was done for at least four points. All diluted samples 
were mixed independently with an equal amount of 2 ng/μl EtBr. 2 μl of the mRNA-EtBr 
solution was spotted onto a saran wrap. The signal intensities of each spot were monitored 
using Gel doc 1000 (Bio-Rad). The relative concentration of mRNA was determined by 
comparing signal intensities to that of the standard curve. 
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5.1.5. Reverse transcription  
5 μg of total RNA in 9 μl of DEPC dH2O was mixed with 2 μl of 50 ng/μl random 
hexamer (Invitrogen, P/N 48190-011), and 1 μl of 500 ng/μl oligo-dT12-18 (Invitrogen, P/N 
18418-012) and incubated at 70 oC for 10 min, followed by chilling on ice. The denatured 
RNA was mixed with 1 μl of 10 mM dNTP (Promega, P/N U1240), 2 μl of 0.1 M DTT, 4 μl 
of 5x cDNA synthesis buffer and 1 μl of SuperScript II reverse transcriptase (200 U/μl) 
(Invitrogen, P/N 18064-014). The reverse transcription reaction was carried out at 25 oC for 
10 min, followed by incubating at 42 oC for 1.5 h and then 80 oC for 10 min. cDNA was 
diluted with dH2O to 80 μl and used as template for conventional PCR or real-time PCR. On 
the other hand, ThermoScript reverse transcriptase (15 U/μl) (Invitrogen, P/N 11146-024) was 
used for cloning full-length cDNA transcripts because it has greater thermal stability. Reverse 
transcription was similar to the protocol mentioned above except that the cDNA synthesis 
temperature was raised to 50 oC.  
5.1.6. Polymerase chain reaction (PCR) 
Both cDNA and denatured bacteria clones can be used as PCR templates. PCR was 
performed in a 20-100 μl reaction mixture containing 1x PCR reaction buffer, 1.5 mM MgCl2, 
50 μM dNTP, 0.25 μM of primer mix and 1-5 U of Taq polymerase (5 U/μl) (Promega, P/N 
M1665). The cycle profile of PCR was as follows: denaturation at 94 oC for 3 min, annealing 
at 48-65 oC for 1.5 min, and extension at 72 oC for 2 min, then followed by 30 cycles of 
denaturation at 94 oC for 1 min, 48-65 oC for 1 min and 72 oC for 1 min and a final extension 
at 72 oC for 10 min.  
The Platinum Pfx DNA polymerase (2.5 U/μl) (Invitrogen, P/N 11708-021) was used for 
PCR expression cloning. A 50 μl PCR reaction mixture contained template DNA, 1x Pfx 
amplification buffer, 1x Enchancer solution, 0.3 mM dNTP, 1 mM MgSO4, 0.3 μM of primer 
mix and 2.5 U of Pfx polymerase. The PCR mixture was first denatured at 94 oC for 3 min, 
followed by 30 cycles of denaturation at 94 oC for 15 sec, annealing at 55 oC for 30 sec and 
extension at 68 oC for 1 min per kb and a final extension at 68 oC for 7 min. 
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5.1.7. Real-Time PCR 
The QuantiTechTM SYBR Green PCR kit (Qiagen, P/N 204143) was used according to 
the manufacturer’s instructions. 1-2 μl of cDNA was mixed with 2 μl of 10 μM primer mix, 
10 μl of QuantiTechTM SYBR Green PCR master mix, and dH2O added to a final volume of 
20 μl. The primer sequences of 18S rRNA, hepcidin and C78 were shown in Chapter 4.3.6, 
4.3.7 and 4.3.8, respectively. Real-time PCR was performed using a Rotor-Gene real-time 
PCR machine (Corbett Research, Australia).  The cycle profile of PCR included an initial hot 
start at 95 oC for 15 min, followed by 40 cycles of 95 oC for 15 sec, 50-60 oC for 30 sec and 
72 oC for 30 sec. All PCR reactions were performed in duplicate. Standard curves of 18S 
rRNA, hepcidin and C78 were generated independently by 10x serial dilution of template 
DNA (diluted PCR product) in each run. Melting curves were analyzed for each sample to 
check for product specificity. The relative copy number of each sample was calculated 
according to the corresponding standard curve using RotorGene v4.6 software. Normalization 
was performed in each sample by dividing the copy number of hepcidin or C78 to that of 18S 
rRNA. The relative expression levels were calculated by arbitrarily designating the lowest 
normalized value as 1. 
5.1.8. TOPO TA cloning 
The TOPO TA cloning kit (Invitrogen, P/N K4500-01) was used for subcloning a given 
PCR product into a pCR2.1-TOPO vector. For PCR products generated by Taq polymerase 
(see Chapter 5.1.6), PCR products were directly used in the TOPO cloning reaction. 4 μl of 
PCR product was mixed gently with 1 μl of salt solution and 1 μl of pCR2.1-TOPO vector, 
incubated for 30 min at RT and chilled on ice. 2 μl of the reaction mixture was mixed gently 
with a vial of One Shot Chemical Competent E. coli and incubated on ice for 25 min. After 
heat shock at 42 oC for 30 sec, the cells were immediately cooled on ice for 2 min, and 250 μl 
of SOC media was then added to the cells. After shaking at 200 rpm for 60 min at 37 oC, 10-
50 μl of the transformation mixture was spread on a perwarmed 100 μg/ml Ampicillin 
containing LB plate with X-gal (40 μl of 40 mg/ml spread on each plate) and incubated 
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overnight at 37 oC. For PCR products amplified by proofreading Pfx polymerase (see Chapter 
5.1.6), an additional step was required. The PCR product was first purified using a PCR 
purification kit (Qiagen, P/N 28104), then incubated in a 10 μl reaction mixture containing 1x 
PCR reaction buffer, 1.5 mM MgCl2, 5 µM dATP, 0.5 U Taq polymerase for 10 min at 72 oC. 
Finally, 4 μl of this reaction was used in the TOPO cloning reaction as described above. 
5.1.9. Competent cells preparation (Rubidium chloride method) 
A single colony of DH5α was inoculated in 5 ml of LB broth and cultured overnight at 37 
oC. 1 ml of the overnight culture was inoculated into 100 ml of LB broth and incubated at 37 
oC with shaking at 250 rpm. The growth of the bacteria culture was monitored using a 
spectrophotometer. When the reading at 600 nm reached 0.48 absorbance units (A600 = 0.48), 
the bacteria culture was then kept on ice for 15 min and centrifuged at 5,000 rpm for 5 min at 
4 oC without applying the ‘BRAKE’ mode. The bacterial cell pellet was resuspended in 40 ml 
of TfbI buffer (see Chapter 4.6.8) and incubated on ice for 15 min. After centrifugation at 
5,000 rpm for 5 min at 4 oC, the cell pellet was then resuspended in 4 ml of TfbII buffer (see 
Chapter 4.6.9). The competent cells were transferred to pre-cooled 1.5 ml tubes in 200 μl 
aliquots and snap-frozen in liquid nitrogen before transferring to –80 oC for long-term storage. 
5.1.10. Subcloning  
5 μg of pcDNA3 vector and 10 μg of pCR2.1-TOPO containing the gene of interest (see 
Chapter 5.1.8) were independently digested with the appropriate restriction enzyme at 37 oC 
for 3 h. After gel electrophoresis, the desired bands were cut out using disposable blades. 
QIAquick Gel Extraction kit (Qiagen, P/N 28704) was used to purify the DNA fragments. 
The concentration of the eluted DNA fragments was determined by gel electrophoresis using 
a quantitative DNA marker (Fermentas, P/N SM0243S, SM0313S). For ligation reactions, the 
molar ratio of vector: insert (gene of interest) was at least 1: 5. 20 μl of ligation mixture 
containing vector, insert, 1x ligation buffer and 1 μl T4 DNA ligase (NEB, P/N M0202S) was 
incubated overnight at 16  oC. 
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10 µl of ligation reaction mixture was added to 100 µl of competent cells (see Chapter 
5.1.9), swirled gently and incubated on ice for 1h. After heat shock at 42 oC for 45 sec and 
snap cooling on ice for 2 min, 0.9 ml of SOC medium was added and incubated at 37 oC with 
shaking at 250 rpm for 1 h. The transformed cells were briefly pelleted at 4,000 rpm, excess 
SOC medium removed, whereupon the cells were spread onto 50 µg/ml Ampicillin-
containing LB agar plates and incubated overnight at 37 oC. 
5.1.11. Plasmid isolation 
Plasmid was isolated from 5 ml of overnight E. coli cultures in LB broth using QIAprep 
Spin Miniprep kit (Qiagen, P/N 27104) according to the manufacturer’s instructions. For 
large scale plasmid isolation, a single colony from a freshly streaked plate was inoculated in 2 
ml LB broth and incubated for 8 h at 37 oC with vigorous shaking. The starter culture was 
then diluted 1/500 into 1 liter of selective LB broth and grown at 37 oC for 16 h with vigorous 
shaking (~250 rpm). Plasmid isolation was then performed using the QIAGEN Plasmid Maxi 
kit (Qiagen, P/N 12163) according to the manufacturer’s instructions. 
5.1.12. DNA sequence analysis 
DNA sequencing was performed using ABI PRISM BigDye Terminator v1.1 cycle 
sequencing Ready Reaction kit (Applied Biosystem, P/N 4337450). 30-90 ng of PCR 
products or 200-500 ng of plasmid DNA in 4.5 µl was mixed with 4 µl of BigDye reaction 
mixture, and 1.5 µl of 1 µM primer and incubated for 25 cycles of 96 oC for 10 sec, 50 oC for 
5 sec and 60 oC for 4 min. The reaction mixture was precipitated with 10 µl dH2O, 2 µl of 3 
M sodium acetate and 50 µl absolute ethanol at RT for 30 min and centrifugation at 13,000 
rpm for 20 min at RT. The pellet was washed with 125 µl 70% alcohol and air dried. DNA 
was resuspended in 15 µl of ABI loading solution and denatured at 95 oC for 2-5 min before 
running on the ABI Prism 377XL automated DNA sequencer.  
5.1.13. Transfection 
Cells grown on coverslips in 6-well tissue culture plates were transfected with pcDNA3 
or pcDNA3 containing gene of interest (see Chapter 5.1.10) using LipofectAMINE 
(Invitrogen, P/N 18324-020) and PLUS reagent (Invitrogen, P/N 11514-015), according to the 
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manufacturer’s instructions. Briefly, 6 µl PLUS reagent was added to 2 µg of plasmid DNA 
diluted in 100 µl OptiMEM I reduced serum medium (GIBCO BRL, P/N 31985) and 
incubated for 15 min at RT. 6 µl of LipofectAMINE diluted in 100 µl OptiMEM was then 
added to the precomplexed DNA, mixed well and incubated for another 15 min at RT. The 
DNA-PLUS-LipofectAMINE complexes were further diluted in 800 µl OptiMEM and added 
to the 6-well plate where cells had been pre-rinsed with OptiMEM. After incubation for 2-4 h 
at 37 oC, the media was discarded, replenished with fresh serum-containing media, and kept at 
37 oC in a 5% CO2 incubator. 
5.1.14. Statistical analysis.  
The statistical differences between experimental groups were analyzed using Wilcoxon 
Signed-Ranks test for paired samples and Mann-Whitney test for unpaired samples. χ2 test 
was used to compare qualitative variables. To demonstrate the presence of a positive or 
negative significant correlation between two parameters, Pearson’s Correlation was employed 
for two continuous data and Spearman’s rank correlation for one continuous and one rank-
order data. P value <0·05 was considered to be statistically significant. 
 
5.2. Methods used in Chapter 6 
5.2.1. Subtracted cDNA library construction 
Two reciprocal subtractive cDNA libraries were generated between cancerous and non-
cancerous liver tissue from an HCC patient using the SuperScript Plasmid System for cDNA 
synthesis and plasmid cloning kit (Life Technologies, P/N 18248-013) according to the 
manufacturer’s instructions with some modifications. A schematic protocol is shown in 
Figure 5-1. 
5.2.1.1 Preparation of tracer cDNA  
5 μg tracer mRNA was reverse transcribed by 5 μl of SuperScript II RT in the presence of 
2 μl of NotI primer-adapter (0.5 μg/μl) as standard protocol (see Chapter 5.1.5). The 20 μl 
reaction mixture was then incubated with 3.75 μl of 0.5 M EDTA (f/c: 60 mM) and 7.5 μl of 
1 N NaOH (f/c: 0.24 N) for 10 min at 37 oC to degrade RNA, followed by adding 18.75 μl of 
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1 M Tris-HCl, pH 7.5 (f/c: 0.375 M) for neutralization. The single strand cDNA was then 
precipitated with ethanol in the presence of ammonium acetate and glycogen. 
cDNA from HCC 
mRNA from paired  
non-cancerous liver 
cDNA tracer 
derived from 5mg  
mRNA 






















Figure 5-1. A schematic protocol for the construction of a HCC-specific subtracted 
library. Tracer cDNA from the HCC tissue was hybridized to a 10-fold excess of biotinylated 
driver mRNA from the non-cancerous liver. The resulting hybrids and excess driver were 
removed by extraction with streptavidin beads to enrich for HCC-specific sequences in the 
tracer. Two rounds of subtraction were performed for further enrichment. 
 
5.2.1.2. Preparation of biotinylated driver mRNA  
100 μg of driver mRNA in 200 μl of TE buffer was mixed with 200 μl of Photoprobe 
(Long Arm) Biotin (Vector Laboratories Inc, P/N SP-1020) and overlaid with mineral oil. The 
thermal coupling was then performed at 94 oC for 30 min and chilled on ice. After adding 400 
μl of 0.1 M Tris, pH 9.5, the reaction was extracted twice with an equal volume of 2-butanol. 
The lower aqueous phase containing biotinylated mRNA was extracted with chloroform to 
remove traces of 2-butanol before precipitation by ammonium acetate and glycogen.  
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5.2.1.3. Hybridization of tracer cDNA and driver mRNA 
5 μg tracer cDNA and 50 μg driver biotinylated mRNA were mixed, concentrated and 
resuspended in 5μl of HEPES buffer (100 mM HEPES, pH7.3, 1 mM EDTA). 5 μl of 68 oC 
pre-warmed 2x hybridization buffer (50 mM HEPES, pH7.3, 10 mM EDTA, 0.2% SDS, 1.5 
M NaCl) was added and overlaid with mineral oil. After 95 oC denaturation for 10 min, the 
first hybridization reaction was carried out using touch-down PCR program, -0.5 oC per cycle, 
30 sec for 54 cycles and then 68 oC for 21 h.  
5.2.1.4. Subtraction 
The removal of biotinylated RNA and DNA hybrids was carried out by extraction with 
VECTREX Avidin D (Vector Laboratories Inc, P/N A-2020) following the manufacturer’s 
instructions. The hybridization mixture was diluted with 140 μl HEPES buffer and 7 μl of 1 
M NaCl, followed by incubating with HEPES buffer-equilibrated VECTREX Avidin D at 37 
oC for 30 min with agitation. After centrifugation, the supernatant was transferred to a new 
tube containing freshly prepared Avidin D and extracted again. The remnant tracer cDNA in 
the supernatant was then mixed with freshly prepared 50 μg biotinylated driver mRNA for a 
second round of hybridization and subsequent subtraction as described above. 
5.2.1.5. Cloning of subtracted tracer cDNA 
Second strand synthesis of the cDNA was carried out in a 50 μl reaction mixture 
containing 10 μl of cDNA, 10 μl of 5x second strand buffer, 1 μl of 10 mM dNTP, 2.7 μl of 2 
mg/ml random hexamers (Pharmacia, P/N 27-2166), 2 μl of DNA polymerase I, large 
(Klenow) fragment (10 U/μl) (NEB, P/N M0210S), 1 μl of 10 mg/ml BSA and 0.5 μl of 
E.coli DNA ligase (10 U/μl) (NEB, P/N M0205S).  After incubation for 2 h at 16 oC, 2 μl of 
T4 DNA polymerase (10 U/μl) was added and incubated for another 10 min, followed by 
adding 6.6 μl of 0.5 M EDTA to stop the reaction. The double-stranded cDNA was then 
purified by QIAquick Nucleotide removal kit (Qiagen, P/N 28304) and concentrated by 
ethanol precipitation. The double-stranded cDNA was first linked with SalI adapter by T4 
DNA ligase (10 U/μl) at 16 oC for 21 h and purified by QIAquick Nucleotide removal kit. 
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The cDNA was then digested with NotI at 37 oC for 2 h and run on a 1% agarose gel. DNA 
bands between 500 bp to 5 kb were eluted from the gel using QIAquick Gel extraction kit 
(Qiagen, P/N 28704). DNA was precipitated with ethanol and ligated to pSPORT1 as 
standard protocol (see Chapter 5.1.10) and transformed into Epicurian Coli XL-2-blue 
ultracompetent cells (Strategene, P/N 200150). 
5.2.2. Spotted microarrays for screening of  subtracted libraries 
5.2.2.1. Microarrays fabrication 
A total of 789 individual cDNA clones derived from the two subtracted libraries were 
picked and grown in 96-well liquid cultures. Inserts in the pSPORT1 plasmid vector were 
PCR amplified by T7 and SP6 primers (see Chapter 4.3.2) flanking the cloning site. 5 μl of 
each denatured bacteria clone was used as template in 100 μl of PCR reaction following the 
protocol outlined in Chapter 5.1.6. Eight housekeeping genes, 96 random selected sequence-
verified EST clones and 4 negative controls (2 plant genes and 2 vector sequences) were 
amplified using specific primers (primer sequences not shown) to serve as controls in the 
microarrays. PCR products were precipitated with 50% isopropanol, washed in 70% ethanol 
and resuspended in 3x SSC buffer. PCR products were examined by running 1.5% agarose 
gels to ensure adequate PCR amplification.  PCR products were then robotically arrayed onto 
poly-L-lysine (Sigma, P/N P8920) coated glass slides using the GMS 417 microarrayer 
(Genetic microsystems, Wobrun, MA). The diameter of the spotting pin used was 150 μm. 
The distance between each spot on the slide was 300 μm. Several cDNA clones were 
independently amplified more than once and spotted at different locations to assess the 
consistency of the techniques. Each microarray consisted of 1278 spot elements printed in 
duplicate; 48 slides were generated per printing.  
Each slide was rehydrated for 10 sec over a water bath, snap-dried for 2 sec on a 100 oC 
heat block, then crosslinked with 550 mJ UV irradiation (Stratalinker, Stratagene). Each slide 
was then washed for 10 min in 0.2% SDS and rinsed in distilled water. After incubating in 
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100 oC water for 8 min, the slides were dehumidified in 95% ethanol for 5 min and air dried. 
The slides were kept at RT in a desiccator until ready for use.  
5.2.2.2. Microarray hybridization  
Labeling and hybridization of cDNA to arrays was carried out using the two-step 
3DNATM Expression Array Detection kit (Genisphere Inc, P/N A100735-Cy3TM kit, 
A100745-Cy5TM kit) according to the manufacturer’s instructions with some modifications. 
10 μg of total RNA from a normal liver control, which served as a reference, was reverse 
transcribed using a Cy3-RT primer. The same amount of total RNA derived from 10 normal 
liver controls, 18 cancerous and paired non-cancerous tissues of HCC were independently 
reverse transcribed with a Cy5-RT primer. A 20 μl cDNA synthesis reaction mixture was 
incubated at 42 oC for 2 h, followed by addition of 3.5 μl of 0.5 M NAOH/50 mM EDTA, 
incubation at 65 oC for 10 min, neutralization with 5 μl of 1 M Tris-HCl, pH 7.5 and addition 
of 60 μl of 3 M ammonium acetate.  The Cy3TM (reference) and Cy5TM (test sample) cDNA 
mixture were combined and precipitated by mixing with 1 μl of COT-1 DNA (GIBCO, P/N 
15279-011), 1 μl of yeast tRNA (GIBCO, P/N 15401-011) and 1 μl of oligo-dT blocking 
reagent (kit provided) in 450 μl of 100% ethanol, and incubated at –20 oC for 30 min. The 
cDNA was resuspended in 3 μl of dH2O and mixed with 15 μl of cDNA hybridization buffer 
(kit provided), incubated at 65 oC for 5 min and then applied to the spotted microarray and 
covered with a glass coverslip. The slides were incubated overnight in humidified ArrayItTM 
hybridization cassettes (TeleChem International, Inc, P/N AHC-6) in a 42 oC water bath. 
Slides were then washed two times each in 2x SSC/ 0.1% SDS and 0.2x SSC/ 0.1% SDS for 
10 min at RT. After a final wash with 0.1x SSC, slides were spin-dried and hybridized with 
2.5 μl of Cy3 and Cy5 3DNA capture reagents in 15 μl of 3DNATM hybridization buffer at 65 
oC overnight. The fluorescent 3DNA capture reagents bind to cDNA through their DNA 
capture sequence (see Chapter 4.3.4) which were complementary to the RT primer, the 5’end 
sequence of the cDNA. The washing steps were carried out as mentioned above. Each array 
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was scanned independently using Cy3 and Cy5 channels of the GMS 418 Array Scanner 
(Genetic Microsystems, Wobrun, MA).  
5.2.2.3. Microarray image analysis 
The fluorescence intensities of each spot were determined using ImaGene 4.0 software 
(Biodiscovery, Los Angeles, CA). Each spot was first defined by manual positioning of a grid 
of circles over the array image. The average pixel intensity within each circle was determined 
and a local background was computed for each spot. Net signal was determined by 
subtraction of this local background from the average intensity for each spot. Spots with low 
intensities (signals around the negative control were considered as background signals) were 
excluded from subsequent analysis. Signal intensities between the Cy5 (test samples) and Cy3 
(reference) were normalized by applying a scale factor to all intensities measured for the Cy5 
channel to generate a Cy5: Cy3 intensity ratio of 1 for the majority of spot elements. The 
calibrated Cy5: Cy3 ratios represented relative gene expression. Replicated spots without 
reproducible signals were excluded from later analysis. In order to look for genes that were 
statistically differentially regulated in HCC, 46 samples were grouped according to their 
pathological identities: non-cancerous (N, n=18) and matched cancerous tissue of HCC (T, 
n=18) and normal liver (NN, n=10). Calibrated Cy3: Cy5 intensity ratios of these 3 groups 
were analyzed by one way-ANOVA F followed by Tukey HSD Post Hoc multiple 
comparisons with significance level of 0.05. 
5.2.3. Affymetrix GeneChips Analysis 
Twenty-seven pairs of cancerous and non-cancerous liver tissues from HCC patients, as 
well as 10 normal liver controls were applied to hybridization process using Affymetrix HG-
U133A and -B GeneChips according to the manufacturer’s recommendations as outlined in 
the GeneChip Expression Analysis Technical Manual.  
5.2.3.1. Preparation of cDNA  
First stranded cDNA was reverse transcribed from 5 μg total RNA in the presence of 2 μl 
of 50 μM T7-oligo(dT) primer (see Chapter 4.3.5) as standard protocol (see Chapter 5.1.5). 
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The synthesis of second strand cDNA was performed by adding 30 μl 5x second-strand 
reaction buffer (Invitrogen, P/N 10812-014), 3 μl of 10 mM dNTP, 1 μl of E.coli DNA ligase 
(10 U/μl) (Invitrogen, P/N 18052-019), 4 μl of E.coli DNA polymerase I (10 U/μl) 
(Invitrogen, P/N 18010-025), 1 μl of E.coli RNase H (2 U/μl) (Invitrogen, P/N 18021-071) 
and 91 μl of dH2O to the first-stranded cDNA product and incubating at 16 oC for 2 h, 
followed by adding 2 μl of T4 DNA polymerase (10 U/μl) (Invitrogen, P/N 18005-025) for 5 
min at 16 oC, then adding 10 μl of 0.5 M EDTA to stop the reaction. The double-stranded 
cDNA product was mixed vigorously with an equal volume of phenol: chloroform: isoamyl 
alcohol (25: 24: 1, pH 8.0) (Invitrogen, P/N 15593-049) and transferred to Phase Lock Gel 
(PLG) tubes (Eppendorf, P/N E0032007953). After spinning at 13,000 rpm for 2 min, PLG 
formed a sealed barrier between the aqueous and organic phases of phenol: chloroform. The 
aqueous phase was transferred to a new tube and precipitated by 0.5 volume of 7.5 M 
ammonium acetate and 2.5 volumes of absolute alcohol, spun immediately at high speed at 
RT for 20 min. After rinsing with 80% ethanol, the cDNA pellet was air dried and 
resuspended in 12 μl of dH2O. 
5.2.3.2. Preparation of biotinylated cRNA  
cDNA was amplified with T7 RNA polymerase up to ~100 μg of biotin-labeled cRNA 
using ENZO BioArray HighYield RNA transcript labeling kit (Affymetrix, P/N 900182) 
following the manufacturer’s instructions. Briefly, 10 μl of double-stranded cDNA was mixed 
with 4 μl of 10x hybridization reaction buffer, 4 μl of 10x biotin labelled ribonucleotides, 4 μl 
of 10x DTT, 4 μl of 10x RNase inhibitor, 2 μl of 20x T7 RNA polymerase, 12 μl of dH2O and 
incubated at 37 oC for 4 h. The biotinylated cRNA was purified using RNeasy Mini kit 
(Qiagen, P/N 74103) with some modification.  The cRNA solution was topped up with dH2O 
to a volume of 100 μl, and then mixed with 350 μl of RLT buffer (without β-
mercaptoethanol) and 250 μl of absolute alcohol. The mixture was then applied to the RNeasy 
mini column and washed with 500 μl RPE buffer. The purified cRNA was eluted by adding 
35 μl of dH2O directly to the column membrane, with 1 min waiting time before centrifuging. 
 88
cRNA yield was determined by a spectrophotometer (see Chapter 5.1.4). 1% agarose gel 
electrophoresis was performed to confirm high quality cRNA which yielded a smear co-
migrating with dsDNA markers ranging from 100 bp to >2 kb, with the average size around 
750 bp. 
5.2.3.3. Probe array hybridization, washing and detection 
Before hybridizing onto GeneChip probe arrays, 15 μg of biotinylated cRNA target in a 
volume of 24 μl had to be treated with 6 μl of 5x fragmentation buffer at 94 oC for 35 min to 
break down the full-length cRNA to 35-200 bp fragments. The fragmented cRNA was then 
reconstituted in a hybridization cocktail mixture containing 15 μl of 20x Eukaryotic 
hybridization control (four biotinylated transcripts comprising bacterial bioB, bioC, and bioD 
and phage cre) (Affymetrix, P/N 900299), 5 μl of 3 nM control oligonucleotide B2 
(Affymetrix, P/N 900299), 3 μl of herring sperm DNA (10 mg/ml) (Promega, P/N D1811), 3 
μl of acetylated BSA (50 mg/ml) (Invitrogen, P/N 15561-020), 150 μl of 2x hybridization 
buffer and 94 μl of dH2O. The hybridization mixture was heated at 99 oC for 5 min and 45 oC 
for 5 min, followed by centrifugation at high speed for 5 min at RT before applying 200 μl of 
the mix to each GeneChip which had been equilibrated with 1x hybridization buffer for 10 
min at 45 oC. Hybridization was performed at 45 oC for 16 h in a rotisserie oven set at 60 rpm.  
After 16 h, the hybridization cocktail was removed from the GeneChip and replaced with 
250 μl of non-stringent wash buffer. The chip was then loaded onto an Affymetrix Fluidic 
station with washing and staining protocols that were programmed specifically for HG-U133 
GeneChip. After non-stringent wash at 25 oC and stringent wash at 50 oC, the chip was 
stained with streptavidin phycoerythrin (SAPE) solution, followed by biotinylatd anti-
streptavidin IgG solution and a second stain with SAPE solution. The washing steps between 
each stain were performed using non-stringent wash buffer. The chip was scanned using the 




5.2.3.4. Data analysis 
The Statistical Algorithms implemented in Affymetrix Microarray Suite version 5.0 were 
used in expression analysis of the GeneChip probe arrays. Signal intensity information in a 
CEL file was converted to a mean intensity for each gene in a CHP file by proprietary 
software (Affymetrix) which included default parameters for filtering and centering the data. 
The average intensity for all genes was normalized to 100. A Detection Algorithm using one-
sided Wilcoxon signed-rank test was performed to determine whether a transcript is reliably 
detected (Present) or not detected (Absent). The probe sets that represented the 25 
differentially expressed genes in spotted microarray analysis were analyzed using Comparison 
Analysis in paired HCC samples which designated non-cancerous tissues as a baseline and the 
corresponding cancerous tissues as experimental. The analysis compares the values of each 
probe pair in the baseline array to its matching probe pair on the experiment arrays. A Change 
Algorithm generates a Change p-value and an associated Change (Increase, Marginal 
Increase, Decrease, Marginal Decrease or No change).  
5.2.4. Hierarchical Clustering 
Hierarchical clustering analysis was performed using Cluster software and visualized 
using TreeView software written by M. Eisen (1). The hierarchical clustering algorithm 
organizes experimental samples on the basis of overall similarities in their gene expression 
profiling. The relative gene expression ratio, either calibrated Cy5: Cy3 ratios (see Chapter 
5.2.2.4) or (signal intensity)/(averaged signal intensity of all samples) (see Chapter 5.2.3.4) 
were log2 transformed and applied to average uncentered linkage clustering to analyze the 
relatedness among expression patterns of the genes.  
 
5.3. Methods used in Chapter 7 
5.3.1. Expression analysis of iron homeostasis-related genes using Affymetrix system 
A total of 71 probe sets representing 40 genes related to iron homeostasis and 4 probe sets 
representing liver-specific transcription factors were selected and analyzed by the statistical 
algorithms implemented in Affymetrix Microarray Suite version 5.0. Twenty one probe sets 
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representing 11 genes that were absent in more than 60% of the samples, determined by 
detection calls, were excluded for further analysis. The remaining 29 of the 40 iron 
homeostasis-related genes (50 probe sets) were analyzed using Comparison Analysis as 
mentioned above (see Chapter 5.2.3.4).  One probe set was selected for each gene and shown 
in Table 7-1. Probe sets with ‘_at’ suffixes (unique probe sets) or those with the highest signal 
intensity among the probe sets were chosen. Relative gene expression ratio (signal intensity/ 
averaged signal intensity of all samples) were log2 transformed, and used for hierarchical 
clustering analysis (see Chapter 5.2.4). 
5.3.2. Iron staining and grading 
Paraffin-embedded tissue sections were stained with hematoxylin-eosin and Perl’s 
Prussian blue. Iron deposition was assessed in cancerous liver tissues and non-cancerous liver 
tissues away from the growing edge of the tumor. Non-cancerous liver tissues in the same 
block containing the tumor as well as in a separate block available from random non-
cancerous liver tissues obtained from the hepatectomy specimens were used in the 
assessment.  Pattern and the degree of iron deposition were assessed by a pathologist who 
performed the analysis without prior knowledge of gene expression profiling results. The 
hepatic iron contents in the liver sections were graded according to Searle et al (2). Iron 
deposition was semi-quantitatively graded on a scale of 0 to 4 based on the magnification at 
which iron granules were readily discernible. Grade 0 (absent): iron granules absent/barely 
discernible at x400; Grade 1 (scarce): barely discernible at x250 but easily discernible at 
x400; Grade 2 (mild): discrete granules resolved at x100; Grade 3 (moderate): discrete 
granules resolved at x25; Grade 4 (severe): massive iron granules visible at x10 or with the 
naked eye.  
5.4. Methods used in Chapter 8 
5.4.1. Northern blot analysis 
A commercial available human 12-Lane multiple tissue Northern (MTN) blot 
(CLOTECH, P/N 7780-1) with 2 μg of poly(A)+ RNA per lane was used. Probes were 
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prepared by purified PCR products of C78 and beta-actin using Strip EZTM DNA kit (Ambion, 
P/N 1470). 25 ng of PCR products in 9 μl of TE buffer was denatured at 100 oC for 10 min 
and chilled on ice. Denatured DNA was added to the reaction mixture containing 5 μl of [α-
32P] dATP (10 mCi/ml) (NEN, P/N BLU012Z250UC) , 2.5 μl  of 10x decamer solution, 5 μl 
of 5x buffer, 2.5 μl of 10x dCTP and 1 μl of Klenow and incubated at 37 oC for 30 min. The 
reaction was stopped with 1 μl of 0.5 M EDTA. The 32P-labeled probe was then diluted with 
TE buffer to 100 μl before purifying with the Nucleotide removal kit (Qiagen, P/N 28304) 
according to the manufacturer’s instructions. The membrane was pre-hybridized in Ultrahyb 
solution (Ambion, P/N 8670) at 42 oC for 2 h in a Hybaid hybridization oven. After 
denaturation at 100 oC for 10 min and chilling on ice, the purified probe was then added to the 
Ultrahyb solution with the membrane and incubated for another 16 h at 42 oC. The membrane 
was first washed in 2x SSC/ 0.05% SDS at RT for 30 min, followed by 0.2x SSC/ 0.1% SDS 
at 60 oC for 30 min. Autoradiography was conducted using Kodak BIOMAX MR film 
(Eastman Kodak, P/N 8701302) with intensifying screens at –80 oC. Phosphoimages were 
also captured for quantitation using Molecular Imager FX Pro MultiImager System (Bio-
Rad). Membranes were stripped using the same kit (Strip EZTM DNA kit). The hybridized 
probe was removed from the membrane by incubating with 1x Probe Degradation Buffer for 2 
min at RT, then transferring to 68 oC for 10 min. After discarding the Probe Degradation 
Buffer, 1x Blot Reconstitution Buffer in 0.1% of SDS was added and incubated for another 10 
min at 68 oC. The success of probe removal was monitored with a Geiger counter or by 
exposing the membrane to a phosphorimager. 
5.4.2. Cloning of a full-length c78 cDNA  
5.4.2.1.  In silico cloning and confirmation of cDNA sequence  
We used in silico cloning as a primary procedure to expand the cloning regions of C78 
from the EST database. First, the C78 sequence was searched against the EST database by the 
BLAST program and found to be highly homologous to EST clone (AA677293). The EST 
sequence was found to be located at position 137866 to 138343 in BAC clone R-638I2 
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(AL157871) using the BLAST program. The GENSCAN Web Server at the Massachusetts 
Institute of Technology (http://genes.mit.edu/GENSCAN.html) was employed to predict 
putative genes in ~13 kb of DNA sequence encompassing the EST sequence from BAC clone 
R-638I2. A putative gene was predicted to encode a protein of 323 amino acids (aa). RT-PCR 
product generated by C78-F and C78-R primers (see Chapter 4.3.10) designed according to 
















Figure 5-2. An overview of the 5’ RLM-RACE protocol. 
 
5.4.2.2. 5’ rapid amplification of cDNA ends  
The FirstChoice TM RLM-RACE kit (Ambion, P/N 1700) was used according to the 
manufacturer’s instructions. The protocol is based on a 5’ RNA ligase-mediated rapid 
amplification of cDNA ends (5’-RLM-RACE) to selectively amplify cDNA from 5'-capped, 
full-length mRNAs. A schematic protocol is shown in Figure 5-2. Briefly, 1-5 µg of total 
RNA from normal liver was treated with calf intestinal phosphatase (CIP) followed by 
tobacco acid pyrophosphatase (TAP) to remove the cap structure. T4 RNA ligase was used to 
ligate the 5’RACE adapter (see Chapter 4.3.12), and the RNA was reverse transcribed by 
random priming using Moloney murine leukemia virus-reverse transcriptase or Thermoscript 
reverse transcriptase (see Chapter 5.1.5). cDNA was first PCR amplified with 5’RACE outer 
primer and C78RC-OR (see Chapter 4.3.13), followed by a second PCR using a nested 
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5’RACE inner primer and C78RC-IR primer (see Chapter 4.3.13). The transcription initiation 
site was mapped by sequencing the PCR products after TA cloning. 
5.4.3. In silico cloning of HDMCP orthologous gene in mouse and rat  
HomoloGene database from the National Center for Biotechnology Information (NCBI) 
shows possible homologous genes of HDMCP in the mouse and rat species. First, the cDNA 
and protein sequences of HDMCP orthologous genes derived from AY569438 (human), 
BC055027 (mouse) and XM_234551 (rat) were analyzed by multiple sequence alignment 
using ClustalW version 1.8 available at GenomeNet service at Kyoto University 
Bioinformatics Center (http://clustalw.genome.ad.jp/). Based on the conserved protein 
sequences in HDMCP orthologs, RatMCP-F and RatMCP-R (see Chapter 4.3.16) were 
designed for rat ortholog and confirmed by autosequencing. On the other hand, the cDNA 
sequence of the mouse ortholog was used as a template to align an ~7 kb rat genomic DNA 
sequence encompassing the sequence of XM_234551 to assist in determining exon 1 with a 
start codon, and assembling the 5’- and 3’-UTR.  
5.4.4. Determination of gene organization of HDMCP orthologs  
Gene organization of each ortholog was determined by BLAST 2 sequence algorithm 
using cDNA sequences and their corresponding genomic DNA sequences, together with the 
consensus rule for splice sites, which are dinucleotides GT and AG at the 5’ and 3’ intron 
boundaries.  
5.4.5. Determination of conserved syntenic regions at HDMCP gene locus in human, 
mouse and rat species  
In order to determine the syntenic regions at the HDMCP gene locus in human, mouse 
and rat genomes, the map location of human, mouse and rat HDMCP orthologs was first 
identified. The gene content of the genomic region flanking the HDMCP gene was 
determined using Map Viewer from the NCBI in human and corresponding mouse and rat 
chromosomes. The regions of synteny between human, mouse and rat chromosome were then 
determined by analyzing and comparing each gene using HomoloGene database from the 
NCBI. 
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5.4.6. Construction of HDMCP-FLAG and UCP2-FLAG protein 
HDMCP was first amplified from cDNA derived from normal liver with specific 
HDMCP-F and -R primers (see Chapter 4.3.14). The PCR product then served as a template 
to generate the HDMCP-FLAG fusion protein using two additional steps of PCR. HDMCP-F 
was the forward primer for both PCRs. A FLAG peptide tag (KDDDDKYD) at the C-
terminus of the fusion protein was first generated by the reverse primer HDMCP-FLGR (see 
Chapter 4.3.14) containing the 3’-end of the HDMCP coding sequence and part of the FLAG 
sequence. The 2nd PCR was then performed using CFLAG  (see Chapter 4.3.14), the reverse 
primer containing a stop codon and part of the FLAG sequence which overlapped with 
HDMCP-FLGR. UCP2-FLAG protein was generated by a similar approach from cDNA of 
human skeletal muscle. UCP2-F and UCP2-FLGR (see Chapter 4.3.15) was used in 1st PCR 
and UCP2-F and CFLAG for 2nd PCR. All PCR amplification were performed using Platinum 
Pfx polymerase (see Chapter 5.1.6). After TA cloning, cDNA inserts were sequenced by 
M13F and M13R (see Chapter 4.3.3). The confirmed recombinant cDNA sequence was then 
subcloned into pcDNA3 (see Chapter 5.1.10). 
5.4.7. Immunostaining and assessment of ΔΨm  
Hep3B cells grown on coverslips in a 6-well tissue culture plate were transfected with 2 
µg of pcDNA3/HDMCP-FLAG plasmid. For time course analysis of HDMCP expression, 
cells were stained at 4, 6 and 24 h after transfection. For ΔΨm restoration studies in HDMCP-
overexpressed cells, fresh media containing test compound (either 5 μM cyclosporin A 
(Novartis), 50 μM bongkrekic acid (Sigma,P/N B6179) or 5 μg/ml oligomycin (Sigma,P/N 
O4876)) was added after cells were transfected for 2 h and incubated for another 22 h. To 
determine the ΔΨm, cells were incubated in media containing 250 nM MitoTracker OrangeTM 
(Molecular Probes, P/N M-7510) at 37 oC for 30 min. Cells were then fixed with 3.7% 
formaldehyde in culture media at 37 oC for 10 min and permeabilized in 0.1% Triton-X-100 
at RT for 5 min. After washing with PBS, non-specific staining was blocked with 10% normal 
goat serum (NGS) in PBS at RT for 1 h. The cells were then incubated overnight with anti-
 95
FLAG mAb (see Chapter 4.5.1) at 4 oC. After incubation at RT for 1 h in Alexa Fluor 488 
conjugated-goat anti-mouse Ab (see Chapter 4.5.5), coverslips were washed in PBS and 
mounted onto slides with DAPI containing VECTASHIELD (Vector Laboratories, P/N H-
1200). Slides were examined using the LSM-510 laser-scanning confocal microscope (Carl 
Zeiss). In addition, cells were incubated with anti-FLAG pAb (see Chapter 4.5.2) and anti-
mitochondrial mAb (see Chapter 4.5.3) or anti-cytochrome c mAb (see Chapter 4.5.4) 24 h 
post-transfection. Alexa Fluor 488-conjugated goat anti-rabbit Ab (see Chapter 4.5.8) and 
Alexa Fluor 546- (see Chapter 4.5.6) or Alexa Fluor 633-conjugated goat anti-mouse Ab (see 
Chapter 4.5.7) were used for primary Ab detection.  
5.4.8. TUNEL (terminal deoxynucleotide transferase dUTP nick end labeling) assay  
The In situ cell death detection kit (Roche, P/N 2156792) uses terminal deoxynucleotidyl 
transferase (TdT) which catalyzes polymerization of tetramethyl-rhodamine (TMR) red 
labeled dUTP to free 3’-OH DNA ends in a template-independent manner. The kit was used 
to detect apoptotic cells at day 3 after Hep3B cells were transfected with pcDNA3-HDMCP-
FLAG. Briefly, cells were fixed with 3.7% formalydehyde for 15 min at RT, rinsed with PBS 
and permeabilized in 0.1% Triton X-100 in 0.1% sodium citrate buffer for 2 min on ice. After 
rinsing with PBS, cells were then treated with 50 µl of TUNEL reaction mixture (5 µl enzyme 
solution in 45 µl label solution) in a humidified chamber at 37 oC for 1 h in the dark, followed 
by rinsing three times with PBS. The direct detection of DNA fragmentation in the red 
channel can be detected by fluorescence microscopy. To visualize HDMCP protein, cells 
were incubated with anti-FLAG mAb followed by incubation of Alexa Fluor 488-conjugated 
goat anti-mouse Ab.  
5.4.9. Determination of ADP/ATP ratio 
The ApoSENSORTM ADP/ATP Ratio Assay kit (Biovision, P/N K255-200) utilizes the 
luciferase enzyme to catalyze the formation of light from ATP and luciferin, and the light can 
be measured using a luminometer.  
   Mg2+
Luciferin + ATP + O2 ⎯⎯⎯→ oxyluciferin + AMP + pyrophosphate +CO2 + light  
   Luciferase 
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293T cells in 6-well plate were transfected with pcDNA3/HDMCP-FLAG,  
pcDNA3/UCP2-FLAG or pcDNA3 vector alone. Cell pellets were collected 24 h after 
transfection and resuspended in Nucleotide Releasing Buffer (NRB). The ATP and ADP were 
assayed by a luminometric method using ApoSENSORTM ADP/ATP Ratio Assay kit 
(Biovision, P/N 1070-200). To measure the ATP level, 1 µl of ATP Monitoring Enzyme 
diluted in 50 µl of NRB was added to 100 µl cell lysate, and read immediately with a 10 sec 
integration on a LumatLB 9507 (Berthold technologies) (data A). To measure the ADP level, 
the sample was read again after 10 to 15 min (data B). 1 µl of ADP Converting Enzyme 
diluted in 50 µl of NRB was then added and read immediately (data C). The ADP level was 
calculated as data C- data B. The background subtracted luminescence values (relative light 
units, RLU) were normalized for total protein in each sample. In order to compare the results 
of eight independent transfections, the RLU/µg protein of vector control was set at 100% to 
compare the changes of ATP, ADP and ADP/ATP ratio in HDMCP- and UCP2-
overexpressed cells. 
5.4.9. Genomic DNA isolation 
Cell pellets were treated with 80 µg/ml of RNase A in genomic DNA extraction buffer 
(10 mM Tris, pH 8.0, 150 mM NaCl, 10 mM EDTA, 0.5% SDS) for 40 min at 37 oC,  
followed by digestion with 200 µg/ml of proteinase K at 50 oC for 4 h. The mixture was 
extracted twice with phenol: chloroform: isoamyl alcohol (25: 24: 1) by gently inverting the 
tube without vortexing. The genomic DNA was precipitated by mixing with 2.5 volumes of 
cold absolute ethanol and 1/10 volume of 5 M NaCl. 
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The present work aims to identify novel HCC-related genes as potential candidates for 
development of comprehensive molecular diagnostic assays and novel therapeutic targets. 
Two reciprocal subtracted cDNA libraries were generated from cancerous and corresponding 
non-cancerous tissue from an HCC patient. Microarrays were generated by spotting a total of 
789 cDNA clones derived from both libraries and a further 104 known genes including 
housekeeping genes and genes involved in tumorigenesis. After screening 18 pairs of HCC 
samples using microarray analysis, 25 genes were identified as differentially expressed genes 
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in HCC. Briefly, expression levels of 12 genes were decreased and 13 genes were increased in 
cancerous tissues compared to non-cancerous tissues. The results were further confirmed by 
27 independent HCC samples using the Affymetrix GeneChip system. Using hierarchical 
clustering analysis, the group of 25 differentially expressed genes was able to segregate 
cancerous tissues and non-cancerous tissues from HCC patients based on the similarity of 
gene profiles.  
 
6.2. Results 
6.2.1. Construction and screening of HCC-specific subtracted cDNA libraries  
A significant reduction of the abundant β-actin house-keeping gene was observed in the 
subtracted cDNA compared to the original non-subtracted cDNA indicating that the 
subtractive hybridization was successful (data not shown). The two reciprocal subtracted 
libraries generated were termed HCC up-regulated library (cancerous tissue as a tracer and 
non-cancerous tissue as a driver) and HCC down-regulated library (non-cancerous tissue as a 
tracer and cancerous tissue as a driver), which contained 175 and 614 cDNA clones 
respectively. To determine the library complexity, 50 randomly selected cDNA clones were 
sequenced. No identical clones were detected. Library clones were classified as known genes, 
EST clones, immunoglobulin genes, and some Pseudomonas aeruginosa sequences.  
In addition to the 789 cDNA clones derived from both HCC-related subtracted libraries, 
another 104 genes comprising house-keeping genes and genes related to tumorigenesis were 
also selected from our in-house EST clone collections and spotted onto the glass slides. The 
HCC-related cDNA microarray, which consisted of a total of 1278 spot elements printed in 
duplicate, were screened by 18 pairs of HCC samples and 10 normal liver tissues. A 
representative image of the two-color fluorescent microarray is shown in Figure 6-1. 
We excluded spots with low fluorescence intensities, poor morphology and inconsistent 
duplicates, leaving 818 out of 1278 spot elements (64%) consisting of 498 library clones and 
16 known genes with replicates for subsequent analysis. The duplicate Cy5: Cy3 ratio of the 
remaining 818 spot elements was perfectly concordant with R2 (square of Pearson correlation 
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coefficiency, measuring similarity in gene expression patterns). The mean of R2 in 46 




















Figure 6-1. Two-color fluorescent image 
of HCC-related cDNA microarray. The 
cDNA microarray was hybridized with 
reference cDNA (normal liver) detected by 
Cy3 capture reagent (green) and tumor 
cDNA (HCC) detected by Cy5 capture 
reagent (red) using a 3DNATM Expression 
Array Detection kit. The inset represents a 
portion of a microarray which shows 
arrays in duplicate. Yellow spots represent 
genes with no change in expression. Red 
and green spots represent genes with 
increased and decreased expression in 




6.2.2. Identification of genes that were differentially regulated in HCCs   
The 46 samples were grouped according to their pathological identities as normal liver 
(NN, n=10); cancerous tissue (T, n=18) and matched non-cancerous tissue (N, n=18) of HCC. 
The averaged Cy5: Cy3 ratios of the 818 spot elements of these three sample groups were 
then analyzed using one way analysis of variance (ANOVA) F test and Tukey HSD Post Hoc 
multiple comparisons with a significance level of 0.05. Seventy-eight out of 818 (9.5%) spot 
elements which represented 28 subtracted cDNA clones and 11 known genes were found to 
be significantly differentially expressed.  
After DNA sequencing, we excluded 12 subtracted clones for further analysis because 10 
of them were EST clones with Alu sequences and 2 of them were immunoglobulin genes. The 
remaining 16 of the 26 clones which represent 14 unique genes and the 11 known genes are 
listed in Table 6-1. Briefly, 12 genes were down- and 13 genes were up-regulated in 
cancerous tissue in comparison with matched non-cancerous liver tissues from HCC patients 
and/or normal liver controls. These were genes involved in transcriptional regulation, 
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translational regulation, protein degradation, the immune system and metabolism of glucose, 
lipids and detoxification. Seven of the 25 differentially expressed genes showed an average 
fold change either equal to or greater than 2 in 18 pairs of HCC samples (Table 6-2). These 
included 3 up-regulated genes (α-tubulin, GAPDH and peptidylprolyl isomerase A) and 4 
down-regulated genes (hepcidin, peptidoglycan recognition protein L precursor, C78, an EST 
clone and c-fos). Furthermore, only a small number of genes showed altered expression in 
non-cancerous liver tissue of HCC patients compared to normal controls (Table 6-1).  
 
Table 6-1. Twenty-five differentially expressed genes in HCC compared to non-
cancerous liver tissues or normal liver controls. 















Downregulated genes (n=12)    
 EST (C78) AA677293 Unknown 0.0005* 0.0050* 0.0005* 0.0005* 
 c-fos # NM_005252 signal transduction 0.0005* 0.0020* 0.0020* 0.0260* 
 Hepcidin NM_021175 iron homeostasis 0.0005* 0.6050 0.0100* 0.0005* 
 Peptidoglycan recognition 
protein L precursor 
NM_052890 innate immunity 0.0005* 0.4210 0.0005* 0.0005* 
 Apolipoprotein AI  NM_000039 lipid metabolism 0.0005* 0.4180 0.0005* 0.0030* 
 α-1B glycoprotein  NM_130786 Plasma glycoprotein  0.0010* 0.4080 0.0010* 0.0090* 
 IGFBP4 # M62403  IGF regulator 0.0020* 0.0070* 0.0030* 0.9040 
 Interferon regulatory factor 3-like NM_001571 unknown 0.0030* 0.0510 0.0020* 0.3160 
 Apolipoprotein C-III   NM_000040 lipid metabolism 0.0030* 0.0350* 0.0020* 0.4170 
 Methallothionein IG  NM_005950 toxic metal metabolism 0.0070* 0.2890 0.0060* 0.1150 
 Metallothionein II BC007034 toxic metal metabolism 0.0090* 0.1330 0.0060* 0.2870 
 α2-HS glycoprotein  AB038689 plasma glycoprotein  0.0330* 0.1190 0.9960 0.0420* 
      
Upregulated genes (n=13)    
 Ribosomal protein L30 L05095 ribosomal protein 0.0005* 0.7010 0.0005* 0.0005* 
 Peptidylprolyl isomerase A # NM_021130 protein processing  0.0005* 0.7130 0.0005* 0.0005* 
 GAPDH # M33197 glycolysis 0.0005* 0.9090 0.0005* 0.0005* 
 α-tubulin # K00558 microtubules 0.0005* 0.9770 0.0010* 0.0005* 
 Ornithine decarboxylase 
antizyme 1 
NM_004152 ODC metabolism 0.0005* 0.3560 0.0080* 0.0005* 
 β-actin # NM_001101 cytoskeleton 0.0005* 0.9990 0.0030* 0.0010* 
 β 2-microglobulin #  AB021288 MHC complex 0.0010* 0.5580 0.0020* 0.0080* 
 Ribosomal protein L37 NM_000997 ribosomal protein 0.0010* 0.9680 0.0110* 0.0010* 
 Mcl-1 #  AF203373 anti-apoptosis 0.0010* 0.9330 0.0050* 0.0030* 
 Prefoldin 5 # AK024094 chaperone  0.0020* 0.3670 0.1640 0.0010* 
 Ubiquitin C # AB009010 protein degradation 0.0030* 0.6840 0.0820 0.0020* 
 Bcl2-associated athanogene BC014774   anti-apoptosis 0.0100* 0.9070 0.0920 0.0110* 
 Junction plakoglobin # BC000441 cell adhesion 0.0150* 0.5380 0.3020 0.0110* 
     
NN denoted normal liver tissue (n=10); T denotes cancerous tissue (n=18) and N denotes the paired non-cancerous liver 
tissues (n=18) from HCC patients   
# genes that are not derived from the subtracted libraries    





6.2.3. Verification of differentially expressed genes using independent samples detected 
by Affymetrix Genechip analysis 
The representative probes IDs of a total of 24 differentially expressed genes (except interferon 
regulatory factor 3-like gene) were selected from the HG-U133-A and -B GeneChip. The 
expression pattern of these 24 probe IDs was then determined by 27 independent pairs of 
HCC samples and 10 normal liver control (Table 6-2). The 12 down-regulated genes showed 
consistently decreased expression in both spotted array and Affymetrix analysis (Table 6-2). 
We have observed that Affymetrix analysis yields greater down-regulation fold changes than 
spotted array analysis, suggesting that the former gives a more linear range of signal 
detection. For the up-regulated genes detected in the spotted array, some did not show an 
increase in expression using Affymetrix analysis. These included β-2-microglobulin (β2m), 
ornithine decarboxylase antizyme 1, ubiquitin C, perfoldin 5, myeloid cell leukemia sequence 
1 (Mcl-1), junction plaskoglobin and Bcl2-associated athanogene (BAG1). 
6.2.4. Segregation of HCC from non-HCC by the differentially expressed genes 
Using hierarchical clustering, we showed that a total of 25 differentially expressed genes 
identified by spotted array analysis were able to segregate the 46 liver samples into two main 
branches, termed ‘non-HCC cluster’ and ‘HCC cluster’. (Figure 6-2A). In agreement with the 
above finding, the 24 equivalent probe IDs in Affymetrix analysis were also able to 
discriminate cancerous tissues from non-cancerous liver tissues in a total of 64 liver samples 
using hierarchical clustering (Figure 6-2B). We showed that all cancerous tissues were 
exclusively clustered under the ‘HCC cluster’, whereas non-cancerous tissue and normal liver 
controls were classified as ‘non-HCC cluster’ in both sets of data (Figure 6-2, A and B). 
Furthermore, the vertical gene dendrogram showed two main branches which represented 
down- and up-regulated genes in the HCC cluster compared to the non-HCC cluster, 







Table 6-2. Comparison of the gene expression changes of 25 differentially expressed 
genes in HCC using spotted microarray analysis and Affymetrix GeneChip analysis. 
 
Down-regulated genes in HCC (n=12) Spotted array  Affymetrix 
 ChangesA N/TC  ChangesB N/TC
 Gene name D I NC median Affymetrix probe IDE D I NC median
 EST (C78) 14 2 2 4.03 237765_at 26 0 1 18.9 
 Hepcidin 17 0 1 3.49 220491_at 26 0 1 29.4 
 Peptidoglycan recognition protein L   
precursor 
14 0 4 3.03 242817_at 24 1 2 6.13 
 c-fos  # 13 2 3 2.14 209189_at 24 1 2 5.50 
 Metallothionein II 13 2 3 1.90 212185_x_at 24 1 2 2.13 
 Methallothionein IG  12 3 3 1.70 204745_x_at 23 1 3 4.94 
 α-1B glycoprotein  13 3 2 1.66 229819_at 18 1 8 1.76 
 α2-HS glycoprotein  13 2 3 1.35 210929_s_at 20 0 7 1.41 
 Interferon regulatory factor 3-like 10 2 6 1.28 NA     
 Apolipoprotein AI 11 0 7 1.26 204450_x_at 24 0 3 1.93 
 Apolipoprotein C-III  7 4 7 1.15 205820_s_at 23 0 4 1.73 
 IGFBP4 # 8 3 7 1.10 201508_at 22 0 5 2.21 
Up-regulated genes in HCC (n=13) Spotted array  Affymetrix 
 ChangesA T/ND  ChangesB T/ND
 Gene name D I NC median Affymetrix probe IDE D I NC median
 GAPDH # 0 17 1 2.37 AFFX-HUMGAPDH/ 
M33197_5_at 
2 21 4 1.44 
 α-tubulin # 0 17 1 2.03 212639_x_at 0 23 4 1.70 
 Peptidylprolyl isomerase A # 0 18 0 2.01 211765_x_at 0 17 10 1.41 
 β-actin # 3 14 1 1.97 AFFX-HSAC07/ 
X00351_5_at 
1 21 5 1.59 
 Prefoldin 5 # 2 13 4 1.73 207132_x_at 1 7 19 1.08 
 Junction plakoglobin # 2 12 4 1.58 201015_s_at 1 10 16 0.99 
 Ornithine decarboxylase antizyme 1 2 13 4 1.58 200077_s_at 4 1 22 1.00 
 β 2-microglobulin  #  3 14 1 1.58 216231_s_at 8 3 16 0.87 
 Bcl2-associated athanogene 3 10 5 1.50 202387_at 5 5 17 1.02 
 Ubiquitin C # 1 13 4 1.41 208980_s_at 2 3 22 1.00 
 Mcl-1 # 1 12 5 1.41 200797_s_at 15 1 11 0.61 
 Ribosomal protein L30 0 13 5 1.39 200062_s_at 0 14 13 1.37 
 Ribosomal protein L37 0 11 7 1.34 200092_s_at 0 9 18 1.17 
A Changes in spotted array analysis represented patient numbers (n=18) in each categories: ’I’ 
and ‘D’ denotes increased and decreased gene expression for more than 1.2 fold, 
respectively, whereas ‘NC’ denotes less than 1.2 fold change while comparing cancerous 
tissue (T) to paired non-cancerous (N) tissues of HCC samples.  
B  Changes in Affymetrix analysis represented patient numbers (n=27) in each categories: ’I’ 
denotes ‘Increase and Mild Increase’, ‘D’ denotes ‘Decrease and Mild Decrease’ and ‘NC’ 
denotes ‘No Change’ while comparing T to N using Comparative algorithm.  
C Median of HCC down-regulated fold change in all samples. 
D Median of HCC up-regulated fold change in all samples.  
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Figure 6-2. Two-dimensional hierarchical clustering for segregation of clinical samples 
into HCC and non-HCC cluster by 25 differentially expressed genes. A, Overall 
expression patterns of 25 selected genes across the 46 liver samples including 10 normal liver 
controls (NN), 18 cancerous (T) and their corresponding distal non-cancerous (N) tissue of 
HCC in spotted array. B, Evaluation of the discrimination ability of the differentially 
expressed genes by 16 independent paired HCC samples using the Affymetrix system. 24 
probe sets derived from Affymetric GeneChip HG-U133A and B were found to be identical to 
the genes mentioned above and were included for analysis. The gene expression level are 
shown with the rows (genes) and column (samples) in cluster order and the relative value to 
the median among all samples is shown in color with a continuum of expression levels from 
dark green (lowest) to bright red (highest). Corresponding gene names are listed in each row. 
The horizontal dendrogram lists the samples studied and provides a measure of the 
relatedness of gene expression in each sample.  
 104
6.3. Discussion 
6.3.1. The analysis of global gene expression profiling of HCC  
Similar to other neoplasms, HCCs manifest diverse clinical pathological features 
including grade of differentiation, proliferation rate, tumor size, encapsulation, potential for 
metastasis, presence of cirrhosis, and recurrence and sensitivity to chemotherapeutic agents. 
Analysis of global gene expression profiling using over ten thousand genes has been proposed 
to be an essential approach for revealing the underlying mechanism of hepatocarcinogenesis 
and discovering novel targets for diagnosis and treatments of HCC. However, several 
independent studies have shown that unless a supervised machine-learning algorithm was 
applied for analysis, no distinct subtypes could be detected among the HCC samples studied, 
suggesting that the genetic basis of HCC is highly heterogeneous (1-3). Furthermore, it has 
been shown that genetic loci that undergo mutation or loss of heterozygosity (LOH) rarely 
affect more than half of all HCCs analyzed, again suggesting the heterogeneity of HCC (4, 5). 
The clinical implication of the observed heterogeneity among HCC samples is that altered 
expression of an individual gene may not be sufficient as a tumor marker, and that most likely 
a set of markers will need to be tested for their ability to accurately diagnose or monitor the 
progression of this malignancy. 
Our objective is to look for potential biomarkers to discriminate HCC from non-
cancerous liver tissue regardless of the individual genetic variability and their clinical 
pathological features. In order to minimize false positive results, we focused only on spot 
elements that had concordant replicates in our spotted array. After applying statistical 
analysis, differentially expressed genes were identified. Real-time RT-PCR was carried out to 
verify the microarray data and identify true genes of interest (data not shown). Most 
importantly, the data were also confirmed by a different approach, Affymetrix analysis using 




6.3.2. Up-regulated genes in HCC  
Among the differentially expressed genes, some may lead to the onset of cancer 
formation whilst others may result from the transformation of normal cells to cancer cells. 
However, it is extremely difficult to discern the cause and effect. Four house-keeping genes, 
namely, β-actin, GAPDH, α-tubulin and PPIA, which were originally included as positive 
controls for microarray hybridization, were up-regulated in cancerous tissues compared to 
matched non-cancerous tissues of HCC patients using spotted array and Affymetrix analysis 
(Table 6-2). Similar findings have also been reported with mRNA expression studies (6) and 
microarray analysis (7). The expression of ribosomal proteins L30 and L37 were up-regulated 
in HCC (Table 6-2) which was in agreement with previous studies showing the increased 
expression of other family members in HCC (8, 9). The altered expression of house-keeping 
genes and translational factors are likely to be involved in the progression of HCC rather than 
the cause. 
6.3.2. Down-regulated genes in HCC 
Among the 13 down-regulated genes in HCC, the following eight genes were highly 
expressed in normal liver: alpha-1B glycoprotein, α2-HS glycoprotein, apolipoprotein AI, 
apolipoprotein C-III, metallothionien IG, hepcidin, peptidoglycan recognition protein L 
precursor and C78 (liver-tissue specific expression of C78 was shown in Chapter 8.2.3.). The 
down-regulation of metallothionein family members has been demonstrated in HCC using 
immunohistochemistry (10) and microarray analysis (11). Various forms of apolipoprotein 
have shown decreased expression in HCC using microarray analysis (11). Taken together, the 
down-regulation of liver-tissue specific genes in the development of HCC indicates the 
dedifferentiation of malignant hepatocytes compared to normal hepatocytes which may result 
in the loss of normal liver function.  
A wide range of up- or down-regulated gene expression fold changes in HCC samples is 
not unexpected given the heterogeneity of HCC. Herein, we observed that for the 12 down-
regulated genes, 66% (18/27) to 96% (26/27) of HCC samples show consistently reduced 
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expression in Affymeterix analysis (Table 6-2), suggesting that the gene expression pattern 
was consistent in these genes. Furthermore, the highest down-regulation fold-change 
represented by the median of the N/T ratio could reach ~30 folds in Affymetrix analysis 
(Table 6-2). Conversely, the up-regulation fold-change represented by the median of the T/N 
ratio was only 2 fold or lower, and the expression of these up-regulated genes was less 
consistent among the HCC samples (Table 6-2). The mechanism of transcriptional 
inactivation of these down-regulated genes is presently unknown.  
It has been suggested that DNA methylation is a crucial mechanism for gene inactivation 
in human neoplasias including HCC (12). We observed the up-regulation of DNA 
methyltransferases (DNMTs) in our Affymetrix analysis (data not shown) which was 
consistent with earlier reports (13, 14), suggesting that aberrant CpG island hypermethylation 
might be a possible mechanism for gene inactivation of these down-regulated genes in HCC. 
However, the underlying mechanisms have yet to be elucidated. 
 
6.4. Conclusion 
Our data showed that no less than 25 differentially expressed genes may be associated 
with the development of HCC. The functional analyses of these differentially expressed genes 
should prove valuable in further understanding the mechanism of hepatocarcinogenesis. We 
focus particularly on hepcidin in association with the development of HCC because recent 
studies have shown that this key iron homeostasis regulator is associated with iron overload, a 
risk factor of HCC. Detailed studies are discussed in Chapter 7. Furthermore, we cloned and 
characterized a novel cDNA fragment, C78 because it is a novel gene which is expressed 
exclusively in the liver. Detailed experimental approaches are described in Chapter 8. 
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7.1. Summary  
The role of iron overload in the development of HCC remains elusive. In this study, 
expression profiling of genes involved in iron homeostasis in conjunction with the 
pathological assessment of hepatic iron content in cancerous and non-cancerous tissues of 
HCC patients enabled us to unravel the underlying molecular mechanisms of iron overload in 
HCC. A pronounced reduction in expression of hepcidin and many key regulators of iron 
homeostasis was detected in cancerous tissues of 27 HCC patients compared with their non-
cancerous tissues, as well as normal controls. This was accompanied by the observation of 
negative iron staining in all cancerous tissues and excessive iron deposits in 20 of the 27 
corresponding non-cancerous liver tissues. Interestingly, hepcidin and transferrin receptor 2 
(TfR2) gene expression was up-regulated in iron overloaded non-cirrhotic, non-cancerous 
liver tissues compared with normal controls. Furthermore, hepcidin and TfR2 gene expression 
correlated positively with iron deposition grading in the non-cancerous liver tissues. In 
summary, our study suggests that hepatic iron overload frequently found in HCC patients 
could be a physiological consequence of HCC development rather than its cause. It is also 
noted that the non-cirrhotic, non-cancerous liver tissues of HCC patients could respond to the 
iron loading.  
 
7.2. Results  
7.2.1. Significant down-regulation of hepcidin gene expression in HCC 
Hepcidin was significantly down-regulated in cancerous tissues of 18 pairs of HCC 
samples using spotted microarrays for differential cDNA library screening (Figure 7-1A). 
Real-time RT-PCR using 7 independent pairs of HCC samples demonstrated 9 to 1330 fold 
reduction of hepcidin gene expression in the cancerous tissues. This represents relative 
expression levels ranging from 1420 to 5120 copies in non-cancerous tissues compared to 1 to 
470 copies observed in cancerous tissues (Figure 7-1B). These results were confirmed when a 
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further 27 independent pairs of HCC samples were studied using Affymetrix GeneChip 
analysis, showing that the median level of expression in cancerous tissues was significantly 
lower than that in non-cancerous liver tissues (75.3 versus 2862.8 intensity units; p<0.001) 
















Figure 7-1. Significant down-regulation of hepcidin gene expression in HCC. Gene 
expression of hepcidin is determined by (A) Differential cDNA library screening with spotted 
microarrays; (B) Real-time RT-PCR; and (C) Affymetrix GeneChip analysis. Numbers of 
non-cancerous (N, triangular) and corresponding cancerous (T, inverted triangular) samples 
used in each study are indicated. Bars represent median values.  Asterisk (*) denotes a 
significant difference at p<0·05 when compared using a Wilcoxon Signed-Ranks test. 
 
7.2.2. Expression of hepcidin in HCC cell lines  
The expression level of hepcidin was monitored in 11 cell lines in comparison with the 
same amount of cDNA derived from normal liver using real-time RT-PCR. Cell lines under 
studied included 5 well-differentiated hepatoma cell lines (HepG2, Hep3B, PCL/PRL/5, 
HuH6-clone 5 and HuH7), 4 undifferentiated-hepatoma cell lines (HLE, SNU-182, SNU-398 
and SNU-449), a liver adenocarcinoma cell line (SKHep-1) and a human fetal hepatocyte cell 
line of WRL68. In general, hepcidin was either absent or expressed at a much lower level in 
cell lines compared to normal liver. Relative expression levels of each gene in equal amounts 
of cDNA were shown as follows: normal liver (1144.0)> HuH7 (69.3)> HepG2 (12.2)> 
HuH6-clone 5 (1.0) for hepcidin. Cell lines not mentioned indicates absence of expression. 
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7.2.3. High frequency of dysregulation of iron homeostasis-related genes in cancerous 
tissues compared to paired non-cancerous liver tissues from HCC patients 
To gain insight into the molecular mechanism underlying the regulation of iron 
homeostasis in HCC, 40 iron homeostasis-related genes were targeted for study in 27 pairs of 
HCC samples using Affymetrix GeneChip analysis. Eleven genes were excluded for further 
study due to absence of gene expression. These genes included iron regulatory protein 2 
(IRP2), hephaestin, heme oxygenase 2, ferrochelatase, lactotransferrin and 6 hemoglobin 
variants. The gene expression changes for the remaining 29 iron homeostasis-related genes in 
27 pairs of HCC samples are summarized in Table 7-1.  
We applied the Changes Algorithm, a relatively reliable method of comparing paired 
samples, to assess the changes in gene expression of all 27 paired samples. A total of 16 of 
the 29 genes showed consistently altered expression, either increased or decreased in cancer 
tissues, in at least 60 % (17/27) of the samples studied (Table 7-1). Although the absolute fold 
changes in gene expression varied between the samples, possibly due to sample heterogeneity, 
the trend was consistent for most of the genes. Fourteen of the 16 genes were down-regulated, 
including hepcidin, transferrin receptor 2 (TfR2), ceruloplasmin, transferrin (Tf), iron 
regulatory protein 1 (IRP1), hemopexin, haptoglobin, albumin, metallothionein 2A, frataxin, 
δ-aminolevulinate synthase 1 (ALAS1) and 3 hemoglobin variants, alpha 1, alpha 2 and beta 
globin. The remaining two genes, ribonucleotide reductase M2 polypeptide (RRM2) and 
lipocalin 2 were up-regulated. Among these genes studied, hepcidin gave the most dramatic 










Table 7-1. Summary of the changes in gene expression pattern of 29 iron homeostasis-
related genes in 27 HCC tissues. 
   Changes in 
HCC B
 N to T  ratio C
Function Probe ID A Gene Name 
Diseases 
associated with loss 
of gene functions  I D NC  median Min Max 
Iron absorption 
regulator   220491_at Hepcidin HH Type 2 
# 0 26 1  29·37 0·92 153 
Iron uptake 210215_at TfR2 HH Type 3 # 1 20 6  1·69 0·55 79·8 
 208691_at TfR1  12 6 9  0.96 0.27 2.51 
 203124_s_at DMT1  6 4 17  1.00 0.53 2.46 
Iron export 227253_at Ceruloplasmin  Aceruloplasminemia # 1 17 9  1·48 0·56 35·6 
 223044_at IREG1 HH Type 4 4 9 14  1.09 0.55 5.85 
Iron transport 214064_at Transferrin Atransferrinemia # 3 18 6  2.19 0.23 12.4 
 212531_at Lipocalin 2  18 1 8  0.39 0.03 6.10 
Iron storage  214211_at H-ferritin HH Type 5 # 15 2 10  0·72 0·18 2·48 
212788_x_at L-ferritin  1 7 19  1·23 0·78 2·25 
Iron responsive 
factor  207071_s_at IRP1  0 19 8  1·66 0·85 4·10 
Iron Salvage  39763_at Hemopexin  0 24 3  2·07 1·13 40.0 
206697_s_at Haptoglobin  0 22 5  1·91 0·78 67.6 
211298_s_at Albumin  0 19 8  1·41 0·97 5·37 
212185_x_at Metallothionein 2A  1 24 2  2·13 0·69 39·5 
 203665_at Heme oxygenase 1  4 8 15  1.30 0.28 4.02 
Putative iron  235754_at HFE HH Type 1 2 0 25  0.85 0.39 1.54 
absorption  228621_at HFE2 HH Type 2a 11 8 8  0.69 0.35 22.5 
regulator 216231_s_at β2-microglobulin  3 8 16  1.15 0.80 2.29 
Mitochondrial  205565_s_at Frataxin Friedreich ataxia # 0 17 9  1·64 0·62 2·67 
Iron metabolism 203646_at Ferredoxin 1  1 10 16  1·41 0·46 5·26 
 200793_s_at Aconitase 2  5 4 18  1.09 0.29 2.21 
Heme synthesis 205633_s_at ALAS1  4 22 1  2·29 0·55 12·3 
204788_s_at PPOX Variegate porphyria  11 0 16  0·73 0·20 1·71 
DNA synthesis 201477_s_at RRM1  11 0 16  0·74 0·39 1·43 
(iron containing) 201890_at RRM2  21 0 6  0·11 0·01 1·28 
Oxygen transport 204018_x_at α1 globin Thalassemia 1 24 2  3.29 0.47 13.9 
(heme containing) 211745_x_at α2 globin Thalassemia 1 24 2  3·40 0·39 16·6 
211696_x_at β globin Thalassemia 1 23 3  3·53 0·41 11·3 
A Probe ID represents Affymetrix probe sets derived from HG-U133-A and -B Genechip.  
B Changes in HCC represent patient numbers in each categories. ’I’ denotes ‘Increase and 
Mild Increase’, ‘D’ denotes ‘Decrease and Mild Decrease’ and ‘NC’ denotes ‘No Change’ 
when comparing cancerous (T) to paired non-cancerous (N) tissues of HCC samples.  
C The fold change of each gene is determined by the intensity unit of non-cancerous liver 
tissues over paired cancerous liver tissues (N to T ratio). The median, Min (minimum) and 
Max (maximum) of N to T ratio are included.  
#denotes diseases reported to be involved in iron overload.  
 
7.2.4. Iron staining of liver tissues revealed hepatic iron overload in most of the patients 
with HCC 
Iron staining was performed in liver sections containing cancerous and surrounding non-
cancerous tissues from the same 27 HCC patients used in the gene expression studies. All 
cancerous tissues were negative for iron staining (Figure 7-2, A and D), whereas different 
degrees of iron deposition (Grade 0 to 3) could be detected in the adjacent non-cancerous 
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liver tissues (Figure 7-2, A and B). Twenty of the 27 non-cancerous liver tissues showed 
significant iron deposits (Grade 2 to 3). Sixty to 95% of iron deposits were found within 
hepatocytes. Iron deposition was highest in the periportal regions with decreased intensity 
towards the central vein. Figure 7-2C showed that iron deposition in the non-cirrhotic, non-
cancerous tissues, which appeared as blue granules, was found predominantly in hepatocytes 
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Figure 7-2. Histopathological examination of hepatic iron overload in HCC patients 
using Perl’s iron stain. (A) Consecutive liver sections on slides containing cancerous lesions 
(arrows) and adjacent non-cancerous liver tissues are stained with Perl’s and H&E stain as 
observed with the naked eye. (B) Representative examples of liver sections stained for Grade 
0, 1, 2 and 3 iron deposition, respectively are shown (x25). Blue staining shows iron 
deposition. T denotes cancerous lesions. (C) Grade 3 iron deposition in non-cancerous liver 
tissues is shown. Arrows indicate the accumulation of iron in hepatocytes; arrowheads 
indicate the persistence of iron deposits in Kupffer cells (x400). (D) Interphase between iron-




7.2.5. Hepatic iron overload is associated with cirrhosis status 
The iron deposition grading in non-cancerous tissues in patients with HCC was found to 
be significantly associated with the cirrhosis status (χ2 test, p=0.0012) but not with the age, 
gender, grading of tumor and size of tumor (Table 7-2). It was shown that all non-cancerous 
tissues with moderate iron deposition (Grade 3) were non-cirrhotic liver tissues (100%, 8/8), 
whereas the majority of those with mild iron deposition (Grade 2) were cirrhotic liver tissues 
(83 %, 10/12). Three cirrhotic and 4 non-cirrhotic, non-cancerous liver tissues studied were 
found to have iron deposition of Grade 0 to 1 which was considered to be physiologically 
normal. 
 
Table 7-2. Univariate analysis of clinical characteristics of 27 HCC patients associated 
with iron deposition grading of their non-cancerous liver tissues. 
 Iron deposition in  
non-cancerous liver 
 
Patient Characteristics Grade 0-1 Grade 2 Grade 3 p valueA
Number of patients  7  12  8  NS 
Age (yrs)(mean [SD]) 63[12] 57[15] 56[15] NS 
Sex (F/M) 2/5 1/11 1/7 NS 
Aetiology factors     NS 
     HBV-positive  7  10  7   
     HCV-positive  0  1  0   
     Alcohol consumption  0  1  0   
     Unknown  0  0  1   
Histology     0·0012* 
     Cirrhosis  3  10 0   
     Non-cirrhosis  4  2  8   
Tumor grade     NS 
     Well differentiated (G1)  1  0  2   
     Moderate differentiated (G2)  4  7  3   
     Poorly differentiated (G3)  2  5  3   
Tumor diameter B    NS 
     <2 cm  0  3  0   
     2-5 cm  4  6  3   
     >5 cm  3  3  5   
A χ2 test was applied with p value of 0·05 as significant.  
B Tumor size was defined as the largest diameter of the tumor.  
NS denotes not significant.  
 
7.2.6. Expression profiling of genes involved in iron homeostasis 
Ten normal liver samples obtained from non-cancerous liver tissues of patients with 
hepatic metastasis of colorectal cancer were employed as baseline controls to monitor the 
alterations of gene expression in cancerous and non-cancerous liver tissues. The relatedness 
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of the 64 liver samples was evaluated by the overall expression profile of 29 genes involved 
in iron homeostasis by hierarchical clustering algorithm. The clinical samples could 
essentially be segregated into two main clusters, defined as HCC and non-HCC cluster in the 
horizontal dendrogram, shown in Figure 7-3. All samples in the HCC cluster were cancerous 
liver tissues, whereas all the normal controls and non-cancerous tissues were clustered as a 
non-HCC cluster. Although we did notice that a few genes showed altered expression in the 
non-cancerous tissues in comparison to normal control, probably reflecting their ability to 
respond to iron loading and inflammatory stimuli, the majority of the iron homeostasis-related 
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Figure 7-3. Segregation of liver samples into HCC and non-HCC cluster by 29 iron 
homeostasis-related genes. Overall gene expression patterns of 29 iron homeostasis-related 
genes are shown along with 64 liver samples, including 27 cancerous (T, blue) and paired 
non-cancerous tissues (N, yellow) from patients with HCC, as well as 10 normal liver (NN, 
black). Relative gene expression ratios were log2 transformed and applied to average 
uncentered linkage clustering. The gene expression levels are shown with the rows (genes) 
and column (samples) in cluster order and the relative value to the mean among all samples is 
shown by color with a continuum of expression levels from dark green (lowest) to bright red 
(highest). The horizontal dendrogram lists the samples studied and provides a measure of the 






7.2.7. Hepcidin and TfR2 gene expression in non-cancerous liver tissues correlated 
positively with iron deposition grading 
In all livers afflicted with HCC, the gene expression levels of hepcidin and TfR2 in the 
cancerous tissues were significantly down-regulated compared to the surrounding non-
cancerous liver tissues (Figure 7-1 and 7-4, respectively). It was further demonstrated that the 
gene expression level of both hepcidin and TfR2 correlated positively with iron deposition 
grading in the non-cancerous liver tissues. However, the correlation was statistically 
significant only for hepcidin (r=0.432, p=0.025) but not TfR2 (r=0.367, p=0.060) (Figure 7-5, 
A and B). In addition, a significant correlation between hepcidin and TfR2 gene expression 
was demonstrated by Pearson’s correlation in the non-cancerous and normal liver samples 

























Figure 7-4. Significant down-regulation of TfR2 gene expression in HCC. Gene 
expression of TfR2 was determined by Affymetrix GeneChip analysis. Numbers of normal 
liver (NN, diamond), non-cancerous liver tissues (N, triangular) and corresponding cancerous 
tissues (T, inverted triangular) used are indicated. Bars represent median values. Asterisk (*) 











































































Figure 7-5. Gene expression of (A) Hepcidin and (B) TfR2 in non-cancerous liver tissues 
from HCC patients are correlated independently with the grade of iron deposition. Gene 
expression levels in iron deposition Grade 0 (square, n=2), Grade 1 (triangular, n=5), Grade 2 
(inverted triangular, n=12) and Grade 3 (diamond, n=8) are shown with median values 
indicated by bars. Spearman rank correlation coefficient and p values with significant 




Since cirrhosis was a confounding factor in hepatic iron deposition, we then compared the 
gene expression levels of hepcidin and TfR2 independently in non-cancerous tissues with and 
without cirrhosis in association with hepatic iron overload (Figure 7-6, A and B), using 
normal liver controls as baseline controls.  There was a trend in the increase of hepcidin gene 
expression in association with iron overload in non-cancerous liver tissues with and without 
cirrhosis (Figure 7-6A). Furthermore, hepcidin gene expression in iron overloaded non-
cirrhotic liver tissues was significantly higher when compared to normal controls, as well as 
iron overloaded cirrhotic liver tissues (Figure 7-6A). Likewise, TfR2 gene expression was 
significantly increased in non-cirrhotic, non-cancerous liver tissues in comparison to normal 
controls, as well as cirrhotic, non-cancerous liver tissues (Figure 7-6B). However, no 
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significant increase in expression of hepcidin and TfR2 was detected in iron overloaded 
cirrhotic, non-cancerous liver tissues compared to normal controls (Figure 7-6, A and B). 
 
 


































































Figure 7-6. Gene expression of (A) Hepcidin and (B) TfR2 in non-cancerous liver tissues 
from HCC patients with cirrhosis (N_cirr, triangular symbols) and non-cirrhosis 
(N_non-cirr, inverted triangular symbols) is compared in the absence (-, open symbols) 
or presence (+, filled symbols) of hepatic iron overload. Normal liver (NN, diamond 
symbols, n=10) is employed as baseline control for gene expression levels. Gene expression 
levels in cirrhotic tissues without iron overload (n=3), and with iron overload (n=10), as well 
as in non-cirrhotic tissues without iron overload (n=4) and with iron overload (n=10), are 
shown with median values indicated by bars. Asterisk (*) denotes a significant difference, set 
at p<0·05 using a Mann-Whitney U test. 
 
 
7.2.8. TfR2 gene expression significantly correlated with several iron homeostasis-
related genes 
The gene expression of TfR2 was significantly correlated with three other genes involved 
in iron salvage, namely, hemopexin (r=0.783, p<0.001), haptoglobin (r=0.659, p<0.001) and 
metallothionein 2A (r=0.705, p<0.001) in all the 64 samples studied regardless of the sample 
origins. Interestingly, in cancerous liver tissues, TfR2 is significantly inversely correlated 
with RRM1 (r=-0.382, p=0.049), RRM2 (r=-0.485, p=0.01) and TfR1 (r=-0.392, p=0.043), 




7.2.9. Transcriptional regulation of hepcidin and TfR2  
It has been shown that there are putative binding sites for hepatic nuclear factor-4 (HNF-
4) and CCAAT/enhancer-binding proteins (C/EBP) in the hepcidin promoter (1), as well as 
C/EBP putative binding sites in the TfR2 promoter (2). Using Affymetrix GeneChip analysis, 
we report here that the four putative liver-specific transcription factors comprising C/EBPα, 
C/EBPβ, HNF3β and HNF4α have detectable gene expression levels in most of the liver 
samples (data not shown). We further analysed their expression levels in relation to hepcidin 
and TfR2 gene expression levels. The significant correlation between hepcidin and C/EBPβ  
was detected only in non-cancerous tissues (r=0.616, p=0.001), but not in cancerous tissues 
(r=0.076, p=0.707). On the other hand, the observation of significant correlation between 
TfR2 and HNF4α was found in non-cancerous tissues (r=0.513, p=0.006), but not in 
cancerous tissues (r=0.307, p=0.119). 
 
7.3. Discussion   
7.3.1. Normal liver tissues as baseline controls for gene expression analysis 
We incorporated normal liver tissues as baseline controls for gene expression analysis to 
ascertain that the altered expression of iron homeostasis-related genes observed in HCC 
patients is either due to the alteration of gene expression in cancerous tissues or the response 
of corresponding non-cancerous tissues to iron overload or inflammatory stimuli. Normal 
liver controls were obtained from non-cancerous liver tissues of patients with hepatic 
metastasis from colorectal cancer. Several groups reported that colorectal cancer rarely 
metastasized to injured liver such as fatty liver, cirrhotic liver and liver with chronic HBV and 
HCV infection (3-5) and hence, they could serve as an alternative source of normal liver 
tissues.  
7.3.2. Impairment of iron homeostasis is related to the development of HCC 
In this study, we have demonstrated that all 27 HCC patients examined have a high 
frequency of dysregulated gene expression of a great majority of the iron homeostasis-related 
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genes in cancerous liver tissues when compared with their surrounding non-cancerous tissues, 
as well as normal controls (Table 7-1). Some of the significantly down-regulated genes in 
HCC including hepcidin, TfR2, transferrin and ceruloplasmin (Table 7-1), are associated with 
HH and/or hepatic iron overload following the loss of their gene function (6). Furthermore, 
IRP1 which is known to post-transcriptionally regulate a number of important iron 
homeostasis-related genes (7), was down-regulated in the majority of cancerous tissues 
compared to paired non-cancerous tissues (Table 7-1), suggesting that the cancerous tissues 
had lost the physiological function of regulating iron homeostasis.   
In view of these observations, we propose that the reduced gene expression of these key 
regulators in iron homeostasis, particularly hepcidin, could induce intestinal iron absorption 
and lead to iron overload in these HCC patients. In agreement with our proposal, excessive 
iron deposition was observed in 20 of the 27 corresponding non-cancerous liver tissues of the 
HCC patients. The observed iron deposition, found predominantly within the periportal 
hepatocytes of non-cancerous liver tissues in our study, which is consistent with an earlier 
report (8), strongly suggests that intestinal absorption of dietary iron is excessive in HCC 
patients. 
7.3.3. The proposed mechanism of enhanced iron accumulation in non-cirrhotic, non-
cancerous liver tissues of HCC patients  
For populations in the Asia-Pacific region, HFE-associated HH is rarely found among 
subjects of non-European ancestry (9). In the current study, the development of HCC in 24 of 
the 27 patients was most likely caused by chronic HBV infection and not hemochromatosis. 
However, the majority of these patients (17/24) were found to have hepatic iron overload. Of 
the remaining 3 HCC patients who all had hepatic iron overload, one had chronic HCV 
infection, another had a history of chronic alcohol abuse and the third was not related to any 
known risk factors of HCC. This is in agreement with a previous observation showing 
significant increase of hepatic iron overload in patients with HCC compared to control 
subjects without HCC (8, 10) 
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The proposed excessive iron absorption in HCC patients might result in iron overload 
which presents as transferrin saturation and appearance of NTBI in the serum. Serum NTBI is 
found in individuals with iron overload (11, 12) (for more information, see Chapter 2.2.2.2.). 
The uptake of NTBI has been postulated to occur through an electrogenic transport 
mechanism that is driven by the negative potential difference across the plasma membrane 
(13). It is known that resting hepatocytes have a regulated transmembrane electrical potential 
difference whereas proliferating malignant hepatocytes are permanently depolarized (14). 
Furthermore, it has been shown in a murine model that the membrane potential of hepatocytes 
from cirrhotic liver is lower compared to hepatocytes from non-cirrhotic liver (15). It is 
therefore likely that the uptake of NTBI by normal hepatocytes is enhanced in comparison to 
that found in cirrhotic liver cells and depolarized cancerous hepatocytes. Consequently, lesser 
amounts of iron accumulate in cirrhotic liver tissues and none in cancerous cells, as is indeed 
the case.  
7.3.4. Non-cirrhotic, non-cancerous liver tissues of HCC patients can still respond to 
iron loading 
Interestingly, hepcidin and TfR2 gene expression was up-regulated in iron overloaded 
non-cirrhotic, non-cancerous liver tissues compared to normal controls (Figure 7-6, A and B). 
Furthermore, the gene expression levels of hepcidin and TfR2 correlated positively with the 
iron deposition grading in the non-cancerous liver tissues of the HCC patients studied (Figure 
7-5, A and B). This is consistent with the independent observations of increased hepcidin 
gene expression and constitutive TfR2 expression during dietary iron overload in a murine 
model system (16, 17).  Conversely, no significant increase of hepcidin and TfR2 gene 
expression was observed in iron overloaded, cirrhotic, and non-cancerous liver tissues of 
HCC patients when compared to normal controls (Figure 7-6, A and B). Therefore, HCC 
patients without cirrhosis could still respond to hepatic iron burden within the non-cancerous 
liver tissues. On the other hand, the lack of response to iron overload stimuli in HCC patients 
with cirrhosis was most likely due to the liver cirrhosis, an irreversible end result of chronic 
liver disease which is known to affect normal liver function.  
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7.3.5. The role of hepcidin and TfR2 in hepatocarcinogenesis 
In vivo studies have demonstrated that hepatic TfR2 expression correlates with the 
changes in transferrin saturation, highlighting a role for TfR2 as a sensor of iron status  (18). 
Furthermore, a significant reduction of hepcidin gene expression in TfR2 mutant mice with 
iron overload and Type 3 HH patients suggests that TfR2 might be a modulator of hepcidin 
production (19). These findings are consistent with our present results demonstrating a 
significant correlation between hepcidin and TfR2 gene expression (r=0.327, p=0.049) in the 
non-cancerous tissues of HCC patients and normal control. Taken together, it appears that 
TfR2 might act as an iron sensor to regulate hepcidin expression in response to iron loading. 
However, the correlation between hepcidin and TfR2 gene expression was not observed in the 
cancerous tissues (r=0.261, p=0.189), suggesting that the physiological regulatory pathway 
was lost during hepatocarcinogenesis.  
We propose that under normal physiological conditions, hepcidin and TfR2 are 
transcriptionally regulated by C/EBPβ  and HNF4α, respectively. This is at odds with an 
earlier report showing that C/EBPα is a key regulator for hepcidin gene expression (1).  The 
explanation for this discrepancy is currently unknown. Moreover, the correlation between 
C/EBPβ and hepcidin gene expression observed in non-cancerous liver tissues is not seen in 
HCC, implying that defects may occur in some essential transcriptional cofactors or 
epigenetic alterations of hepcidin expression may have occurred during hepatocarcinogenesis. 
7.3.6. Does the lack of iron accumulation in cancerous tissues mean the cell proliferation 
is independent of iron supply? 
 It is of particular interest to note that no iron staining could be observed within the 
cancerous tissues of HCC patients regardless of the degree of iron deposition in the adjacent 
non-cancerous liver tissues (Figure 7-2, A and D). The lack of iron accumulation in cancer 
cells has also been demonstrated in HH patients who developed HCC and in HCC-bearing 
rats loaded with iron (20, 21). It is likely that the usage of iron in cancer cells is preferential 
for proliferation rather than storage. This is supported by the detection of increased expression 
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of ribonucleotide reductase (RRM1, RRM2) (Table 7-1), an essential enzyme for cell 
proliferation (22), and the reduced expression of L-ferritin (Table 7-1), an iron storage protein 
(23). Furthermore, the significant inverse correlation between TfR2 and RRM1 or RRM2 
observed only in cancerous liver tissues is consistent with a previous report demonstrating 
that proliferating cells have reduced TfR2 mRNA expression in comparison to stationary cells  
(24). 
We have demonstrated that TfR2, the most likely molecule proposed to be responsible for 
TfR1-independent-mediated iron uptake at physiological transferrin concentration in 
hepatocytes (2, 24, 25), was significantly down-regulated in cancerous tissues in comparison 
to paired non-cancerous liver tissues of HCC patients. Interestingly, we also observed an 
increase in TfR1 expression in the cancerous tissues and the significant inverse correlation 
with the expression of TfR2 (r=-0.392, p=0.043). This suggests that the uptake of iron in 
cancer cells could have been shifted to a more efficient pathway that utilizes TfR1, a receptor 
with 30 fold higher affinity for transferrin compared to TfR2 (26). Hence, despite the down-
regulation of TfR2, TfR1 could still account for the uptake of iron by the cancer cells. In 
general, a high proliferative status is associated with a high density of TfR1 (27). 
 
7.4. Conclusion 
Although iron is a known potential carcinogen that plays a role in the development of 
HCC (28, 29), our present study suggests that the hepatic iron overload frequently found in 
HCC patients could be a physiological consequence of HCC development rather than its 
cause. This is supported by the impaired expression of many key regulators of iron 
homeostasis detected within the cancerous tissues of HCC patients that could perturb the 
homeostatic balance of iron metabolism, resulting in excessive absorption of dietary iron. 
Nevertheless, it is also noted that the non-cirrhotic, non-cancerous liver tissues of HCC 
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We report the identification of a novel cDNA fragment that shows significantly reduced 
expression in cancerous tissues compared with paired non-cancerous liver tissues in patients 
with HCC. The full-length transcript of 1733 bp encodes a protein of 308 amino acids that has 
all the hallmark features of mitochondrial carrier proteins. We designate the novel protein as 
HDMCP (HCC-down-regulated mitochondrial carrier protein). The HDMCP orthologs in 
human, mouse and rat are found to exhibit close similarity in protein sequence and gene 
organization, as well as exclusive expression in the liver. Moreover, conserved syntenic 
regions have been demonstrated at the HDMCP gene locus in the human, mouse and rat 
genome. Over-expression of HDMCP in transiently transfected cancer cells results in the loss 
of staining by MitoTracker dye, indicating that HDMCP could induce the dissipation of 
mitochondrial membrane potential (ΔΨm). However, HDMCP-mediated disruption of ΔΨm 
is not related to mitochondrial permeability transition or apoptosis. The dissipation of ΔΨm is 
accompanied by a significant reduction of cellular ATP in 293T cells overexpressing HDMCP 
or uncoupling protein 2 (UCP2). Our present findings suggest that HDMCP might be one of 





8.2.1. Identification of a significantly down-regulated cDNA fragment in cancerous liver 
tissues compared with paired non-cancerous liver tissues from HCC patients  
We employed spotted microarrays to screen a total of 789 cDNA clones derived from two 
reciprocal subtracted cDNA libraries generated from cancerous and paired non-cancerous 
liver tissues from an HCC patient (see Chapter 6.2.1.). Among the differentially expressed 
cDNA clones, C78 was found to be the most significantly and consistently down-regulated 
novel cDNA fragment in the cancerous tissues compared with paired non-cancerous liver 
tissues in a total of 18 pairs of HCC samples (see Table 6-2). Figure 8-1A shows the 
significant down-regulation of C78 in cancerous tissues of 18 pairs of HCC samples using 
spotted microarrays for differential cDNA libraries screening. Real-time RT-PCR using seven 
independent pairs of HCC samples demonstrated 3 to 460 fold reduction of C78 gene 
expression in the cancerous tissues. This represents relative expression levels ranging from 
115 to 725 copies in non-cancerous tissues compared with 1 to 40 copies observed in 
cancerous tissues (Figure 8-1B). These results were further confirmed when 27 independent 
pairs of HCC samples were studied using Affymetrix GeneChip analysis showing the median 
expression level in cancerous tissues was significantly lower than that in non-cancerous liver 
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Figure 8-1. Significant down-regulation of HDMCP gene expression in HCC. Gene 
expression of HDMCP is determined by (A) Differential cDNA library screening with spotted 
microarrays, (B) Real-time RT-PCR, and (C) Affymetrix GeneChip analysis.  Numbers of 
non-cancerous (N,▲) and paired cancerous samples (T, ▼) used in each study are indicated. 
Bars represent median values. Asterisk (*) denotes a significant difference at p<0.05 when 
compared using a Wilcoxon Signed-Ranks test. 
 
8.2.2. Quantitative real-time RT-PCR studies in HCC cell lines 
We investigated the endogenous expression of C78 in 11 HCC cell lines (see Chapter 7.2.2) 
in comparison with the same amount of cDNA derived from a normal liver using real-time 
RT-PCR. C78 was shown to be significantly down-regulated in the HCC cell lines compared 
with that of the normal liver sample. After normalization to 18S rRNA for equal amount of 
template loading, the relative expression levels were shown as follows: normal liver (~50,000 
copies); Hep3B, HuH6-C5, HepG2 (~230-265 copies); SNU-499 (~160 copies); HuH7, 
WRL68 (~25-40 copies); PLC/PRF/5, HLE, SNU398, SKHep1 and SNU186 (~1-10 copies). 
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8.2.3. Northern blot analysis revealed the exclusive expression of C78 in liver tissue  
A C78 cDNA fragment probe was applied to poly (A)+RNA isolated from 12 different 
human tissue types in order to determine the tissue distribution of C78. Figure 8-2 shows that 
the C78 mRNA transcript of ~1.8 kb could be detected predominantly in the liver. No signal 












































































Figure 8-2. Northern blot analysis demonstrates the tissue distribution of C78. A human 
Multiple-Tissue NorthernTM blot with 2 μg mRNA per lane was hybridized with the C78 
probe. C78 is expressed exclusively in liver tissue, and the size detected is ~1.8 kb. β-actin 
was used as a RNA loading control. Sizes of the molecular mass markers are indicated on the 
left. 
 
8.2.4. Cloning of full-length C78 and the detection of an alternatively spliced C78 
transcript  
The initially isolated C78 cDNA fragment contains 197 nucleotides (nt) plus a tail of A 
residues. We first used in silico cloning to extend the sequence of C78 to 477 nt by 
identifying a highly homologous EST clone, IMAGE clone 454792 (AA677293). By using 
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the GENSCAN program, a putative gene could be predicted within a stretch of a ~13 kb DNA 
sequence encompassing the 477 nt DNA sequence from the BAC clone R-638I2 (AL157871).  
As predicted, a 1.5 kb DNA fragment was generated by RT-PCR using primers designed from 
the GENSCAN-predicted gene. 5’-RACE using cDNA generated by both SuperScript II and 
ThermoScript reverse transcriptase, both amplified a consistent product of ~350 bp. However, 
the latter template generated an additional band of ~420 bp (data not shown). According to 
the sequences of both DNA fragments, they shared identical transcription initiation sites and 
their 3’-end sequence overlapped with the 1.5 kb fragment mentioned above. After comparing 
to the human genomic DNA sequence, the shorter fragment was subsequently found to 
comprise exon 1 to 4, whereas the longer fragment was found to splice at a different 3’-splice 
acceptor in intron 2 which therefore generated an additional stretch of 61 nt between exon 2 
and 3 (Figure 8-3).  
We concluded that we have obtained the full-length C78 cDNA of 1733bp (AY569438, 
see Appendix I) which is consistent with the 1.8 kb transcript identified in the liver mRNA 
(Figure 8-2). Nucleotide sequence analysis revealed that the full-length C78 cDNA comprised 
an open reading frame for a polypeptide of 308 aa, and the 5’- and 3’-UTR of 73 and 733 nt 
in length, respectively (Figure 8-3). Furthermore, we had also identified an alternatively 
spliced transcript which was found to encode a peptide of only 30 aa in length due to a 
premature termination codon present within the additional 61 nt stretch (AY570298, see 
Appendix I).  
Several cDNA sequences in UniGene Cluster Hs.108268 (Chromosome 14 open reading 
frame 68, C14orf68) were found to have a coding region identical to the C78 cDNA sequence 
but with minor variations of DNA sequences at the UTR. The C78 cDNA identified in the 
present study (AY569438, see Appendix I) has longer 5’- and 3’-UTR in comparison to the 
reported cDNA sequence (BX248260). The other two cDNA sequences (XM208731, 
AK092001) both have a stretch of 97 nt missing at the 3’-UTR. 
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     ►◄1 
     GTTGAGGCCACCCTGGTGGCACCAAAGCCCTCTCAGGCAGGCAGACCCAGGGCCTCCCCGCCACACCTTGTTC      73  
             ∗   
HDMCP-F→                    1►◄2                                        2►◄3 
   ATGGATTTTGTCGCTGGAGCCATCGGAGGCGTCTGCGGTGTTGCTGTGGGCTACCCCCTGGACACGGTGAAGGTC     148 
M  D  F  V  A  G  A  I  G  G  V  C  G  V  A  V  G  Y  P  L  D  T  V  K  V   25      
                                                                  3►◄4 
   AGGATCCAGACGGAGCCAAAGTACACAGGCATCTGGCACTGCGTCCGGGATACGTATCACCGAGAGCGCGTGTGG     223 
    R  I  Q  T  E  P  K  Y  T  G  I  W  H  C  V  R  D  T  Y  H  R  E  R  V  W   50        
                                          ←C78RC-IR    C78-F→ 
   GGCTTCTACCGGGGCCTCTCGCTGCCCGTGTGCACGGTGTCCCTGGTATCTTCCGTGTCTTTTGGCACCTACCGC     298 
G  F  Y  R  G  L  S  L  P  V  C  T  V  S  L  V  S  S  V  S  F  G  T  Y  R   75     
 
3    CACTGCCTGGCGCACATCTGCCGGCTCCGGTACGGCAACCCTGACGCCAAGCCCACCAAGGCCGACATCACGCTC     37
    H  C  L  A  H  I  C  R  L  R  Y  G  N  P  D  A  K  P  T  K  A  D  I  T  L  100   
                            4►◄5    ←C78RC-OR 
   TCGGGATGCGCCTCCGGCCTCGTCCGCGTGTTCCTGACGTCGCCCACTGAGGTGGCCAAAGTCCGCTTGCAGACG     448 
  G  C  A  S  G  L  V  R  V  F  L  T  S  P  T  E  V  A  K  V  R  L  Q  T  125     S
 
   CAGACACAGGCGCAGAAGCAGCAGCGGCGGCTTTCGGCCTCGGGGCCGTTGGCTGTGCCCCCCATGTGTCCTGTG     523 
Q
 
  T  Q  A  Q  K  Q  Q  R  R  L  S  A  S  G  P  L  A  V  P  P  M  C  P  V  150 
   CCCCCAGCCTGCCCAGAGCCCAAGTACCGCGGGCCACTGCACTGCCTGGCCACGGTAGCCCGTGAGGAGGGGCTG     598 
P  P  A  C  P  E  P  K  Y  R  G  P  L  H  C  L  A  T  V  A  R  E  E  G  L  175   
    
   TGCGGCCTCTACAAGGGCAGCTCGGCCCTGGTCTTACGGGACGGCCACTCCTTTGCCACCTACTTCCTTTCCTAC     673 
C  G  L  Y  K  G  S  S  A  L  V  L  R  D  G  H  S  F  A  T  Y  F  L  S  Y  200 
                                           5►◄6 
   GCGGTCCTCTGCGAGTGGCTCAGCCCCGCTGGCCACAGCCGGCCAGATGTCCCGGGCGTGCTGGTGGCCGGGGGC     748 
A  V  L  C  E  W  L  S  P  A  G  H  S  R  P  D  V  P  G  V  L  V  A  G  G  225 
 
   TGTGCAGGAGTCCTGGCCTGGGCTGTGGCCACCCCCATGGACGTGATCAAGTCGAGACTGCAGGCAGACGGGCAG     823 
C  A
    
  G  V  L  A  W  A  V  A  T  P  M  D  V  I  K  S  R  L  Q  A  D  G  Q  250   
   GGCCAGAGGCGCTACCGGGGTCTCCTGCACTGTATGGTGACCAGCGTTCGAGAGGAGGGACCCCGGGTCCTTTTC     898 
G  Q  R  R  Y  R  G  L  L  H  C  M  V  T  S  V  R  E  E  G  P  R  V  L  F  275  
 
   AAGGGGCTGGTACTCAATTGCTGCCGCGCCTTCCCTGTCAACATGGTGGTCTTCGTCGCCTATGAGGCAGTGCTG     973 
K  G  L  V  L  N  C  C  R  A  F  P  V  N  M  V  V  F  V  A  Y  E  A  V  L  300   
     
   AGGCTCGCCCGGGGTCTGCTCACATAGCCGGTCCCCACGCCCAGCGGCCCACCCACCAGCAGCTGCTGGAGGTCG    1
R  L  A  R  G  L  L  T                                                     308 
048  
 
   TAGTGGCTGGAGGAGGCAAGGGGTAGTGTGGCTGGGTTCGGGACCCCACAGGGCCATTGCCCAGGAGAATGAGGA    1123      
   GCCTCCCTGCAGTGTTGTCGGCCGAGGCCTGAGCTCGCCCTGCCCAGCTACTGACCTCAGGTCGAGGGGCCCGCC    1198  
                                                              ←HDMCP-R 
   AGCCATCAGCCAGGGTTGGCCTAGGGTGGCAGGAGCCAGGGAGGAGTGGGCCTCTTTGATGAGAGCGTTGAGTTG    1273       
                                                                      ←C78-MR 
   CATGGAGTCGGTTGTTCATCCCAGCCTCCCCATGGCCCTCGCCTCCCATGTCTTTGAAGCACCCCTCCAGGGAGT    1348     
    
   CAGGTGTGTGCTCAGCCACCCTCTGCCCCATTCCTAGACCCTCACCCCCACCACTGTTCCTGTGTCTTCACGAGC    1423  
    C78RT-F→  
   TGTCCCTTACAGGCAGGGGCTTCCCACAGGCTGGGGGCCTCGGGGCGGGGAGCATGAGCTGGGCTGGCACCACGA    1498     
   CTGAGGGCTCCCGGCTCGGCTTCTTCCCCACAGCAGGCTGCTCAGAGGGGGTGCTGCCGGGACTGCCATGCCCAC    1573    
   CTGAGAGGGGCCTGGGGTGGCCGTCCTCGGCCGGTTAGGGAATTTGGGGTGAGGTTCCTCAGGAGCCCTCACTCT    1648  
                       ←C78-R 
   GCCTGTGGACGCTGCACCTGCCACTTAAAGACCCCAAAGACTCTGTTGGGAACTGTTGTCAATAAAATGTTTCTG    1723 
           6►◄   
   AGGATGTTCA                                                                     1733 
 
Figure 8-3. Full-length nucleotide sequence of C78 and its corresponding deduced amino 
acid sequence. The full nucleotide sequence of C78 is numbered from 1 to 1733 (bp). The 
corresponding deduced amino acid sequence is shown below the nucleotide sequence and is 
numbered from 1 to 308 (aa). The translation initial site (ATG), stop codon (TAG) and the 
potential polyadenylation signal (AATAAA) are underlined. The exon boundary is indicated 
by ►◄, shown above the nucleotides, together with the exon number. An asterisk at exon 2 
and 3 boundaries denotes the insertion of an additional 61 nt to generate the alternatively 
spliced form (AY570298). The various primers employed in experiments are shaded and 
named. They were synthesized using either the sequences as shown (right arrows) or the 




8.2.5. C78 is a mitochondrial carrier protein, and is tentatively designated as HDMCP  
Sequence analysis reveals that the 308 aa polypeptide encoded by the full-length C78 
clone is highly similar to mitochondrial carrier proteins. Figure 8-4 shows the comparative 
alignment of the deduced amino acid sequence of C78 and three human mitochondrial carrier 
proteins, that is, C14orf69 (Q8N8R3), mitochondrial carnitine/acylcarnitine carrier protein 
(CAC) (O43772), and mitochondrial glutamate carrier 1 (GHC1) (Q9H936). Like the other 
mitochondrial carrier proteins, C78 comprises three highly conserved homologous tandem 
repeats of ~100 aa each with the typical mitochondrial carrier signature 
GX3GX8PX(D/E)X(I/L/V)(K/R)X(R/K)XQX20-30GX4(Y/W)(R/K)GX9P (1). Each repeated 
element is made of two anti-parallel transmembrane hydrophobic α-helices (Figure 8-4, open 
boxes) linked by an extensive hydrophilic region (Figure 8-4, solid line). The three tandem 
repeats are linked by short extra-membranous hydrophilic loops (Figure 8-4, dashed line). 
Thus a total of six hydrophobic segments (Figure 8-4, denoted as TM1 to TM6) are capable of 
being folded into membrane-spanning α-helices with the three long hydrophilic segments 
connecting the two α-helices in each repeat protruding into the mitochondrial matrix (2-4). 
The tripartite structure and the similarity of its hydrophobic profile to those of the other 
mitochondrial carrier proteins clearly indicate that C78 belongs to this superfamily. 
Tentatively, we designated C78 as HDMCP (HCC-down-regulated mitochondrial carrier 
protein).  
Within the mitochondrial carrier protein family, HDMCP shows the highest similarity 
(37%) to a putative mitochondrial carrier protein encoded by the c14orf69 gene. Similar to 
c14orf69 protein but unlike most of the other family members, the protruding N-terminus of 
the polypeptide chain is absent in HDMCP (Figure 8-4), indicating that the N-terminus is 
embedded in the inner membrane of the mitochondria. It was also noticed that the hydrophilic 
loop between TM3 and TM4 in the HDMCP protein was of comparable length to the 
glutamate/H+ symporter carrier, but was extraordinarily long when compared with most of the 
other mitochondrial carrier proteins (Figure 8-4). A unique stretch of protein sequence in the 
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hydrophilic loop of HDMCP (shown in italics, Figure 8-4) was found to have the consensus 
cAMP- and cGMP-dependent protein kinase phosphorylation site at Ser137 (Figure 8-4, shown 




   TM1 
HDMCP     -----------MDFVAGAIGGVCGVAVGYPLDTVKVRIQT--------EPKYTGIWHCVRDTYHRERVWGFYR 
c14orf69  ---------MALDFLAGCAGGVAGVLVGHPFDTVKVRLQVQSV----EKPQYRGTLHCFKSIIKQESVLGLYK 
CAC       MADQPKPISPLKNLLAGGFGGVCLVFVGHPLDTVKVRLQTQPPSLPGQPPMYSGTFDCFRKTLFREGITGLYR 
GHC1      --MADKQISLPAKLINGGIAGLIGVTCVFPIDLAKTRLQNQQN----GQRVYTSMSDCLIKTVRSEGYFGMYR 
                      .:: *  .*:  *   .*:* .*.*:*            * .  .*. .    *   *:*: 
 
   TM2         TM3 
HDMCP     GLSLPVCTVSLVSSVSFGTYRHCLAHICRLRYGNPDAKPTKADITLSGCASGLVRVFLTSPTEVAKVRLQTQT 
c14orf69  GLGSPLMGLTFINALVFGVQGNTLRALG---------HDSPLNQFLAGAAAGAIQCVICCPMELAKTRLQLQD 
CAC       GMAAPIIGVTPMFAVCFFGFGLGKKLQQKHP----EDVLSYPQLFAAGMLSGVFTTGIMTPGERIKCLLQIQA 
GHC1      GAAVNLTLVTPEKAIKLAANDFFRHQLSKDG-----QKLTLLKEMLAGCGAGTCQVIVTTPMEMLKIQLQDAG 
          * .  :  ::   :: :                      :  .   :*  :*     :  * *  *  **        
 
                                                                         TM4  
HDMCP     QAQKQQRRLSASGPLAVPPMCPVPPACPEPKYRGPLHCLATVAREEGLCGLYKGSSALVLRDGHSFATYFLSY 
c14orf69  AG-------------------------PARTYKGSLDCLAQIYGHEGLRGVNRGMVSTLLRETPSFGVYFLTY 
CAC       SS-------------------------GESKYTGTLDCAKKLYQEFGIRGIYKGTVLTLMRDVPASGMYFMTY 
GHC1      RIAAQRKILAAQGQLSAQGGAQPSVEAPAAPRPTATQLTRDLLRSRGIAGLYKGLGATLLRDVPFSVVYFPLF 
                                            . .    :    *: *: :*    ::*:      **  : 
 
   TM5 
HDMCP     AVLCEWLSPAGH--SRPDVPGVLVAGGCAGVLAWAVATPMDVIKSRLQADGQ-G-QRRYRGLLHCMVTSVREE 
c14orf69  DALTRALGCEPG--DRLLVPKLLLAGGTSGIVSWLSTYPVDVVKSRLQADGLRG-APRYRGILDCVHQSYRAE 
CAC       EWLKNIFTPEGKRVSELSAPRILVAGGIAGIFNWAVAIPPDVLKSRFQTAPP---GKYPNGFRDVLRELIRDE 
GHC1      ANLNQLGRPASE--EKSPFYVSFLAGCVAGSAAAVAVNPCDVVKTRLQSLQRGVNEDTYSGILDCARKILRHE 
            * .         ..      ::**  :*      . * **:*:*:*:           *: .      * * 
            
          TM6 
HDMCP     GPRVLFKGLVLNCCRAFPVN-MVVFVAYEAVLRLARGLLT---------------------- 
c14orf69  GWRVFTRGLASTLLRAFPVN-AATFATVTVVLTYARGEEAGPEGEAVPAAPAGPALAQPSSL 
CAC       GVTSLYKGFNAVMIRAFPAN-AACFLGFEVAMKFLNWATPNL-------------------- 
GHC1      GPSAFLKGAYCRALVIAPLFGIAQVVYFLGIAESLLGLLQDPQA------------------ 
          *   : :*             *    . .                                      
Figure 8-4. Comparative alignment of the deduced amino acid of HDMCP with 
members of the human mitochondrial carrier proteins. Alignment of the amino acid 
sequences of HDMCP and its homologs: protein C14orf69 (Q8N8R3), mitochondrial 
carnitine/acylcarnitine carrier protein (CAC) (O43772) and mitochondrial glutamate carrier 1 
(GHC1)(Q9H936) was carried out using the ClustalW program. Identical (*), conserved 
substituted (:) and semiconserved substituted (.) amino acids are shown. Gaps (-) are 
introduced to maximize alignment. The most prominent feature of the multiple alignment is 
the high conservation of three repeated segments of ~100-aa with the typical mitochondrial 
carrier signature GX3GX8PX(D/E)X(I/L/V)(K/R)X(R/K)XQX20-30GX4(Y/W)(R/K)GX9P, 
which are shaded for ease of identity. Each repeat contains two anti-parallel transmembrane 
(TM) hydrophobic α-helices (open boxes), linked by an extensive hydrophilic region (solid 
lines). The three repeats are linked by short extra-membranous hydrophilic loops (dashed 
line). Unique stretches of protein sequence at the hydrophilic loop between TM3 and TM4 in 
HDMCP and GHC1 are shown in italics. An occurrence of the consensus cAMP- and cGMP-
dependent protein kinase phosphorylation site as predicted by ScanProsite software analysis is 
found at Ser137 as shown in boldface.  
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8.2.6. Gene conservation between the human HDMCP genes and their mouse and rat 
orthologs 
Based on NCBI databases, UniGene clusters, and HomoloGene orthologs, the putative 
HDMCP orthologs were found in the mouse species (UniGene Cluster Mm.202653, 
expressed sequence AI876593) and in the rat species (LocusLink LOC299316, similar to 
expressed sequence AW491445). The deduced polypeptide encoded by the mouse cDNA 
sequence (BC055027) in Mn.202653 is highly homologous to those encoded by the human 
HDMCP cDNA sequence (87.3% identity). 
On the other hand, based on the conserved protein sequences in HDMCP orthologs, we 
concluded that the first 17 aa of protein sequence encoded by rat cDNA sequence 
(XM_234551) in LOC299316 was an unrelated amino acid sequence. Further investigation 
revealed the wrong prediction of exon 1 in this sequence entry. We have identified the 
putative exon 1 with a start codon and coding region encoding the first 9 aa which was 
identical to that of the mouse ortholog. In addition, 579 bp of 3’-UTR in exon 6 is missing in 
this rat cDNA sequence (AY603424, see Appendix I).  
Both the mouse and rat ortholog encoded 310 aa. Figure 8-5 showed the conserved 
protein sequence in human, mouse and rat orthologs of HDMCP. The polypeptide encoded by 
human HDMCP is highly homologous to the mouse ortholog (87.3% identity) and the rat 
ortholog (86.0% identity). Moreover, the similarity is even higher between the mouse and rat 
ortholog (94.8% identity). 
A comparison of the gene organization of the HDMCP ortholog from human (~7 kb), 
mouse and rat species (both ~5.7 kb) revealed the remarkable conservation of splice sites in 
all six exons (data not shown). Identical lengths of exons at the coding regions were observed 




  Human      MDFVAGAIGGVCGVAVGYPLDTVKVRIQTEPKYTGIWHCVRDTYHRERVWGFYRGLSLPV 
 Mouse      MDFVAGAIGGVCGVAVGYPLDTVKVRIQTEAKYAGIWHCIRDTYRQERVWGFYRGLSLPV 
 Rat        MDFVAGAIGGVCGVAVGYPLDTVKVKIQTEAKYTSIWHCVRDTYRQERLWGFYRGLSLPV 
            *************************:****.**:.****:****::**:*********** 
 
 Human      CTVSLVSSVSFGTYRHCLAHICRLRYGNPDAKPTKADITLSGCASGLVRVFLTSPTEVAK 
 Mouse      CTVSLVSSVSFGTYHHCLAHICRFRYGSTDAKPTKADITLSGCASGLVRVFLTSPTEVAK 
 Rat        CTVSLVSSVSFGTYHHCLAHICRFRYGSTDVKPTKADITLSGCASGLVRVFLTSPTEVAK 
            **************:********:***..*.***************************** 
 
 Human      VRLQTQTQAQKQQRRLSASGPLAVPPMCPVPPACPEP--KYRGPLHCLATVAREEGLCGL 
 Mouse      VRLQTQTQAQTQQRRSSASWTSGAPALCPTPTACLEPRPKYSGPLHCLVTVAREEGLRGL 
 Rat        VRLQTQAQSQTQQRRPSASWTSVAPALCPAPTACLEPRPKYSGPLHCLVTVAREEGLRGL 
            ******:*:*.**** *** .  .*.:**.*.** **  ** ******.******** ** 
 
 Human      YKGSSALVLRDGHSFATYFLSYAVLCEWLSPAGHSRPDVPGVLVAGGCAGVLAWAVATPM 
 Mouse      YKGSSALLLREGHSFATYFLSYAMLCEWLTPAGHSQPDVLGVLVAGGCAGVLAWAVATPM 
 Rat        YKGSSALLLREGHSFATYFLSYAVLSEWLTPAGQSQPDVLGVLVAGGCAGVLAWAVATPM 
            *******:**:************:*.***:***:*:*** ******************** 
 
 Human      DVIKSRLQADGQGQRRYRGLLHCMVTSVREEGPRVLFKGLVLNCCRAFPVNMVVFVAYEA 
 Mouse      DVIKSRLQADGQGQHRYRGLLHCVVTSVREEGPRVLFKGLALNCCRAFPVNMVVFVAYEA 
 Rat        DVIKSRLQADGQGQQRYRGLLHCVVTSVREEGPRVLFKGLALNCCRAFPVNMVVFVAYEA 
            **************:********:****************.******************* 
 
 Human      VLRLARGLLT 
 Mouse      VLRLTQSLLT 
 Rat        VLRLTQGLLT 
            ****::.*** 
 
Figure 8-5. Conservation of HDMCP ortholog in protein sequence. Alignment of the 
protein sequence of HDMCP ortholog in human, mouse and rat counterparts was carried out 
by the ClustalW program. Identical (*), conserved substituted (:) and semiconserved 













Figure 8-6. Conservation of HDMCP ortholog in gene organization. Schematic 
representation of the conserved gene organization of HDMCP ortholog in human, mouse and 
rat is shown. Black and white boxes represent exons that correspond to coding regions and 
UTR, respectively. Lines represent intervening introns. Numbers in the boxes represent 
sequence number of exons. Numbers above boxes represent the lengths of exons which is 




8.2.7. Synteny between the human HDMCP genes and its mouse and rat orthologs  
We have characterized a large region of the human, mouse and rat genomes flanking the 
HDMCP gene locus and have demonstrated conserved syntenic regions at human 
chromosome 14q32.31, mouse chromosome 12F1 and rat chromosome 6q32 (Figure 8-7A). 
The order of genes that map proximal or distal to the HDMCP gene locus is highly conserved 
(Figure 8-7B). The human chromosomal region comprises 10 genes in the order: EVL-
C14orf66-YY1-C14orf69-HDMCP-WARS-MGC4645-KIAA1446-DLK1-MEG3, and 
appears to exhibit conserved syntenic homology with the corresponding mouse and rat 
regions as shown in Figure 8-7B.  
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Figure 8-7.  Local genetic maps of the conserved syntenic regions at the HDMCP gene 
locus in the human, mouse and rat chromosomes. (A) The localization of HDMCP 
orthologous genes were indicated by red in the ideogram of human (Homo sapiens) 
chromosome 14 (14q32.31), mouse (Mus musculus) chromosome 12 (12F1) and rat (Rattus 
norvegicus) chromosome 6 (6q32). (B) Orthologous genes in human, mouse and rat 
chromosome are linked by dashed line as determined by HomoloGene, a resource of curated 
and calculated orthologs for genes in the NCBI. The direction of transcription of each gene is 
indicated by an arrow. The boldface type in the box represents HDMCP orthologs in human, 
mouse and rat. 
HDMCP orthologs 
B Mus musculus  
   (chr 12F1) 
↓ EVL 
↑ 2210008A03Rik  
↓ YY1  
↑ C030003J19Rik 
↓ AI876593 
↑ WARS  
↓ B930090D16  
↑ LOC268598 
↓ DLK1 
↓ MEG3  
Homo sapiens  
(chr 14q32.31) 
↓ EVL  
↑ C14orf66  
↓ YY1  
↑ C14orf69  
↓ HDMCP  
↑ WARS  
↓ MGC4645  
↑ KIAA1446  
↓ DLK1  
↓ MEG3  
Rattus norvegicus 
       (chr 6q32) 
↓ EVL  
↑ LOC314438  
↓ LOC314440  
↑  LOC314441  
↓  LOC299316  
↑ LOC314442  
↓ BEGAIN  





 8.2.8. HDMCP localized in mitochondria  
To demonstrate the subcellular localization of HDMCP, we transiently transfected an 
expression plasmid pcDNA3/HDMCP-FLAG into Hep3B cells. Confocal microscopy 
revealed the punctate distribution of the FLAG-tagged HDMCP protein in the cytoplasm of 
the transfected cells (Figure 8-8A, green cells, indicated by arrows). As expected, the FLAG-
tagged products (green) co-localized with mitochondrial marker (Figure 8-8B, blue) that 
showed a cyan color in the merged image (Figure 8-8D), confirming that HDMCP is 























Figure 8-8. HDMCP is localized to mitochondria causing the loss of ΔΨm. Hep3B cells 
were transiently transfected with expression vectors encoding HDMCP-FLAG for 24h. Cells 
were incubated with MitoTracker OrangeTM before being subjected to immunostaining using 
anti- FLAG pAb and anti-mitochondrial mAb. Confocal images of anti-FLAG (green, A), 
anti-mitochondria (blue, B) and MitoTracker (red, C), as well as a superimposed image (D) 




 8.2.9. Overexpression of HDMCP induced the loss of ΔΨm 
To address the function of HDMCP, Hep3B cells transfected with pcDNA3/HDMCP-
FLAG were stained with MitoTracker OrangeTM, a ΔΨm-sensitive dye (5). We showed that 
all mitochondria of the non-transfected cells stained red with MitoTracker (Figure 8-8C). 
However, transfected cells overexpressing HDMCP-FLAG were devoid of MitoTracker 
staining (Figure 8-8C, indicated by arrows). The merged confocal images of FLAG (green), 
mitochondria (blue) and MitoTracker (red) revealed that HDMCP-FLAG colocalized with 
mitochondria but not with MitoTracker in the transfected cells (Figure 8-8D, cyan). In non-
transfected cells, mitochondria colocalized with MitoTracker but not FLAG (Figure 8-8D, 
magenta). These data suggested that HDMCP could induce the dissipation of ΔΨm in the 
transfected cells. 
Consistent with the above observations, overexpression of HDMCP in the transfected 
HepG2 cells and CNE-2 cells also showed the exclusion of MitoTracker staining in the 
mitochondria (data not shown). For cells transfected with vector control or with unrelated 
genes tagged with FLAG, all showed the staining of mitochondria with MitoTracker (data not 
shown). Taken together, our observations strongly suggest that HDMCP is directly relevant to 












We then carried out a time course analysis of the HDMCP-mediated dissipation of ΔΨm 
in HDMCP-overexpressed cells. Four hours after transfection, the HDMCP protein could be 
detected in the cytoplasm and at this time point, it colocalized with MitoTracker as shown by 
a yellow color in the superimposed image (Figure 8-9A, arrow). At 6 h, some of the 
HDMCP-overexpressed cells started losing their ΔΨm, as shown by an increase in the green 
staining and a decrease in the yellow staining in the superimposed image (Figure 8-9B, arrow 
with asterisk). At 24 h, the transfected cells were totally devoid of ΔΨm, and showed a 
complete absence of MitoTracker staining (Figure 8-9C, arrows). We also noticed that 
HDMCP expression was associated with the presence of aggregated mitochondrial structures 
around the nuclear periphery, compared with the dispersed staining of mitochondria in the 































Figure 8-9. Time course analysis of HDMCP-mediated dissipation of ΔΨm in HDMCP-
overexpressed cells. Hep3B cells were transiently transfected with expression vectors 
encoding HDMCP-FLAG for (A) 4h, (B) 6h and (C) 24h. Cells were incubated with 
MitoTracker OrangeTM before being subjected to immunostaining using anti-FLAG mAb. 
Superimposed confocal images of MitoTracker (red), anti-FLAG (green) and bright field are 
shown. Arrows indicate HDMCP-overexpressed cells. Arrow with asterisk indicates cells 
starting to lose the MitoTracker stain. Bars denote 20 μm. 
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8.2.10. HDMCP-induced loss of ΔΨm is not associated with mitochondrial permeability 
transition and apoptosis  
The dissipation of ΔΨm in HDMCP-overexpressed cells prompted us to examine whether 
the expression of HDMCP was associated with mitochondrial permeability transition, which 
is usually accompanied by the release of cytochrome c into the cytoplasm, leading to 
apoptosis (6-9).  
First, we carried out experiments to detect the presence of characteristic apoptotic 
features, such as TUNEL-positive nuclei, membrane blebbing cells, and the release of 
cytochrome c from the mitochondria. The HDMCP-overexpressed cells were studied with the 
TUNEL staining method at day 3 after transfection. When compared with non-transfected 
cells, neither TUNEL-positive nuclear staining nor membrane blebbing could be detected in 

















Figure 8-10. TUNEL assay at day 3 after Hep3B transfected with pcDNA3/HDMCP-
FLAG. HDMCP-overexpressed cells were stained green by anti-FLAG mAb. Red nuclei 
represented positive staining for TUNEL assay. Bar denotes 20 μm. 
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In order to understand whether the loss of ΔΨm in HDMCP-overexpressed cells was 
related to the release of cytochrome c, double fluorescent staining experiments were carried 
out. The staining of cytochrome c could be detected in the mitochondria of both non-
transfected and HDMCP-overexpressed cells (Figure 8-11, A and D). Colocalizations of the 
staining of HDMCP (Figure 8-11B, red) and cytochrome c (Figure 8-11A, green) appeared as 
yellow color in the superimposed image (Figure 8-11C, arrows). The HDMCP-overexpressed 
cells showed exclusion of MitoTracker staining, indicating the loss of ΔΨm (arrows, Figure 
8-11E). However, the majority of the mitochondria still retained cytochrome c in the 





























Figure 8-11. Loss of ΔΨm induced by HDMCP overexpression does not induce the 
release of cytochrome c from mitochondria. Hep3B cells were transient transfected with 
expression vectors encoding HDMCP-FLAG for 24h. Cells were incubated with MitoTracker 
OrangeTM before subjected to immunostaining using anti-FLAG pAb and anti-cytochrome c 
mAb. Confocal images of anti-cytochrome c (green, A, D), anti-FLAG (red, B) and 
MitoTracker (red, E), as well as superimposed images (C, F) are shown. Arrows indicate 






To investigate whether the destabilization of ΔΨm was directly related to the opening of 
the permeability transition pore complex (PTP) that resulted in mitochondrial permeability 
transition, the HDMCP-overexpressed cells were treated with two PTP inhibitors, cyclosporin 
A (CsA) and bongkrekic acid (BA). Both PTP inhibitors were not able to prevent the 
exclusion of MitoTracker in HDMCP- overexpressed cells (Figure 8-12, A and B), suggesting 










Figure 8-12. The loss of ΔΨm is not associated with mitochondrial PTP opening in 
HDMCP-overexpressed cells. Hep3B cells were transiently transfected with 
pcDNA3/HDMCP-FLAG plasmid and incubated with (A) cyclosporin A and (B) bongkrekic 
acid for 24 h. Cells were incubated with MitoTracker Orange before subjected to 





8.2.11. The loss of ΔΨm in most of the HDMCP-overexpressed cells could not be 
completely restored by oligomycin  
It was observed that most of the HDMCP-overexpressed cells maintained a loss of ΔΨm 
following treatment with oligomycin, a ΔΨm stabilizer that inhibits the action of F0F1-
ATPase. At the same time, we also observed that the ΔΨm of a small number of HDMCP-
overexpressed cells could be partially restored in the presence of oligomycin as shown by the 
























Figure 8-13. The partial restoration of ΔΨm was observed after treatment of 5 μg/ml of 
oligomycin for 24 h. Cells were incubated with MitoTracker Orange before being subjected 
to immunostaining using anti-Flag mAb. Superimposed confocal images of MitoTracker 
(red), anti-FLAG (green) and bright field are shown. Arrows indicate HDMCP-FLAG 
overexpressed cells. Arrows with asterisk indicate cells with restored mitochondrial 





8.2.12. HDMCP and UCP2 similarly induced the dissipation of ΔΨm accompanied by a 
significant drop in the level of cellular ATP  
In order to study the uncoupling activity of HDMCP, we repeatedly attempted to establish 
cell lines that stably expressed HDMCP by using a Tet-off system, but we were unsuccessful. 
To overcome this difficulty, we have employed 293T cells that are known to have a high 
efficiency of transfection. UCP2 was cloned and employed as a positive control throughout 
our study. Transfected 293T cells overexpressing HDMCP and UCP2 that were stained with 
MitoTracker Orange and anti-FLAG antibody showed the dissipation of ΔΨm (Figure 8-14, A 
and B, respectively). Moreover, the levels of total cellular ATP measured 24 h after 
transfection dropped to 57.3 ± 18.1% (mean ± S.D.) (p=0.012) in HDMCP-overexpressed 
cells and 60.5 ± 16.4 % (p=0.012) in UCP2-overexpressed cells when compared with vector 
control (100%) (Figure 8-14C). Although the ADP level was not significantly different in 
 145
HDMCP- and UCP2-overexpressed cells compared with vector control (Figure 8-14C), the 
ADP/ATP ratio was significantly increased in cells overexpressing HDMCP (p=0.012) and 



























































Figure 8-14. Ectopic expression of HDMCP and UCP2 in 293T cells results in 
dissipation of ΔΨm and a significant drop in the level of cellular ATP. 293T cells were 
transiently transfected with pcDNA3 vector alone or expression vectors encoding  HDMCP-
FLAG and UCP2-FLAG for 24h. Cells were incubated with MitoTracker OrangeTM before 
being subjected to immunostaining using anti-FLAG pAb. Superimposed confocal images of 
MitoTracker (red), and anti-FLAG (green) are shown in cells transfected with (A) HDMCP 
and (B) UCP2. Bar denotes 20 μm. (C) Measurement of cellular ATP and ADP levels, as well 
as the ADP/ATP ratio were performed using the luminometric method in 8 independent sets 
of transfection. Values were normalized to vector control (100%) in order to compare the 
changes in HDMCP- and UCP2-overexpressed cells. Asterisk (*) denotes a significant 
difference at p<0.05 when compared with control using the Wilcoxon Signed-Ranks test. 
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8.2.13. HDMCP and UCP2 similarly induced cellular oncosis 
The detection of reduced ATP synthesis was accompanied by the observation of increased 
cell death in 293T cells transfected with either HDMCP or UCP2, but not vector control (data 
not shown). Genomic DNA electrophoresis was performed and revealed DNA smearing in 
these dead cells (Figure 8-15, lane 2 and 3), suggesting that the cell death was related to 
oncosis but not apoptosis. 
 
 



















Figure 8-15. HDMCP and UCP2 similarly induced cellular oncosis revealed by genomic 
DNA electrophoresis. Genomic DNA extracted from 293T cells transfected with pcDNA3 
vector control (lane 1), pcDNA3/HDMCP-FLAG (lane 2) and pcDNA3/UCP2-FLAG (lane 3) 









8.3. Discussion  
8.3.1. The observation of conserved HDMCP orthologous genes 
The pronounced similarity of protein sequences and gene organization detected within 
HDMCP orthologs (Figure 8-5, 8-6), as well as their predominant expression in liver tissue 
indicate that they are structurally and functionally conserved throughout mammalian 
evolution. Furthermore, the presence of syntenic regions at the HDMCP gene loci in the 
human, mouse and rat genome (Figure 8-7B) indicate that the HDMCP orthologs are most 
likely derived from a common ancestral gene region. Our finding is in agreement with the 
reported observations that a large number of syntenic segments are present and conserved 
between mice and humans (10).  
8.3.2. Comparison of HDMCP and mitochondrial carrier protein family members 
Based on the hallmark features of mitochondrial carrier proteins (Figure 8-4) and the 
specific cellular localization at mitochondria (Figure 8-8D), HDMCP is postulated to be a 
mitochondrial carrier protein. Through homology searching of the GenBankTM database, 
HDMCP is highly homologous to a putative protein encoded by C14orf69 (37%), a gene 
located directly upstream of the HDMCP gene (Figure 8-7B). Unlike HDMCP, the EST 
clones identical to C14orf69 are detected in multiple tissues and not specifically expressed in 
the liver. Therefore, it appears that these two mitochondrial carrier proteins are not 
functionally redundant.   
We have demonstrated that transient expression of HDMCP in cancer cells leads to a 
dramatic dissipation of ΔΨm (Figure 8-8C). By using UCP2 as a positive control, we further 
confirmed that the expression of HDMCP resulted in the loss of ΔΨm which was 
accompanied by a significant reduction of cellular ATP and an increase in the ADP/ATP ratio. 
(Figure 8-14C). This is consistent with the fact that uncoupling of oxidative phosphorylation 
results in decreased ΔΨm and cellular ATP. The reduction of ATP synthesis likely results 
from the loss of intact ΔΨm. Although HDMCP has relatively low amino acid homology to 
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UCP1 and its homologues (25 to 26%), our data suggest that HDMCP, like UCP2, is a 
functional uncoupling protein.  
8.3.3. Regulation of cellular oncosis by HDMCP 
 In some apoptotic pathways, the loss of ΔΨm has been reported to be a consequence of 
mitochondrial permeability transition that coincides with the release of cytochrome c from 
mitochondria (7, 8, 11, 12). Two known inhibitors of the PTP, cyclosporin A and bongkrekic 
acid, which stabilize ΔΨm have failed to prevent HDMCP-induced depolarization (Figure 8-
12, A and B). These data suggest that overexpression of HDMCP in cells could cause a 
concomitant change in the mitochondrial structure and the dissipation of ΔΨm which might 
not be relevant to mitochondrial permeability transition. In addition, the redistribution of 
cytochrome c and apoptosis were not observed in cells overexpressing HDMCP which had 
lost their ΔΨm.  
Nevertheless, the loss of ΔΨm in cells overexpressing HDMCP or UCP2 was 
concomitant with the observation of cell death (data not shown). This explained why we were 
unsuccessful in establishing cell lines that stably expressed HDMCP, similar to Mills et al. 
who failed to establish UCP2 stably expressing cell lines (13). It is known that cell death can 
proceed through either apoptosis which is an energy-dependent process or oncosis which is 
induced by energy depletion. (see Chapter 3.4.2. for more informations). Our current 
observation was similar to a previous study showing that UCP2-overexpressed cells with a 
dramatic fall in ΔΨm and reduction of ATP did not induce apoptosis but led to cellular 
oncosis (13). These data suggest a central role for mitochondria in regulating oncotic cell 
death and add to the evidence that oncotic cell death may also be subjected to molecular 
regulation and may play a homeostatic role in the overall tissue response to acute metabolic 
stress. HDMCP and UCP2 might selectively modulate the cellular response to oncotic stimuli 
without affecting the overall cellular threshold to apoptosis. 
8.3.4. HDMCP-induced loss of ΔΨm  can be partially restored by oligomycin  
Oligomycin has been known to block the main proton channel to allow proton retention in 
the intermembrane space of mitochondria and thus generate a higher ΔΨm. In the presence of 
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oligomycin, most of the HDMCP-overexpressed cells could apparently still pump out protons, 
resulting in the loss of ΔΨm (Figure 8-13, arrows). This observation suggests that ‘proton 
leak’ could be induced by HDMCP. On the other hand, under the same conditions, we 
observed that only a small number of HDMCP-overexpressed cells could partially restore 
ΔΨm (Figure 8-13, arrows with asterisk). This could suggest that in the presence of 
oligomycin, the retention of protons could delay the dissipation of ΔΨm induced by HDMCP. 
8.3.5. HDMCP could induce dissipation of ΔΨm, which uncouples oxidative 
phosphorylation in the IMM. 
Our findings have demonstrated that the dissipation of ΔΨm induced by overexpressing 
HDMCP in transfected cells was not due to PTP opening (Figure 8-16, pathway I). The 
concomitant observation of reduced ATP synthesis in HDMCP-overexpressed cells suggested 
that proton dissipation did not contribute to ATP production by ATP synthase (Figure 8-16, 
pathway II). Rather, it was most likely due to the proton leakage induced by HDMCP (Figure 














Figure 8-16. A schematic representation demonstrates that HDMCP could induce 
dissipation of ΔΨm, which uncouples oxidative phosphorylation in the IMM. 
 
8.3.6. Proposed biological functions of HDMCP  
It has been shown that reactive oxygen species (ROS) are involved in the pathogenesis of 
various liver diseases (14-16). Mild uncoupling of respiration has been proposed as the 
mechanism which prevents the accumulation of ROS generated by mitochondria (17), 
increases the sensitivity and rate of response of oxidative phosphorylation to effectors (18), 
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might function to prevent the accumulation of ROS, thereby protecting hepatocytes from 
oxidative stress associated with various liver diseases. Mitochondrial carrier proteins are 
known to catalyze the transport of a variety of metabolites, nucleotides and cofactors into and 
out of the mitochondrial matrix (3, 4, 20). Like most of the carrier proteins, HDMCP could 
also play a role in determining the availability of some unknown metabolites present in the 
cytoplasm and mitochondrial matrix. Further investigations are required to clarify the 
involvement of HDMCP in more specific metabolic pathways in the liver. 
8.3.7. The reduced expression of HDMCP in HCC might be related to selectively uptake 
of rhodacyanine dyes in the cancerous tissues 
The down-regulation of HDMCP in cancerous tissues of HCC patients might allow the 
bypass of the physiological ‘proton leak’ which results in the elevation of ΔΨm in the HCC 
cancer cells. This is in agreement with the observation that cancer cells generally have an 
elevated ΔΨm compared with normal epithelial cells (21). The inherent differences in the 
ΔΨm between cancer cells and normal cells have been shown to contribute to the selective 
accumulation of rhodacyanine dyes in the mitochondria of cancer cells (21-23). Delocalised 
lipophilic cations (DLCs) are a new class of putative anti-cancer agents that have been 
employed for photochemotherapy and photodynamic therapy (PDT) (24-26). DLCs exploit 
the differences of ΔΨm between normal and cancer cells with the goal to achieve selective 
cytotoxicity for cancer cells. The identification of HDMCP might therefore also allow the 
discovery of new DLCs for HCC-specific photodynamic therapy. 
 
8.4. Conclusion 
The specific expression of HDMCP in liver tissue and its ability to induce the potent 
dissipation of ΔΨm have prompted us to suggest that it might be a putative uncoupling 
protein, which mediates the uncoupling of oxidative phosphorylation in the liver. Moreover, 
the identification of the bioenergetic function of HDMCP in liver mitochondria should prove 
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valuable for further understanding the mechanism of hepatocarcinogenesis, as well as liver 
diseases that are associated with energy metabolism  
 
8.4. References 
 1.  Kobayashi K, Sinasac DS, Iijima M, Boright AP, Begum L, et al. The gene mutated in 
adult-onset type II citrullinaemia encodes a putative mitochondrial carrier protein. Nat 
Genet 1999; 22(2):159-163. 
 2.  Kuan J, Saier MH, Jr. The mitochondrial carrier family of transport proteins: structural, 
functional, and evolutionary relationships. Crit Rev Biochem Mol Biol 1993; 
28(3):209-233. 
 3.  Palmieri F. Mitochondrial carrier proteins. FEBS Lett 1994; 346(1):48-54. 
 4.  Walker JE, Runswick MJ. The mitochondrial transport protein superfamily. J Bioenerg 
Biomembr 1993; 25(5):435-446. 
 5.  Scorrano L, Petronilli V, Colonna R, Di Lisa F, Bernardi P. 
Chloromethyltetramethylrosamine (Mitotracker Orange) induces the mitochondrial 
permeability transition and inhibits respiratory complex I. Implications for the 
mechanism of cytochrome c release. J Biol Chem 1999; 274(35):24657-24663. 
 6.  Zamzami N, Kroemer G. The mitochondrion in apoptosis: how Pandora's box opens. 
Nat Rev Mol Cell Biol 2001; 2(1):67-71. 
 7.  Pastorino JG, Chen ST, Tafani M, Snyder JW, Farber JL. The overexpression of Bax 
produces cell death upon induction of the mitochondrial permeability transition. J Biol 
Chem 1998; 273(13):7770-7775. 
 8.  Kroemer G, Reed JC. Mitochondrial control of cell death. Nat Med 2000; 6(5):513-519. 
 9.  Crompton M. The mitochondrial permeability transition pore and its role in cell death. 
Biochem J 1999; 341 ( Pt 2):233-249. 
 10.  O'Brien SJ, Menotti-Raymond M, Murphy WJ, Nash WG, Wienberg J, et al. The 
promise of comparative genomics in mammals. Science 1999; 286(5439):458-481. 
 11.  Marchetti P, Castedo M, Susin SA, Zamzami N, Hirsch T, et al. Mitochondrial 
permeability transition is a central coordinating event of apoptosis. J Exp Med 1996; 
184(3):1155-1160. 
 12.  Zamzami N, Kroemer G. Apoptosis: mitochondrial membrane permeabilization--the 
(w)hole story? Curr Biol 2003; 13(2):R71-R73. 
 13.  Mills EM, Xu D, Fergusson MM, Combs CA, Xu Y, Finkel T. Regulation of cellular 
oncosis by uncouping protein 2. J Biol Chem 2002; 277(30):27385-27392. 
 14.  Pessayre D, Berson A, Fromenty B, Mansouri A. Mitochondria in steatohepatitis. 
Semin Liver Dis 2001; 21(1):57-69. 
 152
 15.  Loguercio C, Federico A. Oxidative stress in viral and alcoholic hepatitis. Free Radic 
Biol Med 2003; 34(1):1-10. 
 16.  Jaeschke H. Reactive oxygen and mechanisms of inflammatory liver injury. J 
Gastroenterol Hepatol 2000; 15(7):718-724. 
 17.  Skulachev VP. Uncoupling: new approaches to an old problem of bioenergetics. 
Biochim Biophys Acta 1998; 1363(2):100-124. 
 18.  Rolfe DF, Brand MD. The physiological significance of mitochondrial proton leak in 
animal cells and tissues. Biosci Rep 1997; 17(1):9-16. 
 19.  Ricquier D, Bouillaud F. The uncoupling protein homologues: UCP1, UCP2, UCP3, 
StUCP and AtUCP. Biochem J 2000; 345 Pt 2:161-179. 
 20.  Aquila H, Link TA, Klingenberg M. Solute carriers involved in energy transfer of 
mitochondria form a homologous protein family. FEBS Lett 1987; 212(1):1-9. 
 21.  Modica-Napolitano JS, Aprille JR. Basis for the selective cytotoxicity of rhodamine 
123. Cancer Res 1987; 47(16):4361-4365. 
 22.  Nadakavukaren KK, Nadakavukaren JJ, Chen LB. Increased rhodamine 123 uptake by 
carcinoma cells. Cancer Res 1985; 45(12 Pt 1):6093-6099. 
 23.  Davis S, Weiss MJ, Wong JR, Lampidis TJ, Chen LB. Mitochondrial and plasma 
membrane potentials cause unusual accumulation and retention of rhodamine 123 by 
human breast adenocarcinoma-derived MCF-7 cells. J Biol Chem 1985; 
260(25):13844-13850. 
 24.  Morgan J, Oseroff AR. Mitochondria-based photodynamic anti-cancer therapy. Adv 
Drug Deliv Rev 2001; 49(1-2):71-86. 
 25.  Modica-Napolitano JS, Joyal JL, Ara G, Oseroff AR, Aprille JR. Mitochondrial toxicity 
of cationic photosensitizers for photochemotherapy. Cancer Res 1990; 50(24):7876-
7881. 
 26.  Modica-Napolitano JS, Aprille JR. Delocalized lipophilic cations selectively target the 
mitochondria of carcinoma cells. Adv Drug Deliv Rev 2001; 49(1-2):63-70. 
 27.  Nobes CD, Brown GC, Olive PN, Brand MD. Non-ohmic proton conductance of the 
mitochondrial inner membrane in hepatocytes. J Biol Chem 1990; 265(22):12903-
12909. 
 28.  Brand MD, Chien LF, Ainscow EK, Rolfe DF, Porter RK. The causes and functions of 



















Nucleotide sequences submitted to GenBank arising from 
thesis work 
 
AY569438   Homo sapiens hepatocellular carcinoma-downregulated mitochondrial carrier 
protein (HDMCP) mRNA, complete cds; nuclear gene for mitochondrial product, 154 
 
 
AY570298 Homo sapiens hepatocellular carcinoma-downregulated mitochondrial carrier 




AY603424 Rattus norvegicus mitochondrial hepatocellular carcinoma-downregulated carrier 





LOCUS       AY569438            1733 bp    mRNA    linear   PRI 18-OCT-2004 
DEFINITION  Homo sapiens hepatocellular carcinoma-downregulated 
mitochondrial carrier protein (HDMCP) mRNA, complete cds; nuclear 
gene for mitochondrial product. 
 
ACCESSION   AY569438 
VERSION     AY569438.1  GI:46095314 
KEYWORDS    . 
SOURCE      Homo sapiens (human) 
  ORGANISM  Homo sapiens 
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; 
Euteleostomi; 
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo. 
REFERENCE   1  (bases 1 to 1733) 
  AUTHORS   Tan,M.G., Ooi,L.L., Aw,S.E. and Hui,K.M. 
  TITLE     Cloning and Identification of Hepatocellular Carcinoma 
            Down-regulated Mitochondrial Carrier Protein, a Novel 
            Liver-specific Uncoupling Protein 
  JOURNAL   J. Biol. Chem. 279 (43), 45235-45244 (2004) 
REFERENCE   2  (bases 1 to 1733) 
  AUTHORS   Tan,M.G.K., Aw,S.E. and Hui,K.M. 
  TITLE     Direct Submission 
  JOURNAL   Submitted (08-MAR-2004) Clinical Research, Singapore General 
            Hospital, Outram Road, Singapore 169608, Singapore 
FEATURES             Location/Qualifiers 
     source          1..1733 
                     /organism="Homo sapiens" 
                     /mol_type="mRNA" 
                     /db_xref="taxon:9606" 
                     /chromosome="14" 
                     /map="14q32.31" 
     gene            1..1733 
                     /gene="HDMCP" 
     5'UTR           1..73 
                     /gene="HDMCP" 
     CDS             74..1000 
                     /gene="HDMCP" 
                     /codon_start=1 
                      
 154
/product="hepatocellular carcinoma-downregulated 
                     mitochondrial carrier protein" 
                     /protein_id="AAS80155.1" 
                     /db_xref="GI:46095315" 
                     






     misc_feature    77..133 
                     /gene="HDMCP" 
                     /note="transmembrane-region site" 
     misc_feature    236..307 
                     /gene="HDMCP" 
                     /note="transmembrane-region site" 
     misc_feature    365..421 
                     /gene="HDMCP" 
                     /note="transmembrane-region site" 
     misc_feature    614..685 
                     /gene="HDMCP" 
                     /note="transmembrane-region site" 
     misc_feature    731..787 
                     /gene="HDMCP" 
                     /note="transmembrane-region site" 
     misc_feature    902..970 
                     /gene="HDMCP" 
                     /note="transmembrane-region site" 
     3'UTR           1001..1733 
                     /gene="HDMCP" 
     polyA_signal    1709..1713 
                     /gene="HDMCP" 
ORIGIN       
        1 gttgaggcca ccctggtggc accaaagccc tctcaggcag gcagacccag ggcctccccg 
       61 ccacaccttg ttcatggatt ttgtcgctgg agccatcgga ggcgtctgcg gtgttgctgt 
      121 gggctacccc ctggacacgg tgaaggtcag gatccagacg gagccaaagt acacaggcat 
      181 ctggcactgc gtccgggata cgtatcaccg agagcgcgtg tggggcttct accggggcct 
      241 ctcgctgccc gtgtgcacgg tgtccctggt atcttccgtg tcttttggca cctaccgcca 
      301 ctgcctggcg cacatctgcc ggctccggta cggcaaccct gacgccaagc ccaccaaggc 
      361 cgacatcacg ctctcgggat gcgcctccgg cctcgtccgc gtgttcctga cgtcgcccac 
      421 tgaggtggcc aaagtccgct tgcagacgca gacacaggcg cagaagcagc agcggcggct 
      481 ttcggcctcg gggccgttgg ctgtgccccc catgtgtcct gtgcccccag cctgcccaga 
      541 gcccaagtac cgcgggccac tgcactgcct ggccacggta gcccgtgagg aggggctgtg 
      601 cggcctctac aagggcagct cggccctggt cttacgggac ggccactcct ttgccaccta 
      661 cttcctttcc tacgcggtcc tctgcgagtg gctcagcccc gctggccaca gccggccaga 
      721 tgtcccgggc gtgctggtgg ccgggggctg tgcaggagtc ctggcctggg ctgtggccac 
      781 ccccatggac gtgatcaagt cgagactgca ggcagacggg cagggccaga ggcgctaccg 
      841 gggtctcctg cactgtatgg tgaccagcgt tcgagaggag ggaccccggg tccttttcaa 
      901 ggggctggta ctcaattgct gccgcgcctt ccctgtcaac atggtggtct tcgtcgccta 
      961 tgaggcagtg ctgaggctcg cccggggtct gctcacatag ccggtcccca cgcccagcgg 
     1021 cccacccacc agcagctgct ggaggtcgta gtggctggag gaggcaaggg gtagtgtggc 
     1081 tgggttcggg accccacagg gccattgccc aggagaatga ggagcctccc tgcagtgttg 
     1141 tcggccgagg cctgagctcg ccctgcccag ctactgacct caggtcgagg ggcccgccag 
     1201 ccatcagcca gggttggcct agggtggcag gagccaggga ggagtgggcc tctttgatga 
     1261 gagcgttgag ttgcatggag tcggttgttc atcccagcct ccccatggcc ctcgcctccc 
     1321 atgtctttga agcacccctc cagggagtca ggtgtgtgct cagccaccct ctgccccatt 
     1381 cctagaccct cacccccacc actgttcctg tgtcttcacg agctgtccct tacaggcagg 
     1441 ggcttcccac aggctggggg cctcggggcg gggagcatga gctgggctgg caccacgact 
     1501 gagggctccc ggctcggctt cttccccaca gcaggctgct cagagggggt gctgccggga 
     1561 ctgccatgcc cacctgagag gggcctgggg tggccgtcct cggccggtta gggaatttgg 
     1621 ggtgaggttc ctcaggagcc ctcactctgc ctgtggacgc tgcacctgcc acttaaagac 






LOCUS       AY570298              345 bp    mRNA    linear   PRI 18-OCT-2004 
DEFINITION  Homo sapiens hepatocellular carcinoma-downregulated 
mitochondrial carrier protein mRNA, complete cds, alternatively 
spliced; nuclear gene for mitochondrial product. 
ACCESSION   AY570298 
VERSION     AY570298.1  GI:45775221 
KEYWORDS    . 
SOURCE      Homo sapiens (human) 
  ORGANISM  Homo sapiens 
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; 
Euteleostomi; 
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo. 
REFERENCE   1  (bases 1 to 345) 
  AUTHORS   Tan,M.G., Ooi,L.L., Aw,S.E. and Hui,K.M. 
  TITLE     Cloning and Identification of Hepatocellular Carcinoma 
            Down-regulated Mitochondrial Carrier Protein, a Novel 
            Liver-specific Uncoupling Protein 
  JOURNAL   J. Biol. Chem. 279 (43), 45235-45244 (2004) 
REFERENCE   2  (bases 1 to 345) 
  AUTHORS   Tan,M.G.K., Aw,S.E. and Hui,K.M. 
  TITLE     Direct Submission 
  JOURNAL   Submitted (10-MAR-2004) Clinical Research, Singapore General 
            Hospital, Outram Road, Singapore 169608, Singapore 
FEATURES             Location/Qualifiers 
     source          1..345 
                     /organism="Homo sapiens" 
                     /mol_type="mRNA" 
                     /db_xref="taxon:9606" 
                     /chromosome="14" 
                     /map="14q32.31" 
     5'UTR           1..73 
     CDS             74..166 
                     /note="HDCMP; alternatively spliced" 
                     /codon_start=1 
                     /product="hepatocellular carcinoma-downregulated 
                     mitochondrial carrier protein" 
                     /protein_id="AAS77211.1" 
                     /db_xref="GI:45775222" 
                     /translation="MDFVAGAIGGVCGVAVGYPLDTVKGLLALP" 
     3'UTR           167..345 
ORIGIN       
        1 gttgaggcca ccctggtggc accaaagccc tctcaggcag gcagacccag ggcctccccg 
       61 ccacaccttg ttcatggatt ttgtcgctgg agccatcgga ggcgtctgcg gtgttgctgt 
      121 gggctacccc ctggacacgg tgaagggcct gctggccttg ccctaggcct ggagccgctc 
      181 gtgcctgaag cccacttctc ctgcaggtca ggatccagac ggagccaaag tacacaggca 
      241 tctggcactg cgtccgggat acgtatcacc gagagcgcgt gtggggcttc taccggggcc 




LOCUS       AY603424            1550 bp    mRNA    linear   ROD 18-OCT-2004 
DEFINITION  Rattus norvegicus mitochondrial hepatocellular carcinoma-
downregulated carrier protein (HDMCP) mRNA, complete cds; nuclear 
gene for mitochondrial product. 
ACCESSION   AY603424 
VERSION     AY603424.1  GI:47558920 
KEYWORDS    . 
SOURCE      Rattus norvegicus (Norway rat) 
  ORGANISM  Rattus norvegicus 
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; 
Euteleostomi; 
            Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; 
            Rattus. 
REFERENCE   1  (bases 1 to 1550) 
  AUTHORS   Tan,M.G., Ooi,L.L., Aw,S.E. and Hui,K.M. 
  TITLE     Cloning and Identification of Hepatocellular Carcinoma 
            Down-regulated Mitochondrial Carrier Protein, a Novel 
            Liver-specific Uncoupling Protein 
  JOURNAL   J. Biol. Chem. 279 (43), 45235-45244 (2004) 
REFERENCE   2  (bases 1 to 1550) 
  AUTHORS   Tan,M.G.K., Aw,S.E. and Hui,K.M. 
  TITLE     Direct Submission 
  JOURNAL   Submitted (21-APR-2004) Clinical Research, Singapore General 
            Hospital, Outram Road, Singapore 169608, Singapore 
FEATURES             Location/Qualifiers 
     source          1..1550 
                     /organism="Rattus norvegicus" 
                     /mol_type="mRNA" 
                     /strain="Wistar" 
                     /db_xref="taxon:10116" 
                     /chromosome="6" 
                     /map="6q32" 
     gene            1..1550 
                     /gene="HDMCP" 
     5'UTR           1..38 
                     /gene="HDMCP" 
     CDS             39..971 
                     /gene="HDMCP" 
                     /codon_start=1 
                     /product="mitochondrial hepatocellular 
                     carcinoma-downregulated carrier protein" 
                     /protein_id="AAT35561.1" 
                     /db_xref="GI:47558921" 







     misc_feature    42..98 
                     /gene="HDMCP" 
                     /note="transmembrane-region site" 
     misc_feature    201..272 
                     /gene="HDMCP" 
                     /note="transmembrane-region site" 
     misc_feature    330..386 
                     /gene="HDMCP" 
                     /note="transmembrane-region site" 
     misc_feature    585..656 
                     /gene="HDMCP" 
                     /note="transmembrane-region site" 
     misc_feature    702..758 
                     /gene="HDMCP" 
                     /note="transmembrane-region site" 
     misc_feature    873..941 
                     /gene="HDMCP" 
                     /note="transmembrane-region site" 
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     3'UTR           972..1550 
                     /gene="HDMCP" 
     polyA_signal    1529..1534 
                     /gene="HDMCP" 
ORIGIN       
        1 cagcaagacc agagcccttc ttgttgccta cactgtccat ggattttgtt gctggggcca 
       61 ttggaggagt ctgcggtgtt gctgtgggct accctctgga tacagtgaag gtcaaaatcc 
      121 agactgaggc caagtacaca agcatctggc actgtgtccg ggacacatat cgtcaagagc 
      181 ggctgtgggg attctacaga ggcctctcac tgcctgtgtg caccgtgtcc ctggtgtcat 
      241 ctgtatcctt cggtacctac caccactgcc tggcccacat ttgccgcttc cggtacggca 
      301 gcacggacgt caagcccacc aaggctgaca tcacactctc aggatgcgcc tctggccttg 
      361 tccgggtgtt cctgacgtca cccactgagg tggccaaagt ccgcctgcag acacaggccc 
      421 aatctcagac acagcagcgg cgaccctcgg cctcctggac atctgtggct cccgctttgt 
      481 gtccagcacc cactgcttgc ctggagccca ggcctaagta cagtgggcca ctacattgtt 
      541 tagtcacagt ggcccgagag gagggtctgc gcggactcta caagggcagc tcggctctac 
      601 tccttcgtga aggccactcc tttgccacct actttctctc ctatgctgtg ctctcggagt 
      661 ggctcacccc tgctggccag agtcagccag atgtcctagg tgtgctggtg gctggaggct 
      721 gtgccggggt cctggcctgg gctgtggcta cgcccatgga cgttatcaag tcccgcctgc 
      781 aggcggatgg gcagggccag cagcgctacc ggggcctcct gcactgtgtg gtgaccagcg 
      841 tgcgggagga gggtcccaga gtgctcttca agggactggc actcaactgc tgccgcgcct 
      901 ttcctgtcaa catggtggtc ttcgtggctt atgaggctgt gctgaggctc actcagggcc 
      961 tgctcacata ggcactggtc agcagcatcc acgttacaca gcagccggag gcaagctcag 
     1021 gatcccacag gactgtcacc cgaacagcag agggccttct gtgctgtgac ttaggggagg 
     1081 cccgagttta gccagcccag tcgctgacca cagtcaggga gtttcatctg ccatctgctt 
     1141 ggtggccatg agtcaggatg gtgtgagtct tcttgaggac acgtgtgtgt cacttgggag 
     1201 tcatctgtca tcgaacaact gttcattcct gttggtacag ccatgcccac actgatttca 
     1261 gagcattccc ttgccaaccc ctaaccccag ttccactcaa cattcaccga ttcacactgt 
     1321 ccccttagag ggaggcttgg gacaagacag caagctggtt acatctggct acaggctggg 
     1381 ctggtcccat cctaggctgc tcgagagagc ccacgttctc actgacccaa ggaatcggtg 
     1441 cagggtatca ccatcaaagt gccatactgc ctgcaggtgc tgtgccggtc acatgaaggt 
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We report the identification of a novel cDNA fragment
that shows significantly reduced expression in cancer-
ous tissue compared with paired non-cancerous liver
tissue in patients with hepatocellular carcinoma (HCC).
The full-length transcript of 1733 bp encodes a protein of
308 amino acids that has all the hallmark features of
mitochondrial carrier proteins. We designate the novel
protein as HDMCP (HCC-down-regulated mitochondrial
carrier protein). The HDMCP orthologs in human,
mouse, and rat are found to exhibit close similarity in
protein sequence and gene organization, as well as ex-
clusive expression in the liver. Moreover, conserved syn-
tenic regions have been demonstrated at the HDMCP
gene locus in the human, mouse, and rat genome. Taken
together, we suggest that HDMCP might have a con-
served and unique biological function in the liver. Over-
expression of HDMCP in transiently transfected cancer
cells results in the loss of staining by MitoTracker dye,
indicating that HDMCP could induce the dissipation of
mitochondrial membrane potential (m). However,
HDMCP-mediated disruption of m is not related to
mitochondrial permeability transition or apoptosis. In
addition, we further demonstrate that the dissipation of
m is accompanied by significant reduction of cellular
ATP in 293T cells overexpressing HDMCP or uncoupling
protein 2 (UCP2). Our present findings suggest that HD-
MCP might be one of the long postulated uncoupling
proteins that catalyze the physiological “proton leak” in
the liver. The down-regulation of HDMCP in HCC can-
cer cells might result in the elevation of m, a common
phenomenon found in cancer cells.
Hepatocellular carcinoma (HCC)1 is one of the most frequent
neoplasms worldwide. It has been suggested that chronic hep-
atitis B and C virus infection, dietary aflatoxin, alcohol con-
sumption, and hepatic iron overload are the etiological factors
for HCC development. However, the pathogenic mechanisms
responsible for HCC are still not well defined.
Mitochondrial defects caused by altered expression of respi-
ratory chain subunits and glycolytic enzymes, decreased oxida-
tion of NADH-linked substrates, as well as mitochondrial DNA
mutations have been proposed to contribute to the development
and progression of various cancer types including HCC (1–5). It
has long been recognized that the most well known function of
mitochondria is the production of ATP through oxidative phos-
phorylation. During mitochondrial respiration, the transfer of
electrons along the respiratory chain in the inner mitochon-
drial membrane is coupled to the translocation of protons (H)
from the mitochondrial matrix into the intermembrane space.
This process generates a proton electrochemical gradient
across the inner mitochondrial membrane, which is known as
the proton-motive force. This proton-motive force is used to
drive the protons back into the matrix through F0F1-ATP syn-
thase resulting in the synthesis of ATP (6, 7). Alternatively, the
proton-motive force can also be dissipated by “proton leak”
catalyzed by multiple parameters, such as classical uncouplers
of oxidative phosphorylation (8, 9), fatty acids (10), and the
uncoupling protein 1 (UCP1) of brown adipose tissue (11, 12).
The mitochondrial membrane potential (m) arises from the
net movement of positive charge across the inner mitochondrial
membrane, reflecting the balance between processes that con-
tribute to the generation of the proton gradient and those that
consume it (7).
In the early 1980s, Chen and co-workers (13–17) discovered
that relative to the mitochondria in normal cells, those in
cancer cells displayed a greater uptake and retention of rhoda-
mine 123, a m-dependent staining dye, suggesting that can-
cer cells generate higher m compared with normal cells. This
is in agreement with a later report showing that m of carci-
noma cells is60 mM higher than that of control epithelial cells
(18). However, to date, no real understanding of the biochem-
ical basis has been proposed for this well defined observation
for cancer cells.
We report here the isolation and characterization of a novel
protein that might be one of the long postulated liver tissue-
specific uncoupling proteins. It bears all the hallmark features
of the mitochondrial carrier proteins and is significantly down-
regulated during the development of HCC. We designate this
novel protein as HCC-down-regulated mitochondrial carrier
protein (HDMCP).
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EXPERIMENTAL PROCEDURES
Tissue Specimens—Paired samples of cancerous and non-cancerous
liver tissue of a total of 52 patients undergoing hepatic resection as
treatment for HCC were retrieved from the National Cancer Centre
Tissue Repository. Resected tissue was immediately snap-frozen in
liquid nitrogen. All samples were collected with written informed con-
sent from the patients. Among the 52 pairs of HCC samples, 18 were
randomly selected for spotted array analysis, 7 for real time reverse
transcription (RT)-PCR analysis, and 27 for Affymetrix analysis.
Cell Culture—HepG2, Hep3B, WRL68, SNU-182, SNU-398, SNU-
449, and SKHep1 were obtained from the American Type Culture
Collection. HuH7, HLE, PLC/PRF/5 and HuH6, clone 5 (HuH6-C5),
were obtained from the Japanese Cancer Research Resources Bank.
CNE-2 (a nasopharyngeal carcinoma cell line) has been described ear-
lier (19). Human embryonic kidney 293T cells were obtained from Dr.
Paula Lam (National Cancer Centre, Singapore). All cell lines were
maintained in Dulbecco’s modified Eagle’s medium supplemented with
10% fetal calf serum, penicillin/streptomycin (100 units/100 g/ml), 2
mM L-glutamate, 0.1 mM nonessential amino acids, and 1 mM sodium
pyruvate in a 37 °C humidified incubator with 5% CO2.
Subtracted cDNA Library Construction and Screening by Micro-
arrays—Two reciprocal subtracted cDNA libraries were generated be-
tween cancerous and non-cancerous liver tissue from an HCC patient
using a cDNA synthesis and plasmid cloning kit (Invitrogen) according
to the recommended protocol with some modifications. Briefly, tracer
cDNA was hybridized twice with biotinylated driver mRNA prepared by
Photoprobe Biotin Labeling/Detection kit (Vector Laboratories). The
removal of biotinylated RNA and DNA hybrid was carried out by
extraction twice with VECTREX Avidin D (Vector Laboratories). Sec-
ond strand DNA of the subtracted cDNA was then generated by random
priming, ligated to pSPORT1, and transformed into Epicurian Coli
XL-2-blue ultracompetent cells (Stratagene).
A total of 789 cDNA clones, including clone C78, the gene focus in the
present study, were derived from these two libraries. These clones were
PCR-amplified, purified, and spotted in duplicate onto glass slides
using the GMS 417 microarrayer (Genetic Microsystems). 10 g of total
RNA were labeled and hybridized to the arrays by using the two-step
3DNATM expression array detection kit (Genisphere Inc). RNA from a
normal liver sample is served as a reference in each hybridization. The
arrays were scanned using the GMS 418 array scanner (Genetic Micro-
systems) and analyzed using ImaGene 4.0 software (Biodiscovery, Los
Angeles). Signal intensities of Cy5 (test samples) and Cy3 (reference)
were normalized by applying a scale factor to all intensities measured
for the Cy5 channel to generate a Cy5/Cy3 intensity ratio of 1 in the
majority of the spot elements. The calibrated Cy5/Cy3 ratios repre-
sented relative gene expression.
RNA Isolation, Real Time RT-PCR, and Northern Blot Analysis—
Total RNAwas extracted using TRIzol reagent (Invitrogen) according to
the manufacturer’s protocol. cDNA was synthesized with random hex-
amers (Invitrogen) and oligo(dT)12–17 primers (Invitrogen) using Super-
Script II reverse transcriptase (Invitrogen). Quantification of C78 and
18 S rRNA expression was performed on a RotorGene real time PCR
machine (Cobett Research, Australia) using QuantiTechTM SYBR
Green PCR kit (Qiagen). The primer sequences were as follows: C78-
RT-F and C78-R (Fig. 3) for C78 and 5-CCTGCGGCTTAATTT-
GACTC-3 and 5-CGCTGAGCCAGTCAGTGTAG-3 for 18 S rRNA. All
PCRs were performed in duplicate. Standard curves of C78 and 18 S
rRNA were generated independently by 10 serial dilution of template
DNA. The relative copy number of each sample was calculated accord-
ing to the corresponding standard curve using RotorGene version 4.6
software. Normalization was performed in each sample by dividing the
copy number of C78 to that of 18 S rRNA. The relative expression levels
were calculated by arbitrarily designating the lowest normalized value
to 1.
A human multiple tissue Northern blot (Clontech) was hybridized
with probes prepared by purified C78 and -actin PCR product and
labeled using Strip EZTM DNA kit (Ambion) in Ultrahyb (Ambion).
Autoradiography was conducted on Kodak BioMax MR film (Eastman
Kodak) at 80 °C.
Affymetrix GeneChips Analysis—5 g of total RNA was used to
generate biotinylated cRNA, followed by hybridizing to Affymetrix HG-
U133A and -B GeneChips according to the manufacturer’s recommen-
dations. After scanning, the average intensity for the genes in total was
normalized to 100. Probe ID representing HDMCP was selected.
Cloning of a Full-length HDMCP cDNA and DNA Sequencing— C78
sequence was searched against the EST data base by the BLAST
program and was found to be highly homologous to EST clone
(AA677293). The EST sequence was found to be located at position
137,866 to 138,343 in BAC clone R-638I2 (AL157871) using the BLAST
program. The GENSCAN web server at the Massachusetts Institute of
Technology (genes.mit.edu/GENSCAN.html) was employed to predict
putative genes in an 13 kb of DNA sequence encompassing the EST
sequence from BAC clone R-638I2. A putative gene was predicted to
encode a protein of 323 amino acids (aa). cDNA was generated from
total RNA derived from a normal liver sample by random priming by
using SuperScript II reverse transcriptase (Invitrogen), as well as Ther-
moScript reverse transcriptase (Invitrogen), according to the manufac-
turer’s instructions. RT-PCR product generated by C78-F and C78-R
primers (Fig. 3), designed according to GENSCAN-predicted exons, was
confirmed by sequencing. In order to get the full-length sequence of
C78, 5-rapid amplification of cDNA ends (5-RACE) was performed
using the FirstChoice TM RLM-RACE kit (Ambion) according to the
manufacturer’s instructions. cDNA was first amplified with a 5-RACE
outer primer (provided in the kit) and C78RC-OR primer (Fig. 3),
followed by a second PCR using a nested 5-RACE inner primer (pro-
vided) and C78RC-IR primer (Fig. 3). The transcription initiation site
was mapped by sequencing the PCR products that were cloned into the
pCR2.1-TOPO vector (Invitrogen). DNA sequencing was performed on
an ABI Prism 377XL automated DNA sequencer using ABI PRISM
BigDye Terminator cycle sequencing Ready Reaction kit (Applied
Biosystem).
In Silico Cloning of HDMCP Orthologous Gene in Mouse and Rat, as
Well as Determining Gene Organization and Conserved Syntenic Re-
gions—HomoloGene data base from the National Center for Biotech-
nology Information (NCBI) shows possible homologous genes of HD-
MCP in the mouse and rat species. First, the cDNA and protein
sequences of HDMCP orthologous genes derived from AY569438 (hu-
man), BC055027 (mouse), and XM_234551 (rat) were analyzed by mul-
tiple sequence alignment using ClustalW version 1.8 available at
GenomeNet service at Kyoto University Bioinformatics Center (clust-
alw.genome.ad.jp/). Based on the conserved protein sequences in HD-
MCP orthologs, and later confirmed by PCR and autosequencing, we
concluded that the first 9 aa of protein sequence encoded by exon 1 in
the rat ortholog was replaced by a stretch of unrelated 17 aa in
XM_234551 (AY603424). Second, the cDNA sequence of the mouse
ortholog was used as a template to align an 7-kb rat genomic DNA
sequence encompassing the sequence of XM_234551, to assist in deter-
mining exon 1 with a start codon, and assembling the 5- and 3-
untranslated regions (UTR). Furthermore, gene organization of each
ortholog was determined by BLAST 2 sequence algorithm using cDNA
sequences and their corresponding genomic DNA sequences, together
with the consensus rule for splice sites, which are dinucleotides GT and
AG next to the 5 and 3 intron boundaries.
In order to determine the syntenic regions at the HDMCP gene locus
in human, mouse, and rat genomes, the map location of human, mouse,
and rat HDMCP orthologs was first identified. The gene content of the
genomic region flanking the HDMCP gene was determined by using
Map Viewer from the NCBI in human and corresponding mouse and rat
chromosomes. The regions of synteny between human, mouse, and rat
chromosome were then determined by analyzing and comparing each
gene using HomoloGene data base from the NCBI.
Construction of HDMCP-FLAG and Uncoupling Protein 2 (UCP2)-
FLAG Protein—HDMCP was first amplified from normal liver RNA
with specific primers HDMCP-F and HDMCP-R (Fig. 3). The PCR
product then served as a template to generate the HDMCP-FLAG
protein using two additional steps of PCR. HDMCP-F was the forward
primer for both PCRs. A FLAG peptide tag (KDDDDKYD) at the C
terminus of the fusion protein was first generated by the reverse primer
containing the 3-end of the HDMCP coding sequence and part of the
FLAG sequence (5-GTCGTCATCCTTGTAATCTGTGAGCAGACC-
CCGGGC-3; the FLAG sequence is underlined). The second PCR was
then performed using the reverse primer containing a stop codon and
part of the FLAG sequence that overlapped with the reverse primer
from the first PCR (C-FLAG, 5-GCCCTACTTATCGTCGTCATCCTT-
3; the stop codon is italic, and the FLAG sequence is underlined). The
UCP2-FLAG protein was generated by a similar approach from cDNA
of human skeletal muscle. Forward primer UCP2-F (5-ATCATGGTT-
GGGTTCAAGGCCACAGAT-3) was used together with first PCR re-
verse primer (5- GTCGTCATCCTTGTAATCGAAGGGAGCCTCTC-
GGGA-3; the FLAG sequence is underlined) and second PCR reverse
primer (C-FLAG, same as above). Platinum Pfx polymerase (Invitrogen)
was used for all amplifications. The first five cycles of amplification
were programmed as 94 °C for 3 min, 50 °C for 1 min, and 72 °C for 1
min. The remaining 25 cycles were programmed as 94 °C for 1 min,
60 °C for 1 min, and 72 °C for 1 min. A single deoxyadenosine (dA) was
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added to the 3-end of the final PCR products by Taq polymerase
(Promega) and cloned into pCR2.1-TOPO vector (Invitrogen). Positive
clones were confirmed by sequencing. Subcloning into pcDNA3 (Invitro-
gen) was performed by restriction enzyme digestion and standard liga-
tion protocols. The gene orientation was verified by restriction enzyme
digestion.
Transfection, Immunostaining, and m Detection—Cells grown on
coverslips in a 6-well tissue culture plate were transfected with 2 g of
pcDNA3/HDMCP-FLAG plasmid using LipofectAMINE (Invitrogen) ac-
cording to the manufacturer’s instructions. For time course analysis of
HDMCP expression, cells were stained at 4, 6, and 24 h after transfec-
tion. For m restoration studies in HDMCP-overexpressed cells, fresh
media containing test compound (either 5 M cyclosporin A, 50 M
bongkrekic acid, or 5 g/ml oligomycin (Sigma)) were added after the
cells were transfected for 2 h and incubated for another 22 h. To
determine the m, cells were incubated in media containing 250 nM
MitoTracker OrangeTM (Molecular Probes) at 37 °C for 30 min. Cells
were then fixed with 3.7% formaldehyde in culture media at 37 °C for 10
min and permeabilized in 0.1% Triton X-100 at room temperature for 5
min. After washing with PBS, nonspecific staining was blocked with
10% normal goat serum in PBS at room temperature for 1 h. The cells
were then incubated overnight with anti-FLAG monoclonal antibody
(mAb) (Stratagene) at 4 °C. After incubation at room temperature for
1 h in Alexa Fluor 488-conjugated goat anti-mouse antibody (Ab) (Mo-
lecular Probes), coverslips were washed in PBS and mounted onto slides
with 4,6-diamidino-2-phenylindole containing VECTASHIELD (Vector
Laboratories). Slides were examined using the LSM-510 laser-scanning
confocal microscope (Carl Zeiss). In addition, cells were incubated with
anti-FLAG polyclonal antibody (pAb) (Sigma) and anti-mitochondrial
mAb (Neomarker) or anti-cytochrome c mAb (Promega) 24 h post-
transfection. Alexa Fluor 488-conjugated goat anti-rabbit Ab and Alexa
Fluor 546- or Alexa Fluor 633-conjugated goat anti-mouse Ab were used
for primary Ab detection.
TUNEL Assay—In situ cell death detection kit (Roche Applied Science)
was used to detect apoptotic cells at day 3 after transfection in Hep3B
cells. Briefly, cells were fixed with 3.7% formaldehyde for 15 min at room
temperature, rinsed with PBS, and permeabilized in 0.1% Triton X-100,
0.1% sodium citrate for 2 min on ice. Cells were then treated with TUNEL
reaction mixture in a humidified chamber at 37 °C for 1 h in the dark,
followed by rinsing three times with PBS. To visualize HDMCP protein,
cells were incubated with anti-FLAGmAb followed by incubation of Alexa
Fluor 488-conjugated goat anti-mouse Ab.
Measurement of ATP and ADP/ATP Ratio—293T cells in 6-well
plates were transfected with pcDNA3/HDMCP-FLAG, pcDNA3/UCP2-
FLAG, or pcDNA3 vector alone, using LipofectAMINE with PLUS re-
agent according to the manufacturer’s instructions. Cell pellets were
collected 24 h after transfection and resuspended in Nucleotide Releas-
ing Buffer (NRB). The ATP and ADP were assayed by a luminometric
method using ApoSENSORTM ADP/ATP ratio assay kit (Biovision). To
measure the ATP level, 1 l of ATP-monitoring enzyme diluted in 50 l
of NRB was added to 100 l of cell lysate and read immediately with a
10-s integration on a LumatLB 9507 (Berthold technologies) (data A).
To measure the ADP level, the sample was read again after 10–15 min
(data B). 1 l of ADP-converting enzyme diluted in 50 l of NRB was
then added and read immediately (data C). The ADP level was calcu-
lated as data C  data B. The background-subtracted luminescence
values (relative light units) were normalized for total protein in each
sample. In order to compare the results of eight independent transfec-
tions, the relative light units/g of protein of vector control was set as
100% to compare the changes of ATP, ADP, and ADP/ATP ratio in
HDMCP- and UCP2-overexpressed cells.
Statistical Analysis—The statistical differences between groups were
analyzed by using Wilcoxon Signed-Ranks test for paired samples. Two-
tailed p values of 0.05 were considered to be statistically significant.
RESULTS
Identification of a Significantly Down-regulated cDNA Frag-
ment in Cancerous Liver Tissue Compared with Paired Non-
cancerous Liver Tissue from HCC Patients—We employed spot-
ted microarrays to screen a total of 789 cDNA clones derived
from two reciprocal subtracted cDNA libraries generated from
cancerous and paired non-cancerous liver tissue from an HCC
patient. Among the differentially expressed cDNA clones, C78
was found to be the most significantly and consistently down-
regulated novel cDNA fragment in the cancerous tissue com-
pared with paired non-cancerous liver tissue in a total of 18
pairs of HCC samples. Fig. 1A shows the significant down-
regulation of C78 in cancerous tissue of 18 pairs of HCC sam-
ples using spotted microarrays for differential cDNA library
screening. Real time RT-PCR using seven independent pairs of
HCC samples demonstrated 3–460-fold reduction of C78 gene
expression in the cancerous tissue. This represents relative
expression levels ranging from 115 to 725 copies in non-can-
cerous tissue compared with 1–40 copies observed in cancerous
tissue (Fig. 1B). These results were further confirmed when 27
independent pairs of HCC samples were studied using Af-
fymetrix GeneChips showing the median expression level in
cancerous tissue was significantly lower than that in non-
cancerous liver tissue (101 versus 1800 intensity unit; p 	
0.001, Wilcoxon Signed-Ranks test) (Fig. 1C).
We investigated the endogenous expression of HDMCP in
HCC cell lines compared with a normal liver sample using real
time RT-PCR. C78 was shown to be significantly down-regu-
lated in the HCC cell lines compared with that of the normal
liver sample. After normalization to 18 S rRNA for an equal
amount of template loading, the relative expression levels were
shown as follows: normal liver (50,000 copies); Hep3B, HuH6-
C5, and HepG2 (230–265 copies); SNU-499 (160 copies);
HuH7 and WRL68 (25–40 copies); PLC/PRF/5, HLE,
SNU398, SKHep1, and SNU186 (1–10 copies).
Northern Blot Analysis Revealed the Exclusive Expression of
C78 in Liver Tissue—C78 cDNA fragment probe was employed
to poly (A) RNA isolated from 12 different human tissue types
in order to determine the tissue distribution of C78. Fig. 2
shows that the C78 mRNA transcript of 1.8 kb could be
detected predominantly in the liver. No signal could be de-
tected in the other tissues examined.
FIG. 1. Significant down-regulation
of HDMCP gene expression in HCC.
Gene expression of HDMCP is deter-
mined by differential cDNA library
screening with spotted microarrays (A),
real time RT-PCR (B), and Affymetrix
Genechips (C). Numbers of non-cancerous
(N, Œ) and paired cancerous samples (T,
) used in each study are indicated. Bars
represent median values. Asterisk de-
notes a significant difference at p  0.05
when compared using the Wilcoxon
Signed-Ranks test.
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Cloning of Full-length C78 and the Detection of an Alterna-
tively Spliced C78 Transcript—The initially isolated C78 cDNA
fragment contains 197 nucleotides (nt) plus a poly(A) tail. We
first extended the sequence of C78 to 477 nt by identifying a
highly homologous EST clone, IMAGE clone 454792
(AA677293). By using the GENSCAN program, a putative gene
could be predicted within the stretch of an 13-kb DNA se-
quence encompassing the 477-nt DNA sequence from the BAC
clone R-638I2 (AL157871). As predicted, a 1.5-kb DNA frag-
ment was generated by RT-PCR by using primers designed
from the GENSCAN-predicted gene.
5-RACE using cDNA generated by both SuperScript II and
ThermoScript reverse transcriptase amplified a consistent
product of 350 bp. However, the latter template generated an
additional band of 420 bp (data not shown). According to the
sequences of both DNA fragments, they shared identical tran-
scription initiation sites, and their 3-end sequence overlapped
with the 1.5-kb fragment mentioned above. After comparing to
the human genomic DNA sequence, the shorter fragment was
subsequently found to comprise exons 1–4, whereas the longer
fragment was found to splice at a different 3-splice acceptor in
intron 2 which therefore generated an additional stretch of 61
nt between exons 2 and 3 (Fig. 3). We concluded that besides
obtaining the full-length C78 cDNA of 1733 bp (AY569438),
we had also identified an alternatively spliced transcript
(AY570298). The predicted full-length product is consistent
with the 1.8-kb transcript identified in the liver mRNA (Fig. 2).
Nucleotide sequence analysis revealed that the full-length
C78 cDNA comprised an open reading frame for a polypeptide
of 308 aa and the 5- and 3-UTR of 73 and 733 nt in length,
respectively (Fig. 3). The alternative splice form, however, was
found to encode a peptide of only 30 aa in length due to a
premature termination codon present within the additional
61-nt stretch (AY570298).
Several cDNA sequences in UniGene Cluster Hs.108268
(chromosome 14 open reading frame 68, C14orf68) were found
to have a coding region identical to the C78 cDNA sequence but
with minor variations of DNA sequences at the UTR. The C78
cDNA identified in the present study (AY569438) has longer 5-
and 3-UTR in comparison to the reported cDNA sequence
(BX248260). The other two cDNA sequences (XM208731 and
AK092001) both have a stretch of 97 nt missing at the 3-UTR.
C78 Is a Mitochondrial Carrier Protein and Is Tentatively
Designated as HDMCP—Sequence analysis reveals that the
308-aa polypeptide encoded by the full-length C78 clone is highly
similar to mitochondrial carrier proteins. Fig. 4 shows the com-
parative alignment of the deduced amino acid sequence of C78
and three human mitochondrial carrier proteins including
C14orf69 (Q8N8R3), mitochondrial carnitine/acylcarnitine car-
rier protein (CAC) (O43772), and mitochondrial glutamate car-
rier 1 (GHC1) (Q9H936). Like the other mitochondrial carrier
proteins, C78 comprises three highly conserved homologous tan-
dem repeats of 100 aa each with the typical mitochondrial
carrier signature GX3GX8PX(D/E)X(I/L/V)(K/R)X(R/K)XQX20–
30GX4(Y/W)(R/K)GX9P (20). Each repeated element is made of
two anti-parallel transmembrane hydrophobic -helices (Fig. 4,
open boxes) linked by an extensive hydrophilic region (Fig. 4,
solid line). The three tandem repeats are linked by short ex-
tramembranous hydrophilic loops (Fig. 4, dashed line). Thus a
total of six hydrophobic segments (Fig. 4, denoted as TM1 to
TM6) are capable of being folded into membrane-spanning -hel-
ices with the three long hydrophilic segments connecting the two
-helices in each repeat protruding into themitochondrial matrix
(21–23). The tripartite structure and the similarity of its hydro-
phobic profile to those of the other mitochondrial carrier proteins
clearly indicate that C78 belongs to this superfamily. Tenta-
tively, we designated C78 asHDMCP (Hepatocellular carcinoma-
down-regulated mitochondrial carrier protein).
Within the mitochondrial carrier protein family, HDMCP
shows the highest similarity (37%) to a putative mitochondrial
carrier protein encoded by the C14orf69 gene. Similar to
C14orf69 protein but unlike most of the other family members,
the protruding N terminus of the polypeptide chain is absent in
HDMCP (Fig. 4), indicating that the N terminus is embedded
in the inner membrane of the mitochondria.
It was also noticed that the hydrophilic loop between TM3
and TM4 in the HDMCP protein was of comparable length to
the glutamate/H symporter carrier but was extraordinarily
long when compared with most of the mitochondrial carrier
proteins (Fig. 4). A unique stretch of protein sequence in the
hydrophilic loop of HDMCP (Fig. 4, shown in italics) was found
to have the consensus cAMP- and cGMP-dependent protein
kinase phosphorylation site at Ser137 (Fig. 4, shown in bold)
when analyzed with the ScanProsite software at the ExPASy
server (www.expasy.ch/cgi-bin/scanprosite).
Gene Conservation between the Human HDMCP Genes and
Their Mouse and Rat Orthologs—Based on NCBI data bases,
UniGene clusters, and HomoloGene orthologs, the putative
HDMCP orthologs were found in the mouse species (UniGene
Cluster Mm.202653, expressed sequence AI876593) and in the
rat species (LocusLink LOC299316, similar to expressed se-
quence AW491445). The deduced polypeptide encoded by the
mouse cDNA sequence (BC055027) in Mn.202653 is highly
homologous to those encoded by the human HDMCP cDNA
sequence (87.3% identity).
On the other hand, based on the conserved protein sequences
in HDMCP orthologs, we concluded that the first 17 aa of
protein sequence encoded by rat cDNA sequence (XM_234551)
in LOC299316 was an unrelated amino acid sequence. Further
investigation revealed the wrong prediction of exon 1 in this
sequence entry. We have identified the putative exon 1 with a
start codon and coding region encoding the first 9 aa, which
was identical to that of the mouse ortholog. In addition, 579 bp
of 3-UTR in exon 6 is missing in this rat cDNA sequence
(AY603424).
Both the mouse and rat ortholog encoded 310 aa. Fig. 5A
showed the conserved protein sequence in human, mouse, and
rat orthologs of HDMCP. The polypeptide encoded by human
HDMCP is highly homologous to the mouse ortholog (87.3%
identity) and the rat ortholog (86.0% identity). Moreover, the
FIG. 2. Northern blot analysis demonstrates the tissue distri-
bution of C78. A human Multiple Tissue NorthernTM blot with 2 g of
mRNA per lane was hybridized with the C78 probe. C78 is expressed
exclusively in liver tissue, and the size detected is 1.8 kb. -Actin is
used as a RNA loading control. Sizes of the molecular mass markers are
indicated on the left.
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similarity is even higher between mouse and rat orthologs
(94.8% identity).
A comparison of the gene organization of the HDMCP or-
tholog from human (7 kb), mouse, and rat species (both 5.7
kb) revealed the remarkable conservation of splice sites in all
the six exons (data not shown). Identical lengths of exons at the
coding regions were observed in all orthologs except for exon 5
of the human ortholog (Fig. 5B).
The fact that 100% of 26 human EST clones in Hs.108268 as
well as 73% of the 68 mouse EST clones in Mm.202653 were
derived from liver tissue suggests that both human and mouse
HDMCP orthologs are liver tissue-specific. This observation is
consistent with our Northern blot analysis of human tissues
and demonstrated the exclusive expression of HDMCP in liver
tissue (Fig. 2).
Synteny between the Human HDMCP Genes and Its Mouse
and Rat Orthologs—We have characterized a large region of
the human, mouse, and rat genomes flanking the HDMCP gene
locus, and we revealed conserved syntenic regions at human
chromosome 14q32.31, mouse chromosome 12F1, and rat chro-
mosome 6q32. The order of genes that map proximal or distal to
the HDMCP gene locus is highly conserved (Fig. 6). The human
chromosomal region comprises 10 genes in the order
EVL-C14orf66-YY1-C14orf69-HDMCP-WARS-MGC4645-KIA-
A1446DLK1-MEG3 and appears to exhibit conserved syntenic
homology with the corresponding mouse and rat regions as
shown in Fig. 6.
HDMCP Localized in Mitochondria—To demonstrate the
subcellular localization of HDMCP, we transiently transfected
an expression plasmid pcDNA3/HDMCP-FLAG into Hep3B
cells. Confocal microscopy revealed the punctate distribution of
the FLAG-tagged HDMCP protein in the cytoplasm of the
transfected cells (Fig. 7A, green cells, indicated by arrows). As
expected, the FLAG-tagged products (green) colocalized with a
mitochondrial marker (Fig. 7B, blue) that showed a cyan color
in the merged image (Fig. 7D), confirming that expression of
HDMCP is in the mitochondria.
Overexpression of HDMCP Induced the Loss of m—To
address the function of HDMCP, Hep3B cells transfected with
pcDNA3/HDMCP-FLAG were stained with MitoTracker Or-
angeTM, a m-sensitive dye (24). We showed that all mito-
chondria of the nontransfected cells stained red with Mito-
Tracker (Fig. 7C). However, transfected cells overexpressing
HDMCP-FLAG were totally devoid of MitoTracker staining
(Fig. 7C, indicated by arrows). The merged confocal images of
FLAG (Fig. 7C, green), mitochondria (blue), and MitoTracker
(red) revealed that HDMCP-FLAG colocalized with mitochon-
dria but not with MitoTracker in the transfected cells (Fig. 7D,
cyan). In nontransfected cells, mitochondria colocalized with
MitoTracker but not FLAG (Fig. 7D, magenta). These data
suggested that HDMCP could induce the dissipation of m in
the transfected cells.
Consistent with the above observations, overexpression of
HDMCP in the transfected HepG2 cells and CNE-2 cells also
FIG. 3. Full-length nucleotide se-
quence of C78 and its corresponding
deduced amino acid sequence. The
full nucleotide sequence of C78 is num-
bered from 1 to 1733 (bp). The correspond-
ing deduced amino acid sequence is
shown below the nucleotide sequence and
is numbered from 1 to 308 (aa). The trans-
lation initial site (ATG), stop codon
(TAG), and the potential polyadenylation
signal (AATAAA) are underlined. The
boundary of exon is indicated by ‹Š,
shown above the nucleotides, with numer-
als indicating the numbers of the exons.
An asterisk at exon 2 and 3 boundary
denotes the insertion of an additional 61
nt to generate the alternatively spliced
form (AY570298). The various primers
employed in the experiments are shaded
and named. They were synthesized using
either the sequences as shown (right ar-
rows) or the complementary sequences as
shown (left arrows).
Liver-specific Uncoupling Protein 45239
showed the exclusion of MitoTracker staining in the mitochon-
dria (data not shown). For cells transfected with vector control
or with unrelated genes tagged with FLAG, all showed the
staining of mitochondria with MitoTracker (data not shown).
Taken together, our observations strongly suggest that HD-
MCP is directly relevant to the loss of m in the HDMCP-
overexpressed cells.
We then carried out a time course analysis of the HDMCP-
mediated dissipation of m in HDMCP-overexpressed cells.
Four hours after transfection, the HDMCP protein could be
detected in the cytoplasm, and at this time point, it colocalized
with MitoTracker as shown by the yellow color in the superim-
posed image (Fig. 8A, arrow). At 6 h, some of the HDMCP-
overexpressed cells started losing their m, as shown by an
increase in the green staining and a decrease in the yellow
staining in the superimposed image (Fig. 8B, arrow with aster-
isk). At 24 h, the transfected cells were totally depleted of m
and gave the complete absence of MitoTracker staining (Fig.
8C, arrows). We also noticed that HDMCP expression was
associated with the presence of aggregated mitochondrial
structures around the nuclear periphery, compared with the
dispersed staining of mitochondria in the cytoplasm of the
nontransfected cells (Fig. 8C).
HDMCP-induced Loss of m Is Not Associated with Mito-
chondrial Permeability Transition and Apoptosis—The dissipa-
tion of m in HDMCP-overexpressed cells prompted us to
examine whether the expression of HDMCP was associated
with mitochondrial permeability transition, which is usually
accompanied by the release of cytochrome c into the cytoplasm,
leading to apoptosis (25–28).
First, we carried out experiments to detect the presence of
characteristic apoptotic features, such as TUNEL-positive nuclei,
membrane blebbing cells, and the release of cytochrome c from
the mitochondria. The HDMCP-overexpressed cells were studied
with the TUNEL staining method at day 3 after transfection.
When compared with nontransfected cells, neither TUNEL-
positive nuclear staining nor membrane blebbing could be de-
tected in the HDMCP-overexpressed cells (data not shown).
In order to understand whether the loss of m in HDMCP-
overexpressed cells was related to the release of cytochrome c,
double fluorescent staining experiments were carried out. The
staining of cytochrome c could be detected in the mitochondria
of both nontransfected and HDMCP-overexpressed cells (Fig. 9,
A and D). Colocalizations of the staining of HDMCP (Fig. 9B,
red) and cytochrome c (Fig. 9A, green) appeared as yellow in the
superimposed image (Fig. 9C, arrows). The HDMCP-overex-
pressed cells showed the exclusion of MitoTracker staining as
an indication of the loss of m (Fig. 9E, arrows). However, the
majority of the mitochondria still retained cytochrome c in the
mitochondria as shown by the green staining (Fig. 9, D and E,
arrows).
To investigate whether the destabilization of m was di-
rectly related to the opening of the permeability transition pore
complex (PTP) that resulted in mitochondrial permeability
transition, the HDMCP-overexpressed cells were treated with
the two PTP inhibitors, cyclosporin A and bongkrekic acid.
Both PTP inhibitors were not able to prevent the exclusion of
MitoTracker in HDMCP-overexpressed cells (data not shown),
suggesting that the loss of m was not related to the opening
of the PTP complex.
The Loss of m in Most of the HDMCP-overexpressed Cells
Could Not Be Restored by Oligomycin—It was observed that
FIG. 4. Comparative alignment of the deduced amino acid of HDMCPwith members of the humanmitochondrial carrier proteins.
Alignment of the amino acid sequences of HDMCP and its homologs: protein C14orf69 (Q8N8R3), mitochondrial carnitine/acylcarnitine carrier
protein (CAC) (O43772), and mitochondrial glutamate carrier 1 (GHC1)(Q9H936) was carried out using the ClustalW program. Identical (*),
conserved substituted (:), and semiconserved substituted (.) amino acids are shown. Gaps () are introduced to maximize alignment. The most
prominent feature of the multiple alignment is the high conservation of three repeated segments of 100 aa with the typical mitochondrial carrier
signature GX3GX8PX(D/E)X(I/L/V)(K/R)X(R/K)XQX20–30GX4(Y/W)(R/K)GX9P, which are shaded for ease of identity. Each repeat contains two
anti-parallel transmembrane (TM) hydrophobic -helices (open boxes), linked by an extensive hydrophilic region (solid lines). The three repeats are
linked by short extramembranous hydrophilic loops (dashed lines). The unique stretch of protein sequence at the hydrophilic loop between TM3
and TM4 in HDMCP and GHC1 is shown in italics. An occurrence of the consensus cAMP- and cGMP-dependent protein kinase phosphorylation
site as predicted by ScanProsite software analysis is found at Ser137 as shown in boldface.
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most of the HDMCP-overexpressed cells maintained a loss of
m following treatment of oligomycin, a m stabilizer that
inhibits the action of F0F1-ATPase (data not shown). At the
same time, we also observed that the m of a small number of
HDMCP-overexpressed cells could be partially restored in the
presence of oligomycin as shown by the colocalization of HD-
MCP and MitoTracker staining (data not shown).
HDMCP and UCP2 Similarly Induced the Dissipation of
m Accompanied by a Significant Drop in the Level of Cellular
ATP—In order to study the uncoupling activity of HDMCP, we
tried extensively to establish cell lines that stably expressed
HDMCP by using a Tet-Off system, but we were unsuccessful.
To overcome this difficulty, we have employed 293T cells that
are known to have a high efficiency of transfection. UCP2 was
cloned and employed as a positive control throughout our
study. Transfected 293T cells overexpressing HDMCP and UCP2
that were stained with MitoTracker Orange and anti-FLAG an-
tibody showed the dissipation of m (Fig. 10, A and B, respec-
tively). Moreover, the levels of total cellular ATP measured 24 h
after transfection dropped to 57.3 
 18.1% (mean 
 S.D.) (p 	
0.012) in HDMCP-overexpressed cells and 60.5 
 16.4% (p 	
0.012) in UCP2-overexpressed cells when compared with vector
control (100%) (Fig. 10C). Although the ADP level was not sig-
nificantly different in HDMCP- and UCP2-overexpressed cells
compared with vector control (Fig. 10C), the ADP/ATP ratio was
significantly increased in cells overexpressing HDMCP (p 	
0.012) and UCP2 (p 	 0.017) (Fig. 10C).
DISCUSSION
The high similarity of protein sequences and gene organiza-
tion detected within HDMCP orthologs (Fig. 5) as well as their
predominant expression in liver tissue indicate that they are
structurally and functionally conserved throughout evolution.
Furthermore, the presence of syntenic regions at the HDMCP
gene loci in human, mouse, and rat genomes (Fig. 6) indicate
that the HDMCP orthologous genes are most likely to be de-
FIG. 5. Conservation of HDMCP ortholog in protein sequence and gene organization. A, alignment of the protein sequence of HDMCP
ortholog in human, mouse, and rat counterparts was carried out by the ClustalW program. Identical (*), conserved substituted (:), and
semiconserved substituted (.) amino acids are shown. Shaded regions represent transmembrane domains. B, schematic representation of the
conserved gene organization of HDMCP ortholog in human, mouse, and rat is shown. Black and white boxes represent exons that correspond to
coding and UTR, respectively. Lines represent intervening introns. Numbers in the boxes represent sequence number of exons. Numbers above
boxes represent the length of exon which is given in bp. Numbers below lines represent length of intron which given in bp.
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rived from a common ancestral gene region. Our finding is in
agreement with the reported observations that a large number
of syntenic segments are present and conserved between mice
and humans (29).
Through homology searching of the GenBankTM data base,
HDMCP is highly homologous to a putative protein encoded by
C14orf69 (37%), a gene located directly upstream of the HD-
MCP gene (Fig. 6). Unlike HDMCP, the EST clones identical to
C14orf69 are detected in multiple tissues and not specifically
expressed in the liver. Therefore, it appears that these two
mitochondrial carrier proteins might not be functionally
redundant.
Based on the hallmark features of mitochondrial carrier
proteins (Fig. 4) and the specific cellular localization at mito-
chondria (Fig. 7D), HDMCP is suggested to be a mitochondrial
carrier protein. We have demonstrated that transient expres-
sion of HDMCP in cancer cells leads to a dramatic dissipation
of m (Fig. 7C). By using UCP2 as a positive control, we
further confirmed that the expression of HDMCP resulted in
the loss of m, which was accompanied by a significant re-
duction of cellular ATP and an increase in the ADP/ATP ratio
(Fig. 10C). This is consistent with the fact that uncoupling of
oxidative phosphorylation results in decreased m and cellu-
lar ATP. The reduction of ATP synthesis likely results from the
loss of intact m. Although HDMCP has relatively low amino
acid homology to UCP1 and its homologs (25–26%), our data
suggest that HDMCP, like UCP2, is a functional uncoupling
protein.
The liver is a major contributor to energy expenditure (30). It
is known that up to 25% of oxygen consumption is used to drive
the proton leak in resting hepatocytes (31, 32). Yet there has
been no report on the identification of a putative molecule that
mediates the uncoupling of oxidative phosphorylation in nor-
mal mammalian hepatocytes. The specific expression of HD-
MCP in liver tissue and its ability to induce the potent dissi-
FIG. 6. Local genetic maps of the conserved syntenic regions at
HDMCP gene locus in human, mouse, and rat chromosome.
Orthologous genes in human (Homo sapiens) chromosome 14q32.31,
mouse (Mus musculus) chromosome 12F1 and rat (Rattus norvegicus)
chromosome 6q32 are linked by dashed lines as determined by Homolo-
Gene, resource of curated and calculated orthologs for genes in the
NCBI. The direction of transcription of each gene is indicated with an
arrow. The boldface type in the box represents HDMCP ortholog in
human, mouse, and rat.
FIG. 7. HDMCP is localized to mitochondria that causing the
loss of m. Hep3B cells were transiently transfected with expression
vectors encoding HDMCP-FLAG for 24 h. Cells were incubated with
MitoTracker OrangeTM before subjected to immunostaining by using
anti-FLAG pAb and anti-mitochondrial mAb. Confocal images of anti-
FLAG (green, A), anti-mitochondria (blue, B), MitoTracker (red, C), as
well as superimposed image (D) are shown. Arrows indicate HDMCP-
overexpressed cells. Bars denote 20 m.
FIG. 8. Time course analysis of HDMCP-mediated dissipation
of m in HDMCP-overexpressed cells. Hep3B cells were tran-
siently transfected with expression vectors encoding HDMCP-FLAG for
4 (A), 6 (B), and 24 h (C). Cells were incubated with MitoTracker
OrangeTM before being subjected to immunostaining using anti-FLAG
mAb. Superimposed confocal images of MitoTracker (red), anti-FLAG
(green), and bright field are shown. Arrows indicate HDMCP-overex-
pressed cells. Arrow with asterisk indicates cell that started to lose the
MitoTracker staining. Bars denote 20 m.
FIG. 9. Loss of m induced by HDMCP overexpression does
not induce the release of cytochrome c from mitochondria.
Hep3B cells were transiently transfected with expression vectors en-
coding HDMCP-FLAG for 24 h. Cells were incubated with MitoTracker
OrangeTM before being subjected to immunostaining using anti-FLAG
pAb and anti-cytochrome c mAb. Confocal images of anti-cytochrome c
(green, A and D), anti-FLAG (red, B), MitoTracker (red, E), as well as
superimposed images (C and F) are shown. Arrows indicate HDMCP-
overexpressed cells. Bars denote 20 m.
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pation of m have prompted us to suggest that it might be one
of the long postulated uncoupling proteins in liver tissue.
In some apoptotic pathways, the loss of m has been re-
ported to be a consequence of mitochondrial permeability tran-
sition that coincides with the release of cytochrome c from
mitochondria (26, 27, 33, 34). Two known inhibitors of the PTP,
cyclosporin A and bongkrekic acid, which stabilize m have
failed to prevent HDMCP-induced depolarization (Fig. 10, A
and B). These data suggest that overexpression of HDMCP in
cells could cause a concomitant change in the mitochondrial
structure and the dissipation of m, which might not be
relevant to mitochondrial permeability transition. In addition,
the redistribution of cytochrome c and apoptosis were not ob-
served in cells overexpressing HDMCP, which had lost their
m. Our observation was further supported by a previous
study showing that UCP2-overexpressed cells with a dramatic
fall in m and reduction of ATP did not induce apoptosis but
led to cellular oncosis, a form of cell death induced by energy
depletion (35).
Oligomycin has been known to block the main proton chan-
nel to allow proton retention in the intermembrane space of
mitochondria and thus generate a higher m. In the presence
of oligomycin, most of the HDMCP-overexpressed cells could
apparently still pump out protons, resulting in the loss of m.
This observation suggests that proton leak could be induced by
HDMCP. On the other hand, under the same conditions, we
observed that only a small number of HDMCP-overexpressed
cells could partially restore m. This could suggest that in the
presence of oligomycin, the retention of protons could delay the
dissipation of m induced by HDMCP.
It has been shown that reactive oxygen species (ROS) are
involved in pathogenesis of various liver diseases (36–38). Mild
uncoupling of respiration has been proposed as the mechanism
to prevent the accumulation of ROS generated by mitochondria
(39), to increase the sensitivity and rate of response of oxidative
phosphorylation to effectors (40), and to regulate metabolic
pathways by adjusting the NAD/NADH ratio (39, 41). HD-
MCP might function to prevent the accumulation of ROS,
thereby protecting hepatocytes from oxidative stress associated
with various liver diseases. Mitochondrial carrier proteins are
known to catalyze the transport of a variety of metabolites,
nucleotides, and cofactors into and out of the mitochondrial
matrix (21, 22, 42). Like most of the carrier proteins, HDMCP
could also play a role in determining the availability of some
unknown metabolites present in the cytoplasm and mitochon-
drial matrix. Further investigations are required to clarify the
involvement of HDMCP in more specific metabolic pathways in
the liver.
The down-regulation of HDMCP in cancerous tissue of HCC
patients might allow the bypass of the physiological proton leak
that results in the elevation of m in the HCC cancer cells.
This is in agreement with the observation that cancer cells
generally have an elevated m compared with normal epithe-
lial cells (18). The inherent differences in the m between
cancer cells and normal cells have been shown to contribute to
the selective accumulation of rhodacyanine dyes in the mito-
chondria of cancer cells (17, 18, 43). Delocalized lipophilic cat-
ions (DLCs) are a new class of putative anti-cancer agents that
have been employed for photochemotherapy and photodynamic
therapy (44–46). DLCs exploit the differences of m between
normal and cancer cells with the goal to achieve selective
cytotoxicity for cancer cells. The identification of HDMCP
might therefore also allow the discovery of new DLCs for HCC-
specific photodynamic therapy.
Moreover, the identification of the bioenergetic function of
HDMCP in liver mitochondria should prove valuable for fur-
ther understanding the mechanism of hepatocarcinogenesis, as
well as liver diseases that are associated with energy metabo-
lism. Functional studies through gene knockout or overexpres-
sion could help to dissect the physiological role of HDMCP in
liver cell metabolism.
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